<CPRS_TEMPLATE>
  <TEMPLATE NAME="AJCC STAGING 7TH. Edition Forms (HYBRID)">
    <TYPE>C</TYPE>
    <STATUS>A</STATUS>
    <ITEMS>
      <TEMPLATE NAME="AJCC 7th Ed. Adrenal Gland Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>ADRENAL GLAND</p>
          <p></p>
          <p>7th Edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p></p>
          <p>CLIN PATH   PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}     TX  Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}     TO  No evidence of primary tumor</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}     T1  Tumor 5 cm or less in greatest </p>
          <p>			  dimension, no extra-adrenal invasion</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}     T2  Tumor greater than 5 cm, no extra-</p>
          <p>			  adrenal invasion</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}     T3  Tumor of any size with local </p>
          <p>			  invasion, but not invading adjacent organs*</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}     T4  Tumor of any size with invasion of </p>
          <p>			  adjacent organs*</p>
          <p></p>
          <p>*Adjacent organs include kidney, diaphragm, great vessels, pancreas, </p>
          <p>spleen, and liver</p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}     NX      Regional lymph nodes cannot be assessed </p>
          <p>{FLD:AJCC X} {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}     N1      Metastasis in regional lymph node(s)</p>
          <p></p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}         M0      No distant metastasis (no pathologic M0;use </p>
          <p>                             clinical M to complete stage group)</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}     M1      Distant metastasis</p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}     I       T1      N0      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}     II      T2      N0      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}     III     T1      N1      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}             T2      N1      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}             T3      N0      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}     IV      T3      N1      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}             T4      N0      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}             T4      N1      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}            Any T   Any N    M1</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}     UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>  Tumor weight in grams: {FLD:AJCC EDIT50}</p>
          <p>  Vascular invasion: {FLD:AJCC EDIT50}    </p>
          <p></p>
          <p>GRADING SYSTEM</p>
          <p>				</p>
          <p>{FLD:X BOX} 2 grade system	    		{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p></p>
          <p> STAGE GROUPING</p>
          <p>{FLD:X BOX} {FLD:X BOX}     0       Tis     N0      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}     IA      T1      N0      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}     IB      T2      N0      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}     IIA     T3      N0      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}     IIB     T1      N1      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}             T2      N1      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}             T3      N1      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}     III     T4      Any N   M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}     IV      Any T   Any N   M1</p>
          <p>{FLD:X BOX}            UNKNOWN STAGE</p>
          <p></p>
          <p> </p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X}Not Applicable</p>
          <p>{FLD:AJCC X}Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:AJCC X}R0 No residual tumor</p>
          <p>{FLD:AJCC X}R1 Microscopic residual tumor</p>
          <p>{FLD:AJCC X}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:AJCC X}National guidelines were used in treatment planning </p>
          <p>{FLD:AJCC X} NCCN </p>
          <p>{FLD:AJCC X} Other (describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Ampulla of Vater Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>AMPULLA OF VATER</p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>{FLD:X BOX}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:X BOX}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p></p>
          <p>CLIN PATH    PRIMARY TUMOR (T)</p>
          <p>{FLD:X BOX} {FLD:X BOX}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:X BOX} {FLD:X BOX}     T0      No evidence of primary tumor</p>
          <p>{FLD:X BOX} {FLD:X BOX}     Tis     Carcinoma in situ</p>
          <p>{FLD:X BOX} {FLD:X BOX}     T1      Limited to ampulla of Vater/sphincter Odd</p>
          <p>{FLD:X BOX} {FLD:X BOX}     T2      Tumor invades duodenal wall</p>
          <p>{FLD:X BOX} {FLD:X BOX}     T3      Tumor invades pancreas</p>
          <p>{FLD:X BOX} {FLD:X BOX}     T4      Tumor invades peripancreatic soft </p>
          <p>				 tissues or other adjacent organs or structures other than </p>
          <p>				 pancreas</p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:X BOX} {FLD:X BOX}     NX      Regional lymph nodes cannot be assessed</p>
          <p>{FLD:X BOX} {FLD:X BOX}     N0      No regional lymph node metastasis</p>
          <p>{FLD:X BOX} {FLD:X BOX}     N1      Regional lymph node metastasis</p>
          <p>{FLD:X BOX} {FLD:X BOX} UNKNOWN STAGE </p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:X BOX}         M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>{FLD:X BOX} {FLD:X BOX}     M1      Distant metastasis</p>
          <p></p>
          <p>Distant metastasis</p>
          <p>               STAGE GROUPING</p>
          <p>{FLD:X BOX} {FLD:X BOX}     0       Tis     N0      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}     IA      T1      N0      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}     IB      T2      N0      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}     IIA     T3      N0      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}     IIB     T1      N1      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}             T2      N1      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}             T3      N1      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}     III     T4      Any N   M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}     IV      Any T   Any N   M1</p>
          <p>{FLD:X BOX}            UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :{FLD:WP 2 LINE}</p>
          <p>Preoperative or pre-treatment carcinoembryonic antigen (CEA): {FLD:X BOX}</p>
          <p>Preoperative or pre-treatment CA 19-9 lab value: {FLD:FREE TEXT 10}</p>
          <p></p>
          <p>GRADING SYSTEM	</p>
          <p>				</p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:X BOX}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:X BOX}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:X BOX}Not Applicable</p>
          <p>{FLD:X BOX}Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:X BOX}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:X BOX}R0 No residual tumor</p>
          <p>{FLD:X BOX}R1 Microscopic residual tumor</p>
          <p>{FLD:X BOX}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:X BOX}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:X BOX}National guidelines were used in treatment planning </p>
          <p>{FLD:X BOX}NCCN </p>
          <p>{FLD:X BOX}Other (describe):</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Anus Staging ">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>ANUS</p>
          <p>(Melanomas, carcinoid tumors and sarcomas are not included)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:X BOX}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:X BOX}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p></p>
          <p>CLIN PATH    PRIMARY TUMOR (T)</p>
          <p>{FLD:X BOX} {FLD:X BOX}     TX     Primary tumor cannot be assessed</p>
          <p>{FLD:X BOX} {FLD:X BOX}     T0     No evidence of primary tumor</p>
          <p>{FLD:X BOX} {FLD:X BOX}     Tis    Carcinoma in situ (Bowen's disease, </p>
          <p>		         High-grade Squamous Intraepithelial Lesion (HSIL),</p>
          <p>                   Anal Intraepithelial Neoplasia II- III (AINII-III</p>
          <p>{FLD:X BOX} {FLD:X BOX}     T1     Tumor 2 cm or less in greatest dimension</p>
          <p>{FLD:X BOX} {FLD:X BOX}     T2     Tumor more than 2 cm but not more than 5 n </p>
          <p>				greatest dimension</p>
          <p>{FLD:X BOX} {FLD:X BOX}     T3     Tumor more than 5 cm in greatest dimension</p>
          <p>{FLD:X BOX} {FLD:X BOX}     T4     Tumor of any size invades adjacent organ </p>
          <p>				(s), vagina,urethra,bladder(Direct invasion of the </p>
          <p>                   rectal wall, perirectal skin, subcutaneous</p>
          <p>                   tissue, or the sphincter muscle(s)is not classified as T4)</p>
          <p>{FLD:X BOX} {FLD:X BOX} UNKNOWN STAGE </p>
          <p></p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:X BOX} {FLD:X BOX}     NX    Regional lymph nodes cannot be assessed </p>
          <p>{FLD:X BOX} {FLD:X BOX}     N0    No regional lymph node metastasis</p>
          <p>{FLD:X BOX} {FLD:X BOX}     N1    Metastasis in perirectal lymph node(s)</p>
          <p>{FLD:X BOX} {FLD:X BOX}     N2    Metastasis in unilateral internal </p>
          <p>			   iliac and/or inguinal lymph node(s)</p>
          <p>{FLD:X BOX} {FLD:X BOX}     N3    Metastasis in perirectal &amp; inguinalnodes 	</p>
          <p>			   and/or bilateral internal iliac and/or inguinal nodes</p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:X BOX}         M0   No distant metastasis (no pathologic M0; use 		</p>
          <p>			   clinical M to complete stage group) </p>
          <p>{FLD:X BOX} {FLD:X BOX}     M1   Distant metastasis</p>
          <p></p>
          <p>        STAGE GROUPING</p>
          <p>{FLD:X BOX} {FLD:X BOX}     0       Tis     N0      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}     I       T1      N0      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}     II      T2      N0      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}             T3      N0      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}     IIIA    T1      N1      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}             T2      N1      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}             T3      N1      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}             T4      N0      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}     IIIB    T4      N1      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}             Any T   N2      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}             Any T   N3      M0</p>
          <p>{FLD:X BOX} {FLD:X BOX}     IV      Any T   Any N   M1</p>
          <p>{FLD:X BOX}         STAGE UNKNOWN</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT: HPV Status {FLD:WP 2}</p>
          <p>GRADING SYSTEM	</p>
          <p>				</p>
          <p>{FLD:X BOX} 2 grade system				{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 		        {FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 			{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available  {FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been</p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:X BOX}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:X BOX}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:X BOX}Not Applicable</p>
          <p>{FLD:X BOX}Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some</p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:X BOX}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:X BOX}R0 No residual tumor</p>
          <p>{FLD:X BOX}R1 Microscopic residual tumor</p>
          <p>{FLD:X BOX}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:X BOX}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:X BOX}National guidelines were used in treatment planning </p>
          <p>{FLD:X BOX}NCCN </p>
          <p>{FLD:X BOX}Other (describe):{FLD:WP 2}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Appendix Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>APPENDIX</p>
          <p>(Carcinomas and carcinoid tumors of the appendix are included, but separately </p>
          <p>categorized) </p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p></p>
          <p>CARCINOMA</p>
          <p></p>
          <p>CLIN PATH            PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      TX  Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      T0  No evidence of primary tumor</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      Tis Carcinoma in situ, intraepithelial or       </p>
          <p>				 invasion of lamina propria*</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      T1  Tumor invades submucosa</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      T2  Tumor invades muscularis propria</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      T3  Tumor invades thru muscularis </p>
          <p>				 propria into subserosa, or into mesoappendix</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      T4  Tumor penetrates visceral </p>
          <p>				 peritoneum, including mucinous peritoneal tumor </p>
          <p>within </p>
          <p>                    the right lower quadrant and/or directly </p>
          <p>                    invades other organs or structures**,***</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      T4a Tumor penetrates visceral peritoneum, </p>
          <p>                    including mucinous peritoneal tumor within the right 	</p>
          <p>				 lower quadrant</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      T4b Tumor directly invades other organs or 	</p>
          <p>				 structures</p>
          <p></p>
          <p></p>
          <p>* Tis includes cancer cells confined within the glandular basement</p>
          <p>membrane (intraepithelial) or lamina propria (intramucosal) with no</p>
          <p>extension through the muscularis mucosae into the submucosa.</p>
          <p>** Direct invasion in T4 includes invasion of the other segments of the </p>
          <p>colorectum by way of the serosa, e.g. invasion of ileum.</p>
          <p>*** Tumor that is adherent to other organs or structures, grossly, is </p>
          <p>classified cT4b. However, if no tumor is present in the adhesion, </p>
          <p>microscopically, the classification should be pT1-3 depending on the </p>
          <p>anatomical depth of wall invasion.</p>
          <p></p>
          <p>CARCINOID </p>
          <p>CLIN   PATH            PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      TX   Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      T0   No evidence of primary tumor</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      T1   Tumor 2cm or less in greatest	dimension</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      T1a  Tumor 1cm or less in greatest dimension</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      T1b  Tumor more than 1cm but not more than 2cm </p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      T2   Tumor more than 2cm but not more than 4cm</p>
          <p>                  or with extension to the cecum</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      T3   Tumor more than 4cm or with extension to </p>
          <p>			    the ileum</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      T4   Tumor directly invades other adjacent 	</p>
          <p>			    organs or structures, e.g., abdominal wall and </p>
          <p>                         skeletal muscle*</p>
          <p>*Tumor that is adherent to other organs or structures, grossly, is classified </p>
          <p>cT4.  However, if no tumor is present in the adhesion, microscopically, the </p>
          <p>classification should be classified pT1-3 depending on the anatomical depth </p>
          <p>of wall invasion.</p>
          <p></p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>               CARCINOMA</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      NX   Regional lymph nodes cannot be assessed</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      N0   No regional lymph node metastasis</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      N1   Metastasis in 1 to 3 regional nodes</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      N2   Metastasis in 4 or more regional lymph 	</p>
          <p>			   nodes</p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>               CARCINOID</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      N1      Regional lymph node metastasis</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>               CARCINOMA</p>
          <p>{FLD:AJCC X}          M0      No distant metastasis (no pathologic M0; </p>
          <p>					use clinical M to complete stage group) </p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      M1      Distant metastasis</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      M1a     Intraperitoneal metastasis beyond </p>
          <p>					the right lower quadrant, including </p>
          <p>pseudomyxoma </p>
          <p>                        peritonei</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      M1b     Non-peritoneal metastasis</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>               CARCINOID</p>
          <p>{FLD:AJCC X}          M0      No distant metastasis (no pathologic M0; </p>
          <p>					use clinical M to complete stage group) </p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    STAGE GROUPING</p>
          <p>CARCINOMA</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      0       Tis     N0      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      I       T1      N0      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}              T2      N0      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      IIA     T3      N0      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      IIB     T4a     N0      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      IIC     T4b     N0      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      IIIA    T1      N1      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}              T2      N1      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      IIIB    T3      N1      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}              T4      N1      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      IIIC    Any T   N2      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      IVA     Any T   N0      M1a  G1</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      IVB     Any T   N0      M1a  G2,3</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}              Any T   N1      M1a  Any G</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}              Any T   N2      M1a  Any G</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      IVC     Any T   Any N   M1b  Any G</p>
          <p>{FLD:AJCC X}         UNKNOWN STAGE</p>
          <p></p>
          <p>CLIN   PATH    STAGE GROUPING</p>
          <p>CARCINOID</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      I       T1      N0      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      II      T2,3    N0      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      III     T4      N0      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}              Any T   N1      M0</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}      IV      Any T   Any N   M1</p>
          <p>{FLD:AJCC X}         UNKNOWN STAGE</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: Grade</p>
          <p>CLINICALLY SIGNIFICANT: Preoperative/Pretreatment carcinoembryonic antigen </p>
          <p>(CEA): Preoperative/Pretreatment CA 19-9: {FLD:AJCC EDIT45}</p>
          <p>Tumor Deposits (TD): {FLD:AJCC EDIT45}</p>
          <p>Microsatellite instability (MSI): {FLD:AJCC EDIT45}</p>
          <p>18q Loss of Heterozygosity (LOH): {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>GRADING SYSTEM	</p>
          <p>		</p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		       {FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		       {FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been</p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X}Not Applicable</p>
          <p>{FLD:AJCC X}Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some</p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:AJCC X}R0 No residual tumor</p>
          <p>{FLD:AJCC X}R1 Microscopic residual tumor</p>
          <p>{FLD:AJCC X}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:AJCC X}National guidelines were used in treatment planning </p>
          <p>{FLD:AJCC X} NCCN </p>
          <p>{FLD:AJCC X} Other (describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Bile Duct -Distal Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>BILE DUCT-DISTAL</p>
          <p>(Sarcoma and carcinoid tumors are not included)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:X BOX}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:X BOX}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:{FLD:AJCC EDIT45}</p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis     Carcinoma in situ</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor confined to the bile duct </p>
          <p>				    histologically</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor invades beyond the wall of the </p>
          <p>				    bile duct</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Tumor invades the gallbladder, </p>
          <p>				    pancreas, duodenum or other adjacent organs without 	</p>
          <p>				    involvement of the celiac axis, or the superior 		</p>
          <p>				    mesenteric artery</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      Tumor invades celiac axis, or the </p>
          <p>				    superior mesenteric artery</p>
          <p>NOTE:  Broad pushing penetration (invasion) is permitted - destructive </p>
          <p>invasion is against this diagnosis.</p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph nodes cannot be </p>
          <p>				    assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X} UNKNOWN STAGE</p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}             M0      No distant metastasis (no pathologic M0; </p>
          <p>                       use clinical M to complete stage group) </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis</p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0       Tis     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IA      T1      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IB      T2      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIA     T3      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIB     T1      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     III     T4      Any N   M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IV      Any T   Any N   M1</p>
          <p>{FLD:AJCC X} UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : {FLD:AJCC X}None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>   Tumor location: {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>   Carcinoembryonic antigen (CEA):{FLD:AJCC EDIT45}</p>
          <p></p>
          <p>   CA 19-9: {FLD:AJCC EDIT45}</p>
          <p></p>
          <p></p>
          <p>GRADING SYSTEM</p>
          <p></p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>Checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X} Not Applicable</p>
          <p>{FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X} RX  Presence of residual tumor cannot be assessed.</p>
          <p>{FLD:AJCC X} R0  No residual tumor</p>
          <p>{FLD:AJCC X} R1  Microscopic residual tumor</p>
          <p>{FLD:AJCC X} R2  Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}  Clinical stage was used in the treatment planning (describe):</p>
          <p>{FLD:AJCC EDIT45}</p>
          <p>{FLD:AJCC X}  National guidelines were used in treatment planning</p>
          <p>     {FLD:AJCC X} NCCN</p>
          <p>     {FLD:AJCC X} Other(describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. BIle Ducts-Intrahepatics Staging ">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>Bile ducts Intrahepatic</p>
          <p>(Sarcomas and metastatic disease are excluded) </p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:X BOX}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:X BOX}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p></p>
          <p> </p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p> </p>
          <p>{FLD:X BOX}    {FLD:X BOX}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     T0      No evidence of primary tumor</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     Tis     Carcinoma in situ (intraductal tumor)</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     T1      Solitary tumor without vascular </p>
          <p>				    invasion</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     T2a     Solitary tumor with vascular invasion</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     T2b     Multiple tumors with or without </p>
          <p>				    vascular invasion </p>
          <p>{FLD:X BOX}    {FLD:X BOX}     T3      Tumor perforating the visceral </p>
          <p>				    peritoneum or involving the local extra hepatic 		</p>
          <p>				    structures by direct invasion</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     T4      Tumor with periductal invasion</p>
          <p>                       REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     NX      Regional lymph node metastasis cannot </p>
          <p>				    be assessed</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     N0      No regional lymph node metastasis</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     N1      Regional lymph node metastasis present</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:X BOX}            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>{FLD:X BOX}    {FLD:X BOX}     M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     0       Tis     N0      M0</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     I       T1      N0      M0</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     II      T2      N0      M0</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     III     T3      N0      M0</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     IVA     T4      N0      M0</p>
          <p>{FLD:X BOX}    {FLD:X BOX}             Any T   N1      M0</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     IVB     Any T   Any N   M1</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     UNKNOWN STAGE</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Tumor growth pattern: {FLD:WP 2 LINE}</p>
          <p>Primary sclerosing cholangitis: {FLD:WP 2 LINE}</p>
          <p>CA 19-9: {FLD:WP 2 LINE}</p>
          <p>GRADING SYSTEM	</p>
          <p>				</p>
          <p>{FLD:X BOX} 2 grade system				{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 		        {FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 			{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available  {FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been</p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:X BOX}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:X BOX}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:X BOX}Not Applicable</p>
          <p>{FLD:X BOX}Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some</p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:X BOX}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:X BOX}R0 No residual tumor</p>
          <p>{FLD:X BOX}R1 Microscopic residual tumor</p>
          <p>{FLD:X BOX}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:X BOX}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:X BOX}National guidelines were used in treatment planning </p>
          <p>{FLD:X BOX}NCCN </p>
          <p>{FLD:X BOX}Other (describe):{FLD:WP 2 LINE}</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Bile Ducts-Perihilar Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>BILE DUCTS, Perihilar (proximal)</p>
          <p>(Sarcomas and carcinoid tumors are not included)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p> {FLD:X BOX}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:X BOX}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     T0      No evidence of primary tumor</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     Tis     Carcinoma in situ</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     T1      Tumor confined to the bile duct with </p>
          <p>                       extension up to the muscle layer or fibrous </p>
          <p>                       tissue.</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     T2a     Tumor invades beyond the wall of the </p>
          <p>				    bil duct to surrounding adipose tissue</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     T2b     Tumor invades adjacent hepatic </p>
          <p>				    parenchyma.</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     T3      Tumor invades unilateral branches of </p>
          <p>				    the portal vein or hepatic artery</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     T4      Tumor invades main portal vein or its </p>
          <p>                       branches bilaterally; or the common hepatic </p>
          <p>                       artery; or the second-order biliary radicals </p>
          <p>                       bilaterally; or unilateral second-order </p>
          <p>                       biliary radicals with contralateral portal </p>
          <p>                       vein or hepatic artery involvement</p>
          <p>{FLD:X BOX}    {FLD:X BOX} UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     NX      Regional lymph node metastasis cannot </p>
          <p>				    be  assessed</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     N0      No regional lymph node metastasis</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     N1      Regional lymph node metastasis </p>
          <p>				   (including nodes along the cystic duct, common bile </p>
          <p>                       duct, hepatic artery, and portal vein)</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     N2      Metastasis to periaortic, pericaval, </p>
          <p>				    superior mesentery artery, and/or celiac artery lymph </p>
          <p>                       nodes</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:X BOX}             M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>{FLD:X BOX}    {FLD:X BOX}     M1      Distant metastasis</p>
          <p></p>
          <p>                       STAGE GROUPING</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     0       Tis     N0      M0</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     I       T1      N0      M0</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     II      T2a-b   N0      M0</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     IIIA    T3      N0      M0</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     IIIB    T1-3    N1      M0</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     IVA     T4      N0-1    M0</p>
          <p>{FLD:X BOX}    {FLD:X BOX}     IVB     Any T   N2      M0</p>
          <p>{FLD:X BOX}    {FLD:X BOX}             Any T   Any N   M1</p>
          <p>{FLD:X BOX}            UNKNOWN STAGE </p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Tumor location: {FLD:WP 2 LINE}</p>
          <p>Papillary variant: {FLD:WP 2 LINE}</p>
          <p>Tumor growth pattern: {FLD:WP 2 LINE}</p>
          <p>Primary sclerosing cholangitis:{FLD:WP 2 LINE}</p>
          <p>CA 19-9{FLD:WP 2 LINE}</p>
          <p>Carcinoembryonic antigen (CEA): {FLD:WP 2 LINE}</p>
          <p>GRADING SYSTEM	</p>
          <p>				</p>
          <p>{FLD:X BOX} 2 grade system				{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 		        {FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 			{FLD:X BOX}Grade III or 3</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been</p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:X BOX}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:X BOX}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:X BOX}Not Applicable</p>
          <p>{FLD:X BOX}Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some</p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:X BOX}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:X BOX}R0 No residual tumor</p>
          <p>{FLD:X BOX}R1 Microscopic residual tumor</p>
          <p>{FLD:X BOX}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:X BOX}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:X BOX}National guidelines were used in treatment planning </p>
          <p>{FLD:X BOX}NCCN </p>
          <p>{FLD:X BOX}Other (describe):{FLD:WP 2 LINE}</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Bone Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>BONE</p>
          <p>(Primary malignant lymphoma &amp; multiple myeloma are not included)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:AJCC X} y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X} y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size: {FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Laterality:</p>
          <p>          {FLD:AJCC X} Left</p>
          <p>          {FLD:AJCC X} Right</p>
          <p>          {FLD:AJCC X} Bilateral</p>
          <p> </p>
          <p> </p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor 8 cm or less in greatest dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor more than 8 cm in greatest dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Discontinuous tumors in the primary bone site.  </p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph nodes cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Regional lymph node metastasis</p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M0      No distant metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1a     Lung</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1b     Other distant sites</p>
          <p> </p>
          <p>       STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IA      T1      N0      M0      G1,2     Low grade     GX</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IB      T2      N0      M0      G1,2     Low grade     GX</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N0      M0      G1,2     Low grade     GX</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIA     T1      N0      M0      G3,4     High grade</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIB     T2      N0      M0      G3,4     High grade</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     III     T3      N0      M0      G3,4*</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVA     Any T   N0      M1a     Any G</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVB     Any T   N1      Any M   Any G</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Any T   Any N   M1b     Any G</p>
          <p> *Ewing' sarcoma is G4</p>
          <p>{FLD:AJCC X}            Stage Unknown</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING:  None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>     Three dimensions of tumor size {FLD:AJCC EDIT8}x{FLD:AJCC EDIT8}x{FLD:AJCC EDIT8}</p>
          <p>     Percentage necrosis post neoadjuvant systematic therapy </p>
          <p>      from pathology report: {FLD:AJCC EDIT15}</p>
          <p>     Number of resected pulmonary metastases from pathology </p>
          <p>      report: {FLD:AJCC EDIT15}  </p>
          <p></p>
          <p> Histologic Grade (G) (also known as overall grade)</p>
          <p> GRADING SYSTEM </p>
          <p>                                 </p>
          <p>{FLD:AJCC X} 2 grade system                              {FLD:AJCC X}    Grade I or 1</p>
          <p>{FLD:AJCC X} 3 grade system                              {FLD:AJCC X}    Grade II or 2</p>
          <p>{FLD:AJCC X} 4 grade system                              {FLD:AJCC X}    Grade III or 3</p>
          <p>{FLD:AJCC X} No 2,3,or 4 grade system is available       {FLD:AJCC X}    Grade IV or 4</p>
          <p>                                                {FLD:AJCC X}    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X} Not Applicable</p>
          <p>{FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X} RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:AJCC X} R0 No residual tumor</p>
          <p>{FLD:AJCC X} R1 Microscopic residual tumor</p>
          <p>{FLD:AJCC X} R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X} Clinical stage was used in treatment planning (describe): {FLD:AJCC W-P2LINES}</p>
          <p>{FLD:AJCC X} National guidelines were used in treatment planning </p>
          <p>   {FLD:AJCC X} NCCN </p>
          <p>   {FLD:AJCC X} Other (describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Breast Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>BREAST </p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:{FLD:AJCC EDIT45}</p>
          <p>Laterality:</p>
          <p>          {FLD:AJCC X} Left</p>
          <p>          {FLD:AJCC X} Right</p>
          <p>          {FLD:AJCC X} Bilateral</p>
          <p> </p>
          <p>CLIN PATH    PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}  TX   Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}  T0   No evidence of primary tumor</p>
          <p>{FLD:AJCC X} {FLD:AJCC X} Tis   Carcinoma in situ</p>
          <p>{FLD:AJCC X} {FLD:AJCC X} Tis  (DCIS) Ductal carcinoma in situ</p>
          <p>{FLD:AJCC X} {FLD:AJCC X} Tis  (LCIS) Lobular carcinoma in situ</p>
          <p>{FLD:AJCC X} {FLD:AJCC X} Tis  (Paget's) Paget's disease of the         </p>
          <p>	          nipple with no tumor. Note: Paget's disease of the nipple is 	</p>
          <p>			NOT associated with invasive carcinoma and/or carcinoma</p>
          <p>              in situ (DCIS and/or LCIS) in the underlying breast parenchyma.  </p>
          <p>			Carcinomas in the breast parenchyma associated with Paget's 	</p>
          <p>			disease are categorized based on the size and characteristics 	</p>
          <p>			of the parenchymal disease, although the presence of</p>
          <p>              Paget's disease should still be noted.</p>
          <p>{FLD:AJCC X} {FLD:AJCC X} T1   Tumor  &lt;or&gt;20 mm in greatest dimension</p>
          <p>{FLD:AJCC X} {FLD:AJCC X} T1mi Tumor &lt;or&gt;1 mm in greatest dimension</p>
          <p>{FLD:AJCC X} {FLD:AJCC X} T1a  Tumor &gt;1 mm but &lt;or&gt;5 mm in greatest demension</p>
          <p>{FLD:AJCC X} {FLD:AJCC X} T1b  Tumor &gt;5 mm but &lt;or&gt;10 mm ingreatest dimension</p>
          <p>{FLD:AJCC X} {FLD:AJCC X} T1c  Tumor &gt;10 mm but &lt;or&gt;20 mm in greatest 		</p>
          <p>		   dimension</p>
          <p>{FLD:AJCC X} {FLD:AJCC X} T2   Tumor &gt;20 mm buy &lt;or&gt;50 mm in greatest 		</p>
          <p>		   dimension</p>
          <p>{FLD:AJCC X} {FLD:AJCC X} T3   Tumor &gt;50 mm in greatest dimension</p>
          <p>{FLD:AJCC X} {FLD:AJCC X} T4   Tumor of any size with direct extension to the </p>
          <p>                       chest wall and/or skin,(ulceration or skin nodules)*</p>
          <p>{FLD:AJCC X} {FLD:AJCC X} T4a  Extension to chest wall, not including 		</p>
          <p>		   pectoralis</p>
          <p>                       muscle adherence/invasion</p>
          <p>{FLD:AJCC X} {FLD:AJCC X} T4b  Ulceration and/or ipsilateral satellite odules</p>
          <p>                       and/or edema (including peau d/orange) of the</p>
          <p>                       skin which do not meet the criteria for</p>
          <p>                       inflammatory carcinoma</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}  T4c     Both T4a and T4b</p>
          <p>{FLD:AJCC X} {FLD:AJCC X}  T4d     Inflammatory carcinoma**</p>
          <p></p>
          <p>      *Note:  Invasion of the dermis alone does not qualify as T4.</p>
          <p>     **Note:  Inflammatory carcinoma is restricted to cases with typical</p>
          <p>       skin changes involving a third or more of the skin of the breast.</p>
          <p>       while the histologic presence of invasive carcinoma invading </p>
          <p>       dermal lymphatics is supportive to the diagnosis, it is not</p>
          <p>       required nor is dermal lymphatic invasion without typical clinical</p>
          <p>       findings sufficient for a diagnosis of inflammatory breast cancer.</p>
          <p></p>
          <p>CLINICAL               REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}            NX      Regional lymph nodes cannot be assessed</p>
          <p>                       (e.g. previously removed)   </p>
          <p>{FLD:AJCC X}            N0      No regional lymph node metastases</p>
          <p>{FLD:AJCC X}            N1      Metastases to movable ipsilateral level I,II</p>
          <p>                       axillary lymph node(s)</p>
          <p>{FLD:AJCC X}            N2      Metastases in ipsilateral level I, II, </p>
          <p>axillary</p>
          <p>                       lymph nodes that are clinically fixed or matted</p>
          <p>                       or in clinically detected* ipsilateral internal</p>
          <p>                       mammary nodes in the absence of clinically evident </p>
          <p>                       axillary lymph node metastasis </p>
          <p>{FLD:AJCC X}            N2a     Metastases in ipsilateral axillary lymph </p>
          <p>                       nodes fixed to one another (matted) or to </p>
          <p>                       other structures.</p>
          <p>{FLD:AJCC X}            N2b     Metastases only in clinically detected*** </p>
          <p>                       ipsilateral internal mammary nodes and </p>
          <p>                       in the absence of clinically evident </p>
          <p>                       axillary lymph node metastasis.</p>
          <p>{FLD:AJCC X}            N3      Metastases in ipsilateral infraclavicular </p>
          <p>                       (level III axillary) lymph node(s) with or</p>
          <p>                       without level I, II axillary lymph node </p>
          <p>                       involvement or in clinically detected* ipsilateral</p>
          <p>                       internal mammary lymph node(s) with clinically</p>
          <p>                       evident level I, II axillary lymph node </p>
          <p>                       metastases; or metastases in ipsilateral </p>
          <p>                       supraclavicular lymph node(s) with or </p>
          <p>                       without axillary or internal mammary lymph </p>
          <p>                       node involvement.</p>
          <p>{FLD:AJCC X}            N3a     Metastases in ipsilateral infraclavicular </p>
          <p>lymph </p>
          <p>                       node(s.</p>
          <p>{FLD:AJCC X}            N3b     Metastases in ipsilateral internal mammary </p>
          <p>lymph </p>
          <p>                       node(s) and axillary lymph node(s)</p>
          <p>{FLD:AJCC X}            N3c     Metastases in ipsilateral supraclavicular </p>
          <p>lymph </p>
          <p>                       node(s)</p>
          <p>PATHOLOGIC CLASSIFICATION OF LYMPH NODES (pN)</p>
          <p>       {FLD:AJCC X}     pNX     Regional lymph nodes cannot be assessed (e.g. </p>
          <p>                       previously removed or not removed for pathological </p>
          <p>                       study)</p>
          <p>       {FLD:AJCC X}     pN0     No regional lymph node metastasis </p>
          <p>histologically, </p>
          <p>       {FLD:AJCC X}     pN0(i-) No regional lymph node metastasis </p>
          <p>histologically,</p>
          <p>                       negative IHC.</p>
          <p>       {FLD:AJCC X}     pN0(i+) Malignant cells in regional lymph node(s) no</p>
          <p>                       greater than 0.2 mm (detected by H&amp;E or IHC</p>
          <p>                       including ITC)</p>
          <p>       {FLD:AJCC X}    pN0(mol-)No regional lymph node metastasis </p>
          <p>histologically,</p>
          <p>                       negative molecular findings (RT-PCR)</p>
          <p>       {FLD:AJCC X}    pN0(mol+)Positive molecular findings (RT-PCR),but no</p>
          <p>                       Regional lymph node metastases detected by</p>
          <p>                       histology or IHC</p>
          <p>       {FLD:AJCC X}     pN1     Micrometastasis in 1 to 3 axillary lymph node</p>
          <p>(s),</p>
          <p>                       and/or in internal mammary nodes with metastases</p>
          <p>                       detected by sentinel lymph node biopsy but not</p>
          <p>                       clinically detected</p>
          <p>       {FLD:AJCC X}     pN1mi   Micrometastasis (greater than 0.2 mm, and/or </p>
          <p>more</p>
          <p>                       Than 200 cells, but more greater than 2.0 mm)</p>
          <p>       {FLD:AJCC X}   pN1a    Metastasis in 1 to 3 axillary lymph nodes, at </p>
          <p>least</p>
          <p>                       One metastasis greater than 2.0 mm.</p>
          <p>       {FLD:AJCC X}     pN1b    Metastasis in internal mammary nodes with </p>
          <p>                       micrometastases or macrometastases detected by</p>
          <p>                       sentinel lymph node biopsy but not clinically </p>
          <p>                       detected.</p>
          <p>       {FLD:AJCC X}     pN1c    Metastasis in 1 to 3 axillary lymph nodes and </p>
          <p>in </p>
          <p>                       internal mammary lymph nodes with micrometastastes</p>
          <p>                       or macrometastases detected by sentinel lymph node</p>
          <p>                       biopsy by not clinically detected**</p>
          <p>                       but not clinically apparent.</p>
          <p>       {FLD:AJCC X}     pN2     Metastasis in 4 to 9 axillary lymph nodes, or </p>
          <p>in </p>
          <p>                       clinically detected*** internal mammary lymph </p>
          <p>                       nodes in the absence of axillary lymph node</p>
          <p>                       metastasis.</p>
          <p>       {FLD:AJCC X}     pN2a    Metastasis in 4 to 9 axillary lymph nodes (at </p>
          <p>                       least one tumor deposit greater than 2.0mm).</p>
          <p>       {FLD:AJCC X}     pN2b    Metastasis in clinically detected*** internal </p>
          <p>                       mammary lymph nodes in the absence of axillary</p>
          <p>                       lymph node metastases.</p>
          <p>       {FLD:AJCC X}     pN3     Metastasis in 10 or more axillary lymph </p>
          <p>nodes, or </p>
          <p>                       in infraclavicular (level III) lymph nodes, or in</p>
          <p>                       clinically detected*** ipsilateral internal mammary</p>
          <p>                       lymph nodes in the presence of 1 or more positive</p>
          <p>                       level I, II axillary lymph nodes; or in more that 3</p>
          <p>                       axillary lymph nodes and in internal mammary lymph</p>
          <p>                       nodes; with micrometastases or macrometastases</p>
          <p>                       detected by sentinel lymph node biopsy but not</p>
          <p>                       clinically detected***.or in ipsilateral</p>
          <p>                       supraclavicular lymph nodes.</p>
          <p>       {FLD:AJCC X}     pN3a    Metastases in 10 or more axillary lymph nodes </p>
          <p>(at </p>
          <p>                       least one tumor deposit greater than 2.0mm) or </p>
          <p>                       metastases to the infraclavicular (level II)</p>
          <p>                       axillary lymph nodes.</p>
          <p>       {FLD:AJCC X}     pN3b    Metastases in clinically detected*** </p>
          <p>ipsilateral </p>
          <p>                       internal mammary lymph nodes or more than 3</p>
          <p>                       axillary lymph nodes and in internal mammary lymph</p>
          <p>                       nodes with micrometastases or macrometastases</p>
          <p>                       detected by sentinel lymph node biopsy but not </p>
          <p>                       clinically detected***.</p>
          <p>       {FLD:AJCC X}     pN3c    Metastasis in ipsilateral supraclavicular </p>
          <p>lymph </p>
          <p>                       nodes.</p>
          <p>      *Classification is based on axillary lymph node dissection with or</p>
          <p>       without sentinel lymph node biopsy.  Classification based solely on</p>
          <p>       sentinel lymph node biopsy without subsequent axillary lymph node</p>
          <p>       dissection is designated (sn) for "sentinel node, " for example</p>
          <p>       pNO(sn).</p>
          <p>     **Note: Not clinically detected is defined as no0t detected by</p>
          <p>       Imaging studies (excluding lymphoscintigraphy) or not detected</p>
          <p>       by clinical examination.</p>
          <p>    ***Note: Clinically detected is defined as detected by </p>
          <p>       imaging studies (excluding lymphoscintigraphy) or by clinical</p>
          <p>       examination and having characteristics highly suspicious for</p>
          <p>       malignancy or a presumed pathologic macrometastasis based on</p>
          <p>       fine needle aspiration biopsy with cytologic examination.</p>
          <p>       Confirmation of clinically detected metastatic disease by fine</p>
          <p>       needle aspiration without excision biopsy designated with an</p>
          <p>       (f) suffix, for example, cN3a(f).  Excisional biopsy of lymph</p>
          <p>       node or biopsy of a sentinel node, in the absence of assignment</p>
          <p>       of a pT, is classified as a clinical N, for example,cN1.</p>
          <p>       Information regarding the confirmation of the nodal status</p>
          <p>       will be designated in sitespecific factors as clinical, fine needle</p>
          <p>       aspiration, core biopsy, or sentinel lymph node biopsy.  Pathologic</p>
          <p>       classification (pNc) is used for excision or sentinel lymph node</p>
          <p>       biopsy only in conjunction with a pathologic T assignment.</p>
          <p>       Note:  Isolated tumor cell clusters (ITC) are defined as small</p>
          <p>       clusters of cells not greater than 0.2 mm, or single tumor cells,</p>
          <p>       or a cluster of fewer than 200 cells in a single histologic cross</p>
          <p>       section. ITCs may be detected by routine histology or by</p>
          <p>       Immunohistochemical (IHC) methods.  Notes containing only ITCs are</p>
          <p>       excluded from the total positive node count for purposes of N</p>
          <p>       classification but should be included in the total number of nodes</p>
          <p>       evaluated.</p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}            M0      No clinical or radiographic evidence of </p>
          <p>distant</p>
          <p>                       metastases (no pathologic MO;  use clinical M to</p>
          <p>                       complete stage group)</p>
          <p>{FLD:AJCC X}           cM0(i+)  No clinical or radiographic evidence of </p>
          <p>distant</p>
          <p>                       metastases, but deposits of molecularly or</p>
          <p>                       microscopically detected tumor cells in circulating</p>
          <p>                       blood, bone marrow or other non-regional nodal</p>
          <p>                       tissue that are no larger than 0.2 mm in a patient</p>
          <p>                       without symptoms or signs of metastases.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant detectable metastases as</p>
          <p>					determined by	    </p>
          <p>                       classic clinical and radiographic means and/or</p>
          <p>                       histologically proven larger than 0.2 mm.</p>
          <p>                       Biopsy of metastatic site performed [ ]Y [ ]N</p>
          <p>                       Source of pathologic metastatic specimen </p>
          <p>{FLD:AJCC EDIT45}</p>
          <p>                       </p>
          <p>CLIN   PATH    STAGE GROUPING</p>
          <p> </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0       Tis     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IA      T1*     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IB      T0      N1mi    M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1*     N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIA     T0      N1**    M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1*     N1**    M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIB     T2      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIA    T0      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1*     N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIB    T4      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T4      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T4      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIC    Any T   N3      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IV      Any T   Any N   M1</p>
          <p> </p>
          <p> *   T1 includes T1mi</p>
          <p> **  T0 and T1 tumors with nodal micrometastases only are excluded from</p>
          <p>     Stage IIA and are classified Stage IB.</p>
          <p></p>
          <p>{FLD:AJCC X}  Stage Unknown</p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING:  None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p></p>
          <p>Paget's disease:{FLD:AJCC EDIT45}</p>
          <p>Tumor grade (Scarf-Bloom-Richardson system):{FLD:AJCC EDIT45}</p>
          <p>Estrogen receptor and test method (IHC, RTpPCR, other):{FLD:AJCC EDIT45}</p>
          <p>Progesterone receptor and test method (IHC, RT-PCR, other):{FLD:AJCC EDIT45}</p>
          <p>HER2 status and test method (IHC, FISH, CISH, RT-PCR, other):</p>
          <p>{FLD:AJCC EDIT45}</p>
          <p>Method of lymph node assessment (e.g. clinical fine needle aspiration, </p>
          <p>   core biopsy, sentinel lymph node biopsy):{FLD:AJCC EDIT50}</p>
          <p>IHC of regional lymph nodes:{FLD:AJCC EDIT50}</p>
          <p>Molecular studies of regional lymph nodes:{FLD:AJCC EDIT50}</p>
          <p>Distant metastases method of detection (clinical, radiolographic,</p>
          <p>   biopsy){FLD:AJCC EDIT50}</p>
          <p>Circulating Tumor Cells (CTC) and method of detection (RT-PCR,</p>
          <p>   immunomagnetic separation, other):{FLD:AJCC EDIT50}</p>
          <p>Disseminated Tumor Cells (DTC:  bone marrow micrometastases) and method</p>
          <p>   of detection (RT-PCR, immunohistochemical, other):{FLD:AJCC EDIT50}</p>
          <p>Multi-gene signature score:{FLD:AJCC EDIT50}</p>
          <p>Response to neoadjuvant therapy will be collected in the registry but</p>
          <p>   does not affect the post neoadjuvant stage:{FLD:AJCC EDIT45}</p>
          <p></p>
          <p>Histologic Grade (G) (also known as overall grade)</p>
          <p>  Grading system</p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>Checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X} Not Applicable</p>
          <p>{FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X} RX  Presence of residual tumor cannot be assessed.</p>
          <p>{FLD:AJCC X} R0  No residual tumor</p>
          <p>{FLD:AJCC X} R1  Microscopic residual tumor</p>
          <p>{FLD:AJCC X} R2  Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}  Clinical stage was used in the treatment planning (describe):</p>
          <p>{FLD:AJCC EDIT45}</p>
          <p>{FLD:AJCC X}  National guidelines were used in treatment planning</p>
          <p>     {FLD:AJCC X} NCCN</p>
          <p>     {FLD:AJCC X} Other:{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Cervix Uteri Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>CERVIX UTERI</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:X BOX}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:X BOX}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size: {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>CLIN   PATH   TNM     FIGO    PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX              Primary tumor cannot be 	</p>
          <p>				 		  assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0              No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis     *       Carcinoma in situ 			</p>
          <p>						  (preinvasive tumor)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      I       Cervical carcinoma confined </p>
          <p>						  to uterus</p>
          <p>                              (extension to corpus should be disregarded)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1a     IA      Invasive carcinoma diagnosed </p>
          <p>						  only by Microscopy  Stromal invasion with a 	</p>
          <p>						  maximal depth of 5.0 mm measured from the base </p>
          <p>						  of the epithelium and a horizontal spread of</p>
          <p>                               7.0 mm or less. Vascular space involvement,</p>
          <p>                               venous of lymphatic, does not affect</p>
          <p>                               classification.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1a1    IA1     Measured stromal invasion 3 </p>
          <p>						  mm or less in</p>
          <p>                               depth &amp; 7 mm or less in horizontal spread.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1a2    IA2     Measured stromal invasion 	</p>
          <p>						  more than 3 mm</p>
          <p>                               and not more than 5.0 mm with a horizontal</p>
          <p>                               spread 7 mm or less.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1b     IB      Clinically visible lesion 	</p>
          <p>						  confined to the</p>
          <p>                               cervix or microscopic lesion greater than</p>
          <p>                               T1a2/A2</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1b1    IB1     Clinically visible 4.0 cm or </p>
          <p>						  less</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1b2    IB2     Clinically visible more than </p>
          <p>						  4.0 cm</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      II      Cervical carcinoma invades 	</p>
          <p>						  beyond uterus</p>
          <p>                               but not to pelvic wall or lower third of</p>
          <p>                               vagina.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2a     IIA     Tumor without parametrial 	</p>
          <p>						  invasion</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2a1    IIAI    Clinically visible lesion 4 </p>
          <p>						  cm or less in</p>
          <p>                               Greatest dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2b     IIB     Tumor with parametrial 	</p>
          <p>						  invasion</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      III     Tumor extends to pelvic wall </p>
          <p>						  and/or </p>
          <p>                               Involves lower 1/3 of vagina and/or causes</p>
          <p>                               hydronephrosis or nonfunctioning kidney</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3a     IIIA    Tumor involves lower 1/3 	</p>
          <p>						  vagina, no</p>
          <p>                               extension to pelvic wall</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3b     IIIB    Tumor extends s to pelvic 	</p>
          <p>						  wall and/or</p>
          <p>                               causes hydronephrosis or nonfunctioning</p>
          <p>                               kidney</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      IVA     Tumor invades mucosa of the </p>
          <p>						  bladder or</p>
          <p>                               rectum, and/or extends beyond true pelvis</p>
          <p>                               (bullous edema is not sufficient to</p>
          <p>                               classify a tumor as T4.</p>
          <p>    *FIGO staging no longer includes Stage 0 (Tis)</p>
          <p>   **All macroscopically visible lesions - even with superficial invasion</p>
          <p>     Are T1b/IB.</p>
          <p> </p>
          <p>CLIN   PATH    TNM     FIGO   REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}                     Regional lymph nodes cannot </p>
          <p>						  be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0              No regional lymph node 	</p>
          <p>					  	  metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      IIIB    Regional lymph node 		</p>
          <p>						  metastasis</p>
          <p> </p>
          <p>CLIN   PATH    TNM     FIGO    DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M0              No distant metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      IVB     Distant metastasis 		</p>
          <p>						  (including peritoneal</p>
          <p>                               spread, involvement of supraclavicular or</p>
          <p>                               mediastinal lymph nodes, lung, liver, or </p>
          <p>                               bone)</p>
          <p> </p>
          <p>CLIN   PATH            STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0*      Tis     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     I       T1      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IA      T1a     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IA1     T1a1    N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IA2     T1a2    N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IB      T1b     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IB1     T1b1    N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IB2     T1b2    N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     II      T2      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIA     T2a     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIA1    T2a1    N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIA2    T2a2    N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIB     T2b     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     III     T3      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIA    T3a     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIB    T3b     Any N   M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1-3    N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVA     T4      Any N   M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVB     Any T   Any N   M1</p>
          <p> </p>
          <p>    FIGO no longer includes Stage 0 (Tis)</p>
          <p></p>
          <p>{FLD:AJCC X}  Stage Unknown</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING:  None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>    FIGO Stage:{FLD:AJCC EDIT50}</p>
          <p>    Pelvic nodal status and method of assessment:{FLD:AJCC EDIT50}</p>
          <p>    Para-aorfic nodal status and method of assessment:{FLD:AJCC EDIT50}</p>
          <p>Distant (mediastinal, scalene) nodal status and method of assessment</p>
          <p>{FLD:AJCC EDIT50}</p>
          <p>Histologic Grade (G) (also known as overall grade)</p>
          <p>  Grading system</p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>Checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X} Not Applicable</p>
          <p>{FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X} RX  Presence of residual tumor cannot be assessed.</p>
          <p>{FLD:AJCC X} R0  No residual tumor</p>
          <p>{FLD:AJCC X} R1  Microscopic residual tumor</p>
          <p>{FLD:AJCC X} R2  Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}  Clinical stage was used in the treatment planning (describe):</p>
          <p>{FLD:AJCC EDIT45}</p>
          <p>{FLD:AJCC X}  National guidelines were used in treatment planning</p>
          <p>     {FLD:AJCC X} NCCN</p>
          <p>     {FLD:AJCC X} Other(describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Colon and Rectum Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>COLON AND RECTUM</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p> </p>
          <p>(Sarcomas, lymphomas, and carcinoid tumors of the large intestine </p>
          <p>are excluded)</p>
          <p></p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p> </p>
          <p>CLIN   PATH            PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis     Carcinoma in situ, intraepithelial </p>
          <p>				    or invasion of lamina propria*</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor invades submucosa</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor invades muscularis propria</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Tumor invades thru the muscularis </p>
          <p>				    propria into pericolorectal tissues</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4a     Tumor penetrates to the surface of </p>
          <p>				    the visceral peritoneum**</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4b     Tumor directly invades or is </p>
          <p>				    adherent to other organs or structures ^,**</p>
          <p> </p>
          <p>* Note: Includes cancer cells confined within the glandular basement</p>
          <p>membrane (intraepithelial) or mucosal lamina propria (intramucosal) with no </p>
          <p>extension through the muscularis mucosae into the submucosa.</p>
          <p></p>
          <p>^Note: Direct invasion in T4 includes invasion of other organs or </p>
          <p>other segments of the colorectum as a result of direct extension </p>
          <p>through the serosa, as confirmed on microscopic examination (for </p>
          <p>example, invasion of the sigmoid colon by a carcinoma of the cecum) </p>
          <p>or, for cancers in a retro-peritoneal or subperitoneal location, </p>
          <p>direct invasion of other organs or structures by virtue of extension</p>
          <p>beyond the muscularis propria (i.e., respectively, a tumor on the </p>
          <p>posterior wall of the descending colon invading the left kidney or </p>
          <p>lateral abdominal wall; or a mid or distal rectal cancer with </p>
          <p>invasion of prostate, seminal vesicles, cervix or vagina).</p>
          <p></p>
          <p>** Note: Tumor that is adherent to other organs or structures, </p>
          <p>grossly, is classified cT4b. However, if no tumor is present in the </p>
          <p>adhesion, microscopically, the classification should be pT1-4a </p>
          <p>depending on the anatomical depth of wall invasion. The V and</p>
          <p>L classifications should be used to identify the presence or absence </p>
          <p>of vascular or lymphatic invasion whereas the PN site-specific factor should </p>
          <p>be </p>
          <p>used for perineural invasion.</p>
          <p></p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph nodes cannot be </p>
          <p>				    assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Metastasis in 1 to 3 regional nodes</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1a     Metastasis in 1 regional lymph node</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1b     Metastasis in 2-3 regional lymph </p>
          <p>				    nodes </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1c     Tumor deposit(s) in the subserosa, </p>
          <p>				    mesentery,or non-peritonealized pericolic or 		</p>
          <p>			         perirectal tissues without regional nodal metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2      Metastasis in 4 or more regional </p>
          <p>				    lymph nodes</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2a     Metastasis in 4 to 6 regional lymph </p>
          <p>				    nodes</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2b     Metastasis in 7 or more regional </p>
          <p>				    lymph nodes</p>
          <p></p>
          <p>Note: A satellite peritumoral nodule in the pericolorectal adipose </p>
          <p>tissue of a primary carcinoma without histologic evidence of </p>
          <p>residual lymph node in the nodule may represent discontinuous </p>
          <p>spread, venous invasion with extravascular spread (V1/2) or a</p>
          <p>totally replaced lymph node (N1/2). Replaced nodes should be counted </p>
          <p>separately as positive nodes in the N category, whereas </p>
          <p>discontinuous spread or venous invasion should be classified and </p>
          <p>counted in the Site-Specific Factor category Tumor Deposits</p>
          <p>(TD).</p>
          <p></p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}             M0      No distant metastasis (no pathologic M0; </p>
          <p>				    use clinical M to complete stage group) </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1a     Metastasis confined to one organ or </p>
          <p>				    site(e.g. liver, lung, ovary, non-regional node)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1b     Metastasis in more than one </p>
          <p>				    organ/site/or the peritoneum</p>
          <p></p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    STAGE GROUPING                  DUKES*  MAC*</p>
          <p></p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0       Tis     N0      M0      -        -</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     I       T1      N0      M0      A        A</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2      N0      M0               B1</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIA     T3      N0      M0      B        B2</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIB     T4a     N0      M0      B        B2</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIC     T4b     N0      M0      B        B3</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIA    T1-T2   N1/N1C  M0      C        C1</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1      N2a     M0      C        C1</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIB    T3-T4a  N1/N1C  M0      C        C2</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2-T3   N2a     M0      C      C1/C2</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1-T2   N2b     M0      C        C1</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIC    T4a     N2a     M0      C        C2</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3-T4a  N2b     M0      C        C2</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T4b     N1/N2   M0      C        C3</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVA     Any T   Any N   M1a     -        -</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVB     Any T   Any N   M1b     -        -</p>
          <p>{FLD:AJCC X}            STAGE UNKNOWN</p>
          <p></p>
          <p>*Dukes B is a composite of better (T3 N0 M0) and worse (T4 N0 M0) </p>
          <p>Prognostic groups, as is Dukes C (Any TN1 M0 and Any T N2 M0). MAC </p>
          <p>is the modified Astler-Coller classification.</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT: Preoperative/Pretreatment </p>
          <p>carcinoembryonic antigen (CEA): {FLD:AJCC EDIT50}</p>
          <p>Tumor Deposits (TD): {FLD:AJCC EDIT45}</p>
          <p>Circumferential Resection Margin (CRM): {FLD:AJCC EDIT45}</p>
          <p>Perineural Invasion (PN): {FLD:AJCC EDIT45}</p>
          <p>Microsatellite instability (MSI): {FLD:AJCC EDIT45}</p>
          <p>Tumor Regression Grade (with neoadjuvant </p>
          <p>therapy): {FLD:AJCC EDIT45}</p>
          <p>KRAS gene analysis: {FLD:AJCC EDIT45}</p>
          <p>18q Loss of Heterozygosity (LOH) assay: {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>GRADING SYSTEM	</p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or </p>
          <p>				</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been</p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X}Not Applicable</p>
          <p>{FLD:AJCC X}Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some</p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:AJCC X}R0 No residual tumor</p>
          <p>{FLD:AJCC X}R1 Microscopic residual tumor</p>
          <p>{FLD:AJCC X}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:AJCC X}National guidelines were used in treatment planning </p>
          <p>{FLD:AJCC X}NCCN </p>
          <p>{FLD:AJCC X}Other (describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Conjuncitiva Carcinoma Staging ">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>CONJUNCTIVA CARCINOMA</p>
          <p>Note: excludes melanoma and malignancies other than carcinoma.</p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p></p>
          <p>CLIN  PATH     PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX   Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0   No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis  Carcinoma in situ</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1   Tumor 5 mm or less in greatest </p>
          <p>				 dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2   Tumor more than 5 mm in greatest </p>
          <p>				 dimension, without nvasion of adjacent structures</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3   Tumor invades adjacent structures </p>
          <p>				 (excluding the orbit)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4   Tumor invades the orbit with or without </p>
          <p>				 furtherextension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4a  Tumor invades orbital soft tissues, </p>
          <p>				 without bone invasion</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4b  Tumor invades bone</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4c  Tumor invades adjacent paranasal</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4d  Tumor invades brain</p>
          <p></p>
          <p>               REGIONAL LYMPH NODES  (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX   Regional lymph nodes cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0   No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1   Regional lymph node metastasis</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}             M0   No distant metastasis (no pathologic M0; use </p>
          <p>                    clinical M to complete stage group)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1   Distant metastasis</p>
          <p></p>
          <p>               STAGE GROUPING:</p>
          <p>No stage grouping is presently recommended by AJCC</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT: Ki-67 growth fraction</p>
          <p></p>
          <p>GRADING SYSTEM       </p>
          <p>                           </p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X}Not Applicable</p>
          <p>{FLD:AJCC X}Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:AJCC X}R0 No residual tumor</p>
          <p>{FLD:AJCC X}R1 Microscopic residual tumor</p>
          <p>{FLD:AJCC X}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:AJCC X}National guidelines were used in treatment planning </p>
          <p>   {FLD:AJCC X}NCCN </p>
          <p>   {FLD:AJCC X}Other (describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Esophagus Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>ESOPHAGUS AND ESOPHAGOGASTRIC JUNCTION</p>
          <p>(Nonmucosal cancers are not included)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p> </p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH            PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis     High grade dysplasia*</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor invades lamina propria, 		</p>
          <p>			  	    muscularis cosae, or submucosa</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1a     Tumor invades lamina propria or </p>
          <p>				    muscularis mucosae</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1b     Tumor invades submucosa </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor invades muscularis propria</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Tumor invades adventitia</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      Tumor invades adjacent structures</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4a     Resectable tumor invading pleura, </p>
          <p>                       pericardium, or diaphragm</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4b     Unresectable tumor invading other </p>
          <p>				    adjacent structures, such as aorta, vertebral body, </p>
          <p>                       trachea, etc.</p>
          <p></p>
          <p>*High-grade dysplasia includes all non-invasive neoplastic </p>
          <p>epithelium that was formerly called carcinoma in situ, a diagnosis </p>
          <p>that is no longer used for columnar mucosae anywhere in the </p>
          <p>gastrointestinal tract.</p>
          <p></p>
          <p>                       REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph nodes cannot be </p>
          <p>				    assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Regional lymph node mets involving </p>
          <p>				    1-2 nodes</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2      Regional lymph node mets involving </p>
          <p>				    3-6 nodes</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N3      Regional lymph node mets involving 7 </p>
          <p>				    or more nodes</p>
          <p></p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}             M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X} ]   M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p>SQUAMOUS CELL CARCINOMA</p>
          <p>                                                      </p>
          <p>CLIN  PATH  STAGE GROUPING      GRADE   LOCATION TUMOR</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}   0     Tis(HGD)N0     M0     1        Any</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}   IA    T1      N0     M0     1,X      Any</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}   IB    T1      N0     M0     2-3      Any</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}         T2-3    N0     M0     1,X    Lower,X   </p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}  IIA    T2-3    N0     M0     1,X  Upper, Middle     </p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}         T2-3    N0     M0     2-3  Lower,X</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}  IIB    T2-3    N0     M0     2-3  Upper,Middle     </p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}         T1-2    N1     M0     Any      Any</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}  IIIA   T1-2    N2     M0     Any      Any</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}         T3      N1     M0     Any      Any</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}         T4a     N0     M0     Any      Any</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}  IIIB   T3      N2     M0     Any      Any</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}  IIIC   T4a     N1-2   M0     Any      Any</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}         T4b     Any    M0     Any      Any</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}         Any     N3     M0     Any      Any</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}  IV     Any     Any    M1     Any      Any</p>
          <p>{FLD:AJCC X}            UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>ADENOCARCINOMA</p>
          <p>* or mixed histology including a squamous component or NOS</p>
          <p>** Location of the primary cancer site is defined by the position of theupper </p>
          <p>(proximal) edge of the tumor in the esophagus</p>
          <p>                                                      </p>
          <p>CLIN   PATH    STAGE GROUPING                GRADE</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0       Tis(HGD)N0     M0     1,X</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IA      T1      N0     M0     1-2,X</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IB      T1      N0     M0     3</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2      N0     M0     1-2,X</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIA     T2      N0     M0     3</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIB     T3      N0     M0     Any</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1-2    N1     M0     Any</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIA    T1-2    N2     M0     Any</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N1     M0     Any</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T4a     N0     M0     Any</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIB    T3      N2     M0     Any</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIC    T4a     N1-2   M0     Any</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T4b     Any    M0     Any</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Any     N3     M0     Any</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IV      Any     Any    M1     Any</p>
          <p>{FLD:AJCC X}            UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>SQUAMOUS CELL CARCINOMA</p>
          <p></p>
          <p>REQUIRED FOR STAGING: </p>
          <p>Location-based on the position of the upper (proximal) edge of the tumor in </p>
          <p>the </p>
          <p>esophagus (Upper or middle-cancers above lower border of interior pulmonary </p>
          <p>vein; </p>
          <p>Lower-below inferior pulmonary vein)</p>
          <p></p>
          <p>Grade: {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Distance to proximal edge of tumor from incisors: {FLD:AJCC EDIT45}</p>
          <p>Distance to distal edge of tumor from incisors: {FLD:AJCC EDIT45}</p>
          <p>Number of regional nodes with extracapsular tumor: {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>ADENOCARCINOMA</p>
          <p>REQUIRED FOR STAGING: </p>
          <p>Grade: {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Distance to proximal edge of tumor from incisors: {FLD:AJCC EDIT45}</p>
          <p>Distance to distal edge of tumor from incisors: {FLD:AJCC EDIT45}</p>
          <p>Number of regional nodes with extracapsular tumor: {FLD:AJCC EDIT45}</p>
          <p></p>
          <p></p>
          <p></p>
          <p>GRADING SYSTEM	</p>
          <p>				</p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been</p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X}Not Applicable</p>
          <p>{FLD:AJCC X}Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some</p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p>{FLD:AJCC X}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:AJCC X}R0 No residual tumor</p>
          <p>{FLD:AJCC X}R1 Microscopic residual tumor</p>
          <p>{FLD:AJCC X}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:AJCC X}National guidelines were used in treatment planning </p>
          <p>{FLD:AJCC X}NCCN </p>
          <p>{FLD:AJCC X}Other (describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Eyelid Carcinoma Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>EYELID CARCINOMA</p>
          <p></p>
          <p>7th Edition AJCC Cancer Staging Manual</p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Clin    Path    PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    TX   Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    TO   No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    Tis  Carcinoma in situ</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    T1   Tumor 5mm or less in greatest dimension</p>
          <p>                   not invading the tarsal plate or eyelid margin, </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    T2a  Tumor more than 5mm, but not more than </p>
          <p>				10mm in greatest dimension. Or, any tumor that invades the </p>
          <p>                   tarsal plate or eyelid margin.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    T2b  Tumor more than 10mm, but not more than </p>
          <p>				20mm in  greatest dimension. Or, involves full thickness </p>
          <p>                   eyelid.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    T3a  Tumor more than 20mm in greatest </p>
          <p>				dimension.Or, any tumor that invades adjacent ocular, or </p>
          <p>                   orbital structures. Any T with perineural tumor </p>
          <p>                   invasion.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    T3b  Tumor complete resection requires </p>
          <p>				enucleation, exenteration or bone resection.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    T4   Tumor is not resectable due to extensive </p>
          <p>				invasion of ocular, orbital, craniofacial structures or </p>
          <p>                   brain.</p>
          <p></p>
          <p>                REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    NX   Regional lymph nodes cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    NO   No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    N1   Regional lymph node metastasis</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}              M0   No distant metastasis (no pathologic M0; use </p>
          <p>                     clinical M to complete stage group)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}      M1   Distant metastasis</p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}   0      Tis     N0     M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}   IA     T1      N0     M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}   IB     T2a     N0     M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}   IC     T2b     N0     M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}   II     T3a     N0     M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}   III A  T3b     N0     M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}   III B  Any T   N1     M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}   III C  T4      Any N  M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}   IV     Any T   Any N  M1</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}   Stage unknown</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: Grade</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>  Sentinel Lymph Node Biopsy (SLNB) results: </p>
          <p>  Regional nodes identified on clinical or radiographic examination:</p>
          <p>  Perineural invasion: </p>
          <p>  Tumor necrosis: </p>
          <p>  Pagetoid spread: </p>
          <p>  More than 3 Mohs micrographic surgical layers required: </p>
          <p>  Immunosuppression - patient has HIV: </p>
          <p>  Immunosuppression - history of solid organ transplant or leukemia: </p>
          <p>  Prior radiation to the tumor field: </p>
          <p>  Excluding skin cancer, patient has history of two or more carcinomas: </p>
          <p>  Patient has Muir-Torre syndrome:</p>
          <p>  Patient has xeroderma pigmentosa: </p>
          <p></p>
          <p>For Eyelid Cutaneous Squamous Cell Carcinoma only (see cSCC, Chapter </p>
          <p>29):</p>
          <p>REQUIRED FOR STAGING:</p>
          <p>    Tumor thickness (in mm): {FLD:AJCC EDIT45}</p>
          <p>    Clark's Level: {FLD:AJCC EDIT45}</p>
          <p>    Presence / absence of perineural invasion:{FLD:AJCC EDIT45} </p>
          <p>    Primary site location on ear or non-glabrous lip:{FLD:AJCC EDIT45} </p>
          <p>    Histologic grade: {FLD:AJCC EDIT45}</p>
          <p>    Size of largest lymph node metastasis: {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>GRADING SYSTEM       </p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X}Not Applicable</p>
          <p>{FLD:AJCC X}Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:AJCC X}R0 No residual tumor</p>
          <p>{FLD:AJCC X}R1 Microscopic residual tumor</p>
          <p>{FLD:AJCC X}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:AJCC X}National guidelines were used in treatment planning </p>
          <p>   {FLD:AJCC X}NCCN </p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Fallopian Tube Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>FALLOPIAN TUBE</p>
          <p></p>
          <p>7th Edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH   TNM     FIGO    PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX             Primary tumor cannot be </p>
          <p>					   	 assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0             No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis     *      Carcinoma in situ (limited to </p>
          <p>						 tubal mucosa)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      I      Tumor limited to the </p>
          <p>						 fallopian tube(s)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1a     IA     Tumor limited to one tube, </p>
          <p>						 without </p>
          <p>                              penetrating the serosal surface; no </p>
          <p>                              ascites</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1b     IB     Tumor limited to both tubes, </p>
          <p>						 without penetrating the serosal surface; no </p>
          <p>                              ascites</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1c     IC     Tumor limited to one or both </p>
          <p>						 tubes with extension onto or through the tubal </p>
          <p>                              serosa, or with malignant cells in </p>
          <p>                              ascites or peritoneal washings</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      II     Tumor involves one or both </p>
          <p>						 fallopian tubes with pelvic extension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2a     IIA    Extension and/or metastasis </p>
          <p>						 to the uterus and/or ovaries</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2b     IIB    Extension to other pelvic </p>
          <p>						 structures</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2c     IIC    Pelvic extension with </p>
          <p>						 malignant cells in ascites or peritoneal 		</p>
          <p>						 washings</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      III    Tumor involves one or both </p>
          <p>						 fallopian tubes, with peritoneal implants 		</p>
          <p>						 outside the pelvis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3a     IIIA   Microscopic peritoneal </p>
          <p>						 metastasis outside the pelvis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3b     IIIB   Macroscopic peritoneal </p>
          <p>						 metastasis outside the pelvis 2 cm or less in 	</p>
          <p>						 greatest dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3c     IIIC   Peritoneal metastasis outside </p>
          <p>						 the pelvis and more than 2 cm in diameter</p>
          <p></p>
          <p>* FIGO no longer includes Stage 0 (Tis)</p>
          <p>Note: Liver capsule metastasis is T3/Stage III; liver parenchymal </p>
          <p>Metastasis is M1/Stage IV. Pleural effusion must have positive cytology for </p>
          <p>M1/Stage IV.</p>
          <p></p>
          <p>                              REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX             Regional lymph nodes cannot </p>
          <p>be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0             No regional lymph node </p>
          <p>metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1             Regional lymph node </p>
          <p>metastasis</p>
          <p></p>
          <p>                              DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}             M0             No distant metastasis (no pathologic </p>
          <p>M0; </p>
          <p>                              use clinical M to complete stage group)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1             Distant metastasis</p>
          <p></p>
          <p>CLIN   PATH   TNM     STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0*     Tis      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     I      T1       N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IA     T1a      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IB     T1b      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IC     T1c      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     II     T2       N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIA    T2a      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIB    T2b      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIC    T2c      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     III    T3       N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIA   T3a      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIB   T3b      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIC   T3c      N0      M0</p>
          <p>                      Any T    N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IV     Any T    Any N   M1</p>
          <p></p>
          <p>*FIGO no longer includes Stage 0 (Tis)</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>FIGO Stage: {FLD:AJCC EDIT45}</p>
          <p>Tumor location :{FLD:AJCC EDIT45} (fimbria, isthmus, unknown)</p>
          <p>Pelvic and paraaortic nodal status: </p>
          <p>  Pelvic-{FLD:AJCC EDIT45}</p>
          <p>  Paraaortic {FLD:AJCC EDIT45}</p>
          <p> (report as number of nodes removed/number of nodes involved with  tumor)</p>
          <p></p>
          <p>GRADING SYSTEM       </p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p>                           </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X}Not Applicable</p>
          <p>{FLD:AJCC X}Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:AJCC X}R0 No residual tumor</p>
          <p>{FLD:AJCC X}R1 Microscopic residual tumor</p>
          <p>{FLD:AJCC X}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:AJCC X}National guidelines were used in treatment planning </p>
          <p>   {FLD:AJCC X}NCCN </p>
          <p>   {FLD:AJCC X}Other (describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Gallbladder Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>GALLBLADDER</p>
          <p>(Carcinoid tumors and sarcomas are not included)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:{FLD:AJCC EDIT45}</p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis     Carcinoma in situ</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor invades lamina propria or     </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1a     Tumor invades lamina propria</p>
          <p>	                  muscular layer</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1b     Tumor invades muscular layer </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor invades perimuscular </p>
          <p>			 onnective tissue; no extension beyond serosa or into 	</p>
          <p>			 liver</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3     Tumor perforates the serosa(visceral </p>
          <p>			peritoneum) and/or one other adjacent organ or      			</p>
          <p>			structure, such as the stomach, duodenum, colon, 		</p>
          <p>			pancreas, omentum, or extrahepatic bile ducts</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      Tumor invades main portal vein or    </p>
          <p>			hepatic artery or invades two or more extrahepatic organs or 	</p>
          <p>	      	        structures</p>
          <p></p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph nodes cannot be 	</p>
          <p>			 assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Metastases to nodes along the cystic </p>
          <p>			 duct, common bile duct, hepatic artery, and/or portal vein</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2      Metastases to periaotic, pericaval, </p>
          <p>			 superior mesentery artery and/or 						</p>
          <p>		         celiac artery lymph nodes</p>
          <p></p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}             M0      No distant metastasis (no pathologic M0;</p>
          <p>                         use clinical M to complete stage group) </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p>Distant metastasis</p>
          <p>               STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0       Tis     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     I       T1      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     II      T2      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIA    T3      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIB    T1-3    N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVA     T4      N0-1    M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVB     Any T   N2      M0</p>
          <p>                       Any T   Any N   M1</p>
          <p>{FLD:AJCC X} UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : {FLD:AJCC X} None</p>
          <p></p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>   Tumor location: {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>   Specimen type: {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>   Extent of liver resection: {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>   Free peritoneal side vs hepatic side for T2: {FLD:AJCC EDIT45}</p>
          <p></p>
          <p></p>
          <p>GRADING SYSTEM</p>
          <p></p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>Checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X} Not Applicable</p>
          <p>{FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X} RX  Presence of residual tumor cannot be assessed.</p>
          <p>{FLD:AJCC X} R0  No residual tumor</p>
          <p>{FLD:AJCC X} R1  Microscopic residual tumor</p>
          <p>{FLD:AJCC X} R2  Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}  Clinical stage was used in the treatment planning (describe):</p>
          <p>{FLD:AJCC EDIT45}</p>
          <p>{FLD:AJCC X}  National guidelines were used in treatment planning</p>
          <p>     {FLD:AJCC X} NCCN</p>
          <p>     {FLD:AJCC X} Other(describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Gastrointestinal Stromal Tumor Staging ">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>GASTROINTESTINAL STROMAL TUMOR</p>
          <p>(This staging system is new for the seventh edition)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:{FLD:AJCC EDIT45}</p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor 2 cm or less</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor more than 2 cm but not more </p>
          <p>than 5 cm</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Tumor more than 5 cm but not more </p>
          <p>than 10 cm</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      Tumor more than 10 cm in greatest </p>
          <p>dimension</p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph nodes cannot be </p>
          <p>assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Regional lymph node metastasis</p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}             M0      No distant metastasis (no pathologic M0;</p>
          <p>                       use clinical M to complete stage group) </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis</p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>               GASTRIC GIST                 MITOTIC RATE</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IA      T1      N0      M0   Low</p>
          <p>                         T2      N0      M0   Low</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IB      T3      N0      M0   Low</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     II      T1      N0      M0   HIGH</p>
          <p>                         T2      N0      M0   HIGH</p>
          <p>                         T4      N0      M0   Low</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIA    T3      N0      M0   HIGH</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIB    T4      N0      M0   HIGH</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IV      Any T   N1      M0   Any rate</p>
          <p>                       Any T   Any N   M1   Any rate</p>
          <p>{FLD:AJCC X} UNKNOWN STAGE</p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>               SMALL INTESTINE GIST         MITOTIC RATE</p>
          <p>              (also used for Esophagus, Colorectal and Peritoneum)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IA      T1      N0      M0   Low</p>
          <p>                         T2      N0      M0   Low</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     II      T3      N0      M0   Low</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIA    T1      N0      M0   HIGH</p>
          <p>                         T4      N0      M0   Low</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIB    T2      N0      M0   HIGH</p>
          <p>                         T3      N0      M0   HIGH</p>
          <p>                         T4      N0      M0   HIGH</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IV      Any T   N1      M0   Any rate</p>
          <p>                       Any T   Any N   M1   Any rate</p>
          <p>{FLD:AJCC X}                    UNKNOWN STAGE</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : Mitotic Rate</p>
          <p></p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>KIT Immunohistochemistry: {FLD:AJCC EDIT45}</p>
          <p>Mutational status of KIT, PDGFRA: {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>GRADING SYSTEM: For GIST the Grade is replaced by mitotic activity</p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>Checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X} Not Applicable</p>
          <p>{FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X} RX  Presence of residual tumor cannot be assessed.</p>
          <p>{FLD:AJCC X} R0  No residual tumor</p>
          <p>{FLD:AJCC X} R1  Microscopic residual tumor</p>
          <p>{FLD:AJCC X} R2  Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}  Clinical stage was used in the treatment planning (describe):</p>
          <p>{FLD:AJCC EDIT45}</p>
          <p>{FLD:AJCC X}  National guidelines were used in treatment planning</p>
          <p>     {FLD:AJCC X} NCCN</p>
          <p>     {FLD:AJCC X} Other(describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Gestational Trophoblastic Tumor Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>GESTATIONAL TROPHOBLASTIC TUMORS </p>
          <p></p>
          <p>7th Edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH   TNM  FIGO  Primary Tumor (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    TX         Primary tumor cannot be assessed </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    T0         No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    T1   I     Tumor confined to uterus</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    T2   II    Tumor extends to other genital </p>
          <p>structures </p>
          <p>                         (ovary, tube, vagina, broad ligaments)by </p>
          <p>                         metastasis or direct extension</p>
          <p></p>
          <p>              REGIONAL LYMPH NODES (N)</p>
          <p>There is no regional nodal designation in the staging of these tumors. </p>
          <p>Nodal metastases should be classified as metastatic (M1) disease.</p>
          <p></p>
          <p>              DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}            M0         No distant metastasis (no pathologic M0; </p>
          <p>use </p>
          <p>                         clinical M to complete stage group)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1         Distant metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1a        Lung metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1b        All other distant metastasis</p>
          <p></p>
          <p>              STAGE GROUPING </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    Stage   T        M        RISK SCORE </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    I       T1       M0       Unknown </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    IA      T1       M0       Low risk</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    IB      T1       M0       High risk</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    II      T2       M0       Unknown</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    IIA     T2       M0       Low risk</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    IIB     T2       M0       High risk</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    III     Any T    M1a      Unknown</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    IIIA    Any T    M1a      Low risk</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    IIIB    Any T    M1a      High risk</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    IV      Any T    M1b      Unknown</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    IVA     Any T    M1b      Low risk</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    IVB     Any T    M1b      High risk</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: Prognostic Risk Scoring Index</p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>  REQUIRED FOR STAGING: Prognostic Risk Scoring Index </p>
          <p>                        __________________________________________________</p>
          <p>                        :                  RISK SCORE </p>
          <p>  ______________________:_________________________________________________</p>
          <p>  PROGNOSTIC FACTOR     :     0      :     1     :     2      :    4 </p>
          <p>  ______________________:____________:___________:____________:___________</p>
          <p>  Age                   :    &lt; 40    : &gt; or = 40 :            : </p>
          <p>  ______________________:____________:___________:____________:___________</p>
          <p>  Antecedent pregnancy  :Hydatidiform: Abortion  :   Term     : </p>
          <p>                        :    mole    :           :  Pregnancy : </p>
          <p>  ______________________:____________:___________:____________:___________</p>
          <p>  Interval months from  :            :           :            : </p>
          <p>     index pregnancy    :   &lt; 4      :   4-6     :   7-12     :   &gt; 12 </p>
          <p>  ______________________:____________:___________:____________:___________</p>
          <p>  Pretreatment hCG      :      3     :   3   4   :    4   5   :       5 </p>
          <p>     (IU/mo)            :   &lt;10      : 10 -10    :  10 -10    :   &gt; 10 </p>
          <p>  ______________________:____________:___________:____________:___________</p>
          <p>  Largest tumor size,   :            :           :            : </p>
          <p>    including uterus    :  &lt; 3 cm    :  3-5 cm   :   &gt; 5 cm   : </p>
          <p>  ______________________:____________:___________:____________:___________</p>
          <p>  Site of metastases    :    Lung    : Spleen,   :  GI tract  :   Brain, </p>
          <p>                        :            : Kidney    :            :   Liver </p>
          <p>  ______________________:____________:___________:____________:___________</p>
          <p>  Number of metastases  :            :           :            : </p>
          <p>    identified          :            :   1-4     :    5-8     :   &gt; 8 </p>
          <p>  ______________________:____________:___________:____________:___________</p>
          <p>  Previous failed       :            :           :   Single   :Two or more</p>
          <p>    chemotherapy        :            :           :    drug    :   drugs </p>
          <p>  ______________________:____________:___________:____________:___________</p>
          <p></p>
          <p>  Low risk is a score of 6 or less. High risk is a score of 7 or greater.</p>
          <p>  TOTAL SCORE:</p>
          <p></p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>FIGO Stage: {FLD:AJCC EDIT50}</p>
          <p></p>
          <p>GRADING SYSTEM       </p>
          <p>                           </p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X}Not Applicable</p>
          <p>{FLD:AJCC X}Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:AJCC X}R0 No residual tumor</p>
          <p>{FLD:AJCC X}R1 Microscopic residual tumor</p>
          <p>{FLD:AJCC X}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:AJCC X}National guidelines were used in treatment planning </p>
          <p>   {FLD:AJCC X}NCCN </p>
          <p>   {FLD:AJCC X}Other (describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Kidney Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>{FLD:AJCC 7TH EDITION HDR}</p>
          <p>AJCC CANCER STAGING 7th EDITION--KIDNEY</p>
          <p></p>
          <p>Type of specimen: {FLD:AJCC EDIT50}</p>
          <p>Histopathologic type: {FLD:AJCC EDIT50}</p>
          <p>Tumor size: {FLD:AJCC EDIT50}</p>
          <p>Laterality: {FLD:AJCC X}Bilateral   {FLD:AJCC X}Left     {FLD:AJCC X}Right</p>
          <p></p>
          <p>PRIMARY TUMOR(T):</p>
          <p>{FLD:AJCC 7TH EDITION CLINICAL STAGING TEXT}                          </p>
          <p>{FLD:AJCC 7TH EDITION PATHOLOGIC STAGING TEXT}</p>
          <p></p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p></p>
          <p>{FLD:AJCC X} y clinical  -                               {FLD:AJCC X} y </p>
          <p>pathologic - </p>
          <p>staging completed                                staging completed</p>
          <p>after neoadjuvant therapy but                    after neoadjuvant therapy</p>
          <p>before subsequent surgery.                       AND subsequent surgery.</p>
          <p>                                              </p>
          <p> {FLD:AJCC X} TX   Primary tumor cannot be assessed               {FLD:AJCC </p>
          <p>X} TX</p>
          <p> {FLD:AJCC X} T0   No evidence of primary tumor                   {FLD:AJCC </p>
          <p>X} T0</p>
          <p> {FLD:AJCC X} T1   Tumor 7 cm or less in greatest dimension,      {FLD:AJCC </p>
          <p>X} T1</p>
          <p>            limited to the kidney</p>
          <p> {FLD:AJCC X} T1a  Tumor 4 cm or less in greatest dimension,      {FLD:AJCC </p>
          <p>X} T1a</p>
          <p>            limited to the kidney</p>
          <p> {FLD:AJCC X} T1b  Tumor more than 4 cm but not more than 7 cm in {FLD:AJCC </p>
          <p>X} T1b</p>
          <p>            greatest dimension limited to the kidney </p>
          <p> {FLD:AJCC X} T2   Tumor more than 7 cm in greatest dimension,    {FLD:AJCC </p>
          <p>X} T2</p>
          <p>            limited to the kidney</p>
          <p> {FLD:AJCC X} T2a  Tumor more than 7 cm but less than or equal to {FLD:AJCC </p>
          <p>X} T2a</p>
          <p>            10 cm in greatest dimension, limited to</p>
          <p>            the kidney</p>
          <p> {FLD:AJCC X} T2b  Tumor more than 10 cm, limited to the kidney   {FLD:AJCC </p>
          <p>X} T2b</p>
          <p> {FLD:AJCC X} T3   Tumor extends into major veins or perinephric  {FLD:AJCC </p>
          <p>X} T3</p>
          <p>            tissues but not into the ipsilateral adrenal</p>
          <p>            gland and not beyond Gerota's fascia</p>
          <p> {FLD:AJCC X} T3a  Tumor grossly extends into the renal vein or   {FLD:AJCC </p>
          <p>X} T3a</p>
          <p>            its segmental (muscle containing) branches,</p>
          <p>            or tumor invades perirenal and/or renal</p>
          <p>            sinus fat but not beyond Gerota's fascia</p>
          <p> {FLD:AJCC X} T3b  Tumor grossly extends into the vena cava below {FLD:AJCC </p>
          <p>X} T3b</p>
          <p>            the diaphragm</p>
          <p> {FLD:AJCC X} T3c  Tumor grossly extends into the vena cava above {FLD:AJCC </p>
          <p>X} T3c</p>
          <p>            the diaphragm or invades the wall of the</p>
          <p>            vena cava</p>
          <p> {FLD:AJCC X} T4   Tumor invades beyond Gerota's fascia(including {FLD:AJCC </p>
          <p>X} T4 </p>
          <p>            contiguous extension into the ipsilateral</p>
          <p>            adrenal gland</p>
          <p></p>
          <p></p>
          <p>REGIONAL LYMPH NODES (N):</p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p></p>
          <p> {FLD:AJCC X} NX   Regional lymph nodes cannot be assessed        {FLD:AJCC </p>
          <p>X} NX</p>
          <p> {FLD:AJCC X} N0   No regional lymph node metastasis              {FLD:AJCC </p>
          <p>X} N0</p>
          <p> {FLD:AJCC X} N1   Regional lymph node metastasis                 {FLD:AJCC </p>
          <p>X} N1</p>
          <p></p>
          <p>DISTANT METASTASIS(M):</p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p> {FLD:AJCC X} M0   No distant metastasis</p>
          <p>      {FLD:AJCC 7TH ED PARANASAL DISTANT METS NOTE}</p>
          <p> {FLD:AJCC X} M1   Distant metastasis                             {FLD:AJCC </p>
          <p>X} M1</p>
          <p></p>
          <p>ANATOMIC STAGE PROGNOSTIC GROUPS:</p>
          <p>Clinical Group     T         N         M       Group   Pathologic</p>
          <p>  {FLD:AJCC X}      I       T1        N0        M0      I           {FLD:AJCC </p>
          <p>X}</p>
          <p>  {FLD:AJCC X}      II      T2        N0        M0      II          {FLD:AJCC </p>
          <p>X}</p>
          <p>  {FLD:AJCC X}      III     T1 or T2  N1        M0      III         {FLD:AJCC </p>
          <p>X}</p>
          <p>                   T3        N0 or N1  M0                  </p>
          <p>  {FLD:AJCC X}      IV      T4        Any N     M0      IV          {FLD:AJCC </p>
          <p>X}</p>
          <p>                   Any T     Any N     M1                  </p>
          <p>  {FLD:AJCC X}                 Stage Unknown                        {FLD:AJCC </p>
          <p>X}</p>
          <p></p>
          <p>Prognostic Factors: (Site-Specific Factors)</p>
          <p>Required for Staging: NONE</p>
          <p>Clinically Significant Factors:</p>
          <p>  Invasion beyond capsule into fat or perisinus tissues: </p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Venous involvement: </p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Adrenal extension:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Fuhrman Grade:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Sarcomatoid features:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Histologic tumor necrosis:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>General Notes:</p>
          <p>For identification of special cases of TNM or pTNM classifications, the "m" </p>
          <p>suffix and "y", "r", and "a" prefixes are used.  Although they do not affect</p>
          <p>the stage grouping, they indicate cases needing separate analysis.</p>
          <p></p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p></p>
          <p> {FLD:AJCC X} m   suffix to indicate the presence of primary      {FLD:AJCC </p>
          <p>X} m</p>
          <p>           tumors in a single site and is recorded</p>
          <p>           in parenthesis: pT(m)NM.</p>
          <p></p>
          <p> {FLD:AJCC X} y   prefix to indicate those cases in which         {FLD:AJCC </p>
          <p>X} y</p>
          <p>           classification is performed during or </p>
          <p>           following initial multimodality therapy.</p>
          <p>           The cTNM or pTNM category is identified</p>
          <p>           by a "y" prefix.  The ycTNM or ypTNM </p>
          <p>           categorizes the extent of tumor actually</p>
          <p>           present at the time of that examination.</p>
          <p>           The "y" categorization is not an estimate</p>
          <p>           of tumor prior to multimodality therapy.</p>
          <p></p>
          <p> {FLD:AJCC X} r   prefix to indicate a recurrent tumor when       {FLD:AJCC </p>
          <p>X} r</p>
          <p>           staged after a disease-free interval and </p>
          <p>           is identified by the "r" prefix: rTNM.</p>
          <p></p>
          <p> {FLD:AJCC X} a   prefix to indicate the stage was determined at  {FLD:AJCC </p>
          <p>X} a</p>
          <p>           autopsy: aTNM.</p>
          <p></p>
          <p>Surgical margins is data field recorded by registrars describing the surgical </p>
          <p>margins of the resected primary site specimen as determined only by the </p>
          <p>pathology report.</p>
          <p></p>
          <p>Neoadjuvant treatment is radiation therapy or systemic therapy (consisting of</p>
          <p>chemotherapy, hormone therapy, or immunotherapy) administered prior to a </p>
          <p>definitive surgical procedure.  If the surgical procedure is not performed,</p>
          <p>the administered therapy no longer meets the definition of neoadjuvant </p>
          <p>therapy.</p>
          <p></p>
          <p>Histologic Grade (G): (also known as overall grade)</p>
          <p></p>
          <p>Grading System                                Grade</p>
          <p> {FLD:AJCC X} 2 grade system                            {FLD:AJCC X} Grade I </p>
          <p>or 1</p>
          <p> {FLD:AJCC X} 3 grade system                            {FLD:AJCC X} Grade II </p>
          <p>or 2</p>
          <p> {FLD:AJCC X} 4 grade system                            {FLD:AJCC X} Grade </p>
          <p>III or 3</p>
          <p> {FLD:AJCC X} No 2, 3, or 4 grade system is available   {FLD:AJCC X} Grade IV </p>
          <p>or 4</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p></p>
          <p>Lypmhatic Vessel Invasion (L) and Venous Invasion (V) have been combined </p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.  The </p>
          <p>College of American Pathologists' (CAP) Checklist should be used as the </p>
          <p>primary </p>
          <p>source.  Other sources may be used in the absence of a Checklist.  Priority </p>
          <p>is </p>
          <p>given to positive results.</p>
          <p></p>
          <p>  {FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>  {FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>  {FLD:AJCC X} Not Applicable</p>
          <p>  {FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p></p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be residual </p>
          <p>tumor at the primary site after treatment because of incomplete resection or </p>
          <p>local and regional disease that extends beyond the limit of ability of </p>
          <p>resection.</p>
          <p></p>
          <p>  {FLD:AJCC X} RX   Presence of residual tumor cannot be assessed</p>
          <p>  {FLD:AJCC X} R0   No Residual Tumor</p>
          <p>  {FLD:AJCC X} R1   Microscopic residual tumor</p>
          <p>  {FLD:AJCC X} R2   Macroscopic residual tumor</p>
          <p></p>
          <p>Additional Information:</p>
          <p></p>
          <p> {FLD:AJCC X}Yes {FLD:AJCC X}No Clinical stage was used in treatment planning </p>
          <p>(describe):</p>
          <p>{FLD:WORD PROCESSING 1 LINE N/R HDB}</p>
          <p></p>
          <p> {FLD:AJCC X}Yes {FLD:AJCC X}No National guidelines were used in treatment </p>
          <p>planning: </p>
          <p>          {FLD:AJCC X}National Comprehensive Cancer Network (NCCN)</p>
          <p>          {FLD:AJCC X}Other (describe):</p>
          <p>{FLD:WORD PROCESSING 1 LINE N/R HDB}</p>
          <p></p>
          <p>{FLD:AJCC 7TH EDITION STAGING ILLUSTRATIONS}</p>
          <p> {FLD:AJCC X}Yes {FLD:AJCC X}No Have you completed the illustration page for </p>
          <p>this AJCC Staging form?</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Lacrimal Gland Carcinoma Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>CARCINOMA OF THE LACRIMAL GLAND</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:{FLD:AJCC EDIT45}</p>
          <p></p>
          <p>Laterality:</p>
          <p> {FLD:AJCC X} Left</p>
          <p> {FLD:AJCC X} Right</p>
          <p> {FLD:AJCC X} Bilateral</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}     T1      Tumor 2 cm or less in greatest 		</p>
          <p>				    dimension, with or without extraglandular extension 	</p>
          <p>				    into the orbital soft tissue.</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}     T2      Tumor more than 2 cm but not more 	</p>
          <p>				    than 4 cm in greatest dimension*</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}     T3      Tumor more than 4 cm in greatest 	</p>
          <p>				    dimension*</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}     T4      Tumor invades periosteum or orbital 	</p>
          <p>				    bone or adjacentstructures </p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}     T4a     Tumor invades periosteum</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}     T4b     Tumor invades orbital bone</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}     T4c     Tumor invades adjacent structures 	</p>
          <p>				    (brain,sinus,pterygoid fossa, temporal fossa)</p>
          <p></p>
          <p>  *As the maximum size of the lacrimal gland is 2cm, T2 and greater tumors</p>
          <p> will usually extend into the orbital soft tissue.</p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}     NX      Regional lymph nodes cannot be 		</p>
          <p>				    assessed</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}     N1      Regional lymph node metastasis</p>
          <p>  </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}           M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>{FLD:AJCC X}   {FLD:AJCC X}     M1      Distant metastasis</p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>No stage grouping is presently recommended</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : {FLD:AJCC X}None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>{FLD:AJCC X} Ki-67 growth fraction {FLD:AJCC EDIT45}</p>
          <p>{FLD:AJCC X} Nuclear NM23 staining {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>GRADING SYSTEM</p>
          <p></p>
          <p>{FLD:X BOX} 2 grade system				{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 		        {FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 			{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available  {FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been</p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:X BOX}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:X BOX}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:X BOX}Not Applicable</p>
          <p>{FLD:X BOX}Unknown/Indeterminate</p>
          <p></p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some</p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:X BOX}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:X BOX}R0 No residual tumor</p>
          <p>{FLD:X BOX}R1 Microscopic residual tumor</p>
          <p>{FLD:X BOX}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:AJCC X}National guidelines were used in treatment planning </p>
          <p>   {FLD:AJCC X}NCCN </p>
          <p>   {FLD:AJCC X}Other (describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Larynx Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>LARYNX </p>
          <p>(Nonepithelial tumors such as those of lymphoid tissue, soft tissue,</p>
          <p>bone and cartilage are not included.)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:AJCC X} y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X} y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:{FLD:AJCC EDIT45}</p>
          <p></p>
          <p> </p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis     Carcinoma in situ</p>
          <p> </p>
          <p>               *****SUPRAGLOTTIS*****</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Limited to 1 subsite w/normal vocal cord mobility.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Invades mucosa of more than one adjacent subsite</p>
          <p>                       of supraglottis or glottis or region outside the </p>
          <p>                       Supraglottis (e.g. mucosa of base of tongue, </p>
          <p>                       vallecula, medial wall of pyriform sinus) without </p>
          <p>                       fixation of the larynx.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Tumor limited to larynx w/vocal cord fixation </p>
          <p>                       and/or invades any of the following: postcricoid area,</p>
          <p>                       pre-epiglottic tissues, paraglottic space, and/or </p>
          <p>                       inner cortex of the thyroid cartilage.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4a     Moderately advanced local disease.</p>
          <p>                         Tumor invades through the thyroid cartilage; </p>
          <p>                         and/or invades beyond the larynx (e.g., trachea, </p>
          <p>                         soft tissues of neck including deep extrinsic muscle </p>
          <p>                         of the tongue, strap muscles, thyroid, or esophagus)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4b     Very advanced local disease.</p>
          <p>                         Tumor invades prevertebral space, encases </p>
          <p>                         carotid artery, or invades mediastinal</p>
          <p>                         structures.</p>
          <p>                       </p>
          <p>               *****GLOTTIS*****</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor limited to vocal cord(s) (may involve</p>
          <p>                       anterior/posterior commissures) with normal</p>
          <p>                       mobility</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1a     Tumor limited to one vocal cord</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1b     Tumor involves both vocal cords</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Extends to supraglottic or subglottis, and/or</p>
          <p>                       with impaired vocal cord mobility</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Tumor limited to the larynx with vocal cord</p>
          <p>                       fixation and/or invades paraglottic space, and/or </p>
          <p>                       inner cortex  of the thyroid cartilage.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4a     Moderately advanced local disease.</p>
          <p>                         Tumor invades through the outer cortex of the </p>
          <p>                         thyroid cartilage and/or invades tissues </p>
          <p>                         beyond the larynx (e.g., trachea, soft tissues</p>
          <p>                         of neck including deep extrinsic muscle of the</p>
          <p>                         tongue, strap muscles, thyroid, or esophagus)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4b    Very advanced local disease.</p>
          <p>                         Tumor invades prevertebral space, encases </p>
          <p>                         carotid artery, or invades mediastinal</p>
          <p>                         structures.</p>
          <p>                       </p>
          <p>               *****SUBGLOTTIS *****</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor limited to the subglottis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Extends to vocal cord w/normal or impaired </p>
          <p>                       mobility</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Limited to larynx with vocal cord fixation</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4a     Moderately advanced local disease.</p>
          <p>                         Tumor invades cricoid or thyroid cartilage </p>
          <p>                         and/or invades tissues beyond the larynx</p>
          <p>                         (e.g., trachea, soft tissues of neck</p>
          <p>                         including deep extrinsic muscles of the</p>
          <p>                         tongue, strap muscles, thyroid, or</p>
          <p>                         esophagus)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4b     Very advanced local disease.</p>
          <p>                         Tumor invades prevertebral space, encases </p>
          <p>                         carotid artery, or invades mediastinal</p>
          <p>                         structures.</p>
          <p>                       </p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph node cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Metastasis in a single ipsilateral node, 3 cm or less</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2      Metastasis in single ipsilat node, &gt;3 cm but not </p>
          <p>                       &gt;6 cm; or multiple ipsilateral nodes, none &gt;6 cm, </p>
          <p>                       or in bilateral or contralat nodes, none &gt;6 cm </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2a     Metastasis in single ipsilat node &gt;3 cm but not &gt;6 cm</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2b     Metastasis in multiple ipsilat nodes, none &gt;6 cm</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2c     Metastasis in bilateral or contralat nodes, none &gt;6 cm</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N3      Metastasis in lymph node &gt;6 cm in greatest dimension</p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}            MX      Presence of distant metastasis cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M0      No distant metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis</p>
          <p> </p>
          <p>STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0       Tis     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     I       T1      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     II      T2      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     III     T3      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVA     T4a     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T4a     N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T4a     N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVB     T4b     Any N   M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Any T   N3      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVC     Any T   Any N   M1</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Size of Lymph Nodes: {FLD:AJCC EDIT50}</p>
          <p>Extracapsular Extension from Lymph Nodes for Head &amp; Neck: {FLD:AJCC EDIT50}</p>
          <p>Head &amp; Neck Lymph Nodes Levels I-III: {FLD:AJCC EDIT50}</p>
          <p>Head &amp; Neck Lymph Nodes Levels IV-V: {FLD:AJCC EDIT50}</p>
          <p>Head &amp; Neck Lymph Nodes Levels VI-VII: {FLD:AJCC EDIT50}</p>
          <p>Other Lymph Node Group: {FLD:AJCC EDIT50}</p>
          <p>Clinical Location of cervical nodes: {FLD:AJCC EDIT50}</p>
          <p>Extracapsular spread (ECS) Clinical: {FLD:AJCC EDIT50}</p>
          <p>Extracapsular spread (ECS) Pathologic: {FLD:AJCC EDIT50}</p>
          <p>Human Papillomavirus (HPV) Status: {FLD:AJCC EDIT50}</p>
          <p>Tumor Thickness: {FLD:AJCC EDIT50}</p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>{FLD:AJCC X} 2 grade system                              {FLD:AJCC X}    Grade I or 1</p>
          <p>{FLD:AJCC X} 3 grade system                              {FLD:AJCC X}    Grade II or 2</p>
          <p>{FLD:AJCC X} 4 grade system                              {FLD:AJCC X}    Grade III or 3</p>
          <p>{FLD:AJCC X} No 2,3,or 4 grade system is available       {FLD:AJCC X}    Grade IV or 4</p>
          <p>                                                {FLD:AJCC X}    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X} Not Applicable</p>
          <p>{FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X} RX  Presence of residual tumor cannot be assessed.</p>
          <p>{FLD:AJCC X} R0  No residual tumor</p>
          <p>{FLD:AJCC X} R1  Microscopic residual tumor</p>
          <p>{FLD:AJCC X} R2  Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}  Clinical stage was used in the treatment planning (describe):{FLD:AJCC W-P INDENT3}</p>
          <p>{FLD:AJCC X}  National guidelines were used in treatment planning:</p>
          <p>     {FLD:AJCC X}  NCCN</p>
          <p>     {FLD:AJCC X}  Other: {FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Lip and Oral Cavity">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>LIP &amp; ORAL CAVITY</p>
          <p>(Nonepithelial tumors such as those of lymphoid tissue, soft</p>
          <p>tissue, bone and cartilage are excluded. Staging for mucosal </p>
          <p>melanoma of the lip and oral cavity is not included in this </p>
          <p>chapter.)  </p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p> </p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:{FLD:AJCC EDIT50}</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis     Carcinoma in situ</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor 2 cm or less in greatest dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor &gt;2 cm but not more than 4 cm</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Tumor &gt;4 cm in greatest dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4a     Moderately advanced local disease*</p>
          <p>                       (lip) Tumor invades through cortical bone, </p>
          <p>                          inferior alveolar nerve, floor of mouth, </p>
          <p>                          or skin of face, i.e., chin or nose.</p>
          <p>                       (oral cavity) Tumor invades adjacent structures</p>
          <p>                          only (e.g., through cortical bone, [mandible </p>
          <p>                          or maxilla] into deep [extrinsic] muscle of </p>
          <p>                          tongue [genioglossus, hyoglossus, palatoglossus, </p>
          <p>                          and styloglossus], maxillary sinus, skin of face) </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4b     Very advanced local disease.</p>
          <p>                       Tumor invades masticator space, pterygoid plates, </p>
          <p>                       or skull base and/or encases internal carotid artery.</p>
          <p></p>
          <p>                *NOTE: Superficial erosion alone of bone/tooth </p>
          <p>                       socket by gingival primary is not sufficient to</p>
          <p>                       classify as T4.</p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph node metastasis cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Metastasis in single ipsilateral node, 3 cm or less.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2      Metastasis in single ipsilateral node &gt;3 cm but not &gt;6cm;</p>
          <p>                       or in multiple ipsilateral nodes, none &gt;6cm; </p>
          <p>                       or in bilateral or contralateral nodes, none &gt;6cm</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2a     Metastasis in single ipsilateral node &gt;3 cm but not &gt;6cm</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2b     Metastasis in multiple ipsilateral nodes, none &gt;6 cm</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2c     Metastasis in bilateral or contralateral nodes, none &gt;6cm</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N3      Metastasis in lymph node &gt;6cm in greatest dimension</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis</p>
          <p></p>
          <p>               STAGE GROUPING  </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0       Tis     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     I       T1      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     II      T2      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     III     T3      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1      N1      M0 </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVA     T4a     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T4a     N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T4a     N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVB     Any T   N3      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T4b     Any N   M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVC     Any T   Any N   M1</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     UNKNOWN STAGE</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT: {FLD:AJCC EDIT50}</p>
          <p>Size of Lymph Nodes: {FLD:AJCC EDIT50}</p>
          <p>Extracapsular Extension from Lymph Nodes for Head &amp; Neck: {FLD:AJCC EDIT50}</p>
          <p>Head &amp; Neck Lymph Nodes Levels I-III: {FLD:AJCC EDIT50}</p>
          <p>Head &amp; Neck Lymph Nodes Levels IV-V: {FLD:AJCC EDIT50}</p>
          <p>Head &amp; Neck Lymph Nodes Levels VI-VII: {FLD:AJCC EDIT50}</p>
          <p>Other Lymph Node Group: {FLD:AJCC EDIT50}</p>
          <p>Clinical Location of cervical nodes: {FLD:AJCC EDIT50}</p>
          <p>Extracapsular spread (ECS) Clinical: {FLD:AJCC EDIT50}</p>
          <p>Extracapsular spread (ECS) Pathologic: {FLD:AJCC EDIT50}</p>
          <p>Human Papillomavirus (HPV) Status: {FLD:AJCC EDIT50}</p>
          <p>Tumor Thickness: {FLD:AJCC EDIT50}</p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>{FLD:AJCC X} 2 grade system                              {FLD:AJCC X}    Grade I or 1</p>
          <p>{FLD:AJCC X} 3 grade system                              {FLD:AJCC X}    Grade II or 2</p>
          <p>{FLD:AJCC X} 4 grade system                              {FLD:AJCC X}    Grade III or 3</p>
          <p>{FLD:AJCC X} No 2,3,or 4 grade system is available       {FLD:AJCC X}    Grade IV or 4</p>
          <p>                                                {FLD:AJCC X}    Grade cannot be assessed</p>
          <p></p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X} Not Applicable</p>
          <p>{FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X} RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:AJCC X} R0 No residual tumor</p>
          <p>{FLD:AJCC X} R1 Microscopic residual tumor</p>
          <p>{FLD:AJCC X} R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X} Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:AJCC X} National guidelines were used in treatment planning </p>
          <p>   {FLD:AJCC X} NCCN </p>
          <p>   {FLD:AJCC X} Other (describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Liver Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>LIVER</p>
          <p>(Excluding intrahepatic bile ducts; Sarcomas and tumors metastatic to the</p>
          <p>Liver are not included.)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:{FLD:AJCC EDIT45}</p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Solitary tumor without vascular </p>
          <p>invasion</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Solitary tumor with vascular </p>
          <p>invasion or multipletumors none more than 5 cm</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3a     Multiple tumors more than 5 cm</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3b     Single tumor or multiple tumors of </p>
          <p>any size involving a major branch of the portal vein or hepatic vein</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      Tumor(s)with direct invasion of </p>
          <p>adjacent organs other than the gallbladder or with perforation of visceral</p>
          <p>peritoneum</p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph nodes cannot be </p>
          <p>assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Regional lymph node metastasis</p>
          <p> </p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}             M0      No distant metastasis (no pathologic M0;</p>
          <p>                       use clinical M to complete stage group) </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     I       T1      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     II      T2      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIA    T3a     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIB    T3b     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIC    T4      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVA     Any T   N1      M0</p>
          <p>                 IVB     Any T   Any N   M1</p>
          <p>{FLD:AJCC X}            UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : {FLD:AJCC X}None</p>
          <p></p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>Alpha Fetoprotein (AFP): {FLD:AJCC EDIT45}</p>
          <p>Fibrosis Score: {FLD:AJCC EDIT45}</p>
          <p>Hepatitis Serology: {FLD:AJCC EDIT45}</p>
          <p>Creatinine*:{FLD:AJCC EDIT45}</p>
          <p>Bilirubin*: {FLD:AJCC EDIT45}</p>
          <p>Prothrombin* time international normalized ratio (INR): {FLD:AJCC EDIT45}</p>
          <p>  * Part of the Model for End Stage Liver Disease score</p>
          <p>GRADING SYSTEM</p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>Checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X} Not Applicable</p>
          <p>{FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X} RX  Presence of residual tumor cannot be assessed.</p>
          <p>{FLD:AJCC X} R0  No residual tumor</p>
          <p>{FLD:AJCC X} R1  Microscopic residual tumor</p>
          <p>{FLD:AJCC X} R2  Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}  Clinical stage was used in the treatment planning (describe):</p>
          <p>{FLD:AJCC EDIT45}</p>
          <p>{FLD:AJCC X}  National guidelines were used in treatment planning</p>
          <p>     {FLD:AJCC X} NCCN</p>
          <p>     {FLD:AJCC X} Other(describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Lung">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>LUNG</p>
          <p>(Carcinoid tumors are included. Sarcomas and </p>
          <p>other rare tumor are not included).</p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:AJCC X} y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X} y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size: {FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Laterality:</p>
          <p>          {FLD:AJCC X}Left</p>
          <p>          {FLD:AJCC X}Right</p>
          <p>          {FLD:AJCC X}Bilateral</p>
          <p></p>
          <p>CLIN   PATH            PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis     Tis Carcinoma in situ</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor &lt; or = 3 cm in greatest dimension, surrounded by </p>
          <p>                       lung or visceral pleura, without bronchoscopic</p>
          <p>                       evidence of invasion more proximal than the </p>
          <p>                       lobar bronchus (i.e. not in the main bronchus)*</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1a     Tumor &lt; or = 2 cm in greatest dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1b     Tumor &gt;2 cm but &lt; or = 3 cm in greatest dimension </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor &gt;3 cm but &lt; or = 7 cm or tumor with any of the </p>
          <p>                       following features (T2 tumors with these </p>
          <p>                       features are classified T2A if &lt; or = 5 cm) </p>
          <p>                       Involves main bronchus, &gt; or = 2 cm distal to the </p>
          <p>                       carina</p>
          <p>                       Invades visceral pleura (PL1 or PL2) </p>
          <p>                       Associated with atelectasis or </p>
          <p>                       obstructive pneumonitis that extends to the </p>
          <p>                       hilar region but does not involve the entire </p>
          <p>                       lung</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2a     Tumor &gt;3 cm but &lt; or = 5 cm in greatest dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2b     Tumor &gt;5 cm but &lt; or = 7 cm in greatest dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Tumor &gt;7 cm or one that directly invades any of </p>
          <p>                       the following: parietal pleural (PL3) chest wall</p>
          <p>                       (including superior sulcus tumors), </p>
          <p>                       diaphragm, phrenic nerve, mediastinal pleura,</p>
          <p>                       partietal pericardium; or tumor in the main </p>
          <p>                       bronchus (&lt; 2 cm distal to the carina* but </p>
          <p>                       without involvement of the carina; or </p>
          <p>                       associated atelectasis or obstructive </p>
          <p>                       pneumonitis of the entire lung or separate </p>
          <p>                       tumor nodule(s) in the same lobe</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      Tumor of any size that invades any of the following:                                                                                                                                                        </p>
          <p>                       mediastimum, heart, great vessels, trachea, </p>
          <p>                       recurrent laryngeal nerve, esophagus, vertebral </p>
          <p>                       body, carina, separate tumor nodule(s) in a </p>
          <p>                       different ipsilateral lobe </p>
          <p></p>
          <p>* The uncommon superficial tumor of any size with its invasive component</p>
          <p>limited to the bronchial wall, which may extend proximal to the main</p>
          <p>bronchus, is also classified T1a</p>
          <p> </p>
          <p>                       REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph nodes cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Metastasis in ipsilateral peribronchial and/or </p>
          <p>                       ipsilateral hilar lymph nodes and intrapulmonary</p>
          <p>                       nodes including involvement by direct extension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2      Metastasis to ipsilateral mediastinal and/or</p>
          <p>                       subcarinal lymph node(s)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N3      Metastasis in contralateral mediastinal, contralateral </p>
          <p>                       hilar, ipsilateral or contralateral scalene or </p>
          <p>                       supraclavicular lymph node(s)</p>
          <p> </p>
          <p> </p>
          <p>                       DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M0      No distant metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1a     Separate tumor nodules(s) in a contralateral lobe;</p>
          <p>                       tumor with pleural nodules or malignant pleural (or</p>
          <p>                       pericardial) effusion**</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1b     Distant metastasis</p>
          <p></p>
          <p>** Most pleural (and pericardial) effusions with lung cancer are due to tumor.  </p>
          <p>In a few patients, however, multiple cytopathologic examinations </p>
          <p>of pleural (pericardial) fluid are negative for tumor, and the fluid is </p>
          <p>nonbloody and is not an exudate. Where these elements and clinical judgement </p>
          <p>dictate that the effusion is not related to the tumor, the effusion should be </p>
          <p>excluded as a staging element and the patient should be classified as M0.  </p>
          <p> </p>
          <p>CLIN   PATH    STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Occult  TX      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0       Tis     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IA      T1a     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1b     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IB      T2a     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIA     T2b     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1a     N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1b     N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2a     N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIB     T2b     N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIA    T1a     N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1b     N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2a     N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2b     N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T4      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T4      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIB    T1a     N3      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1b     N3      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2a     N3      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2b     N3      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N3      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T4      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T4      N3      M0                  </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IV      Any T   Any N   M1a</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Any T   Any N   M1b</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Stage Unknown</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING:  None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Pleural/Elastic Layer-Invasion (based on H&amp;E and elastic stains)</p>
          <p>{FLD:AJCC EDIT50}</p>
          <p>Separate Tumor Nodules:{FLD:AJCC EDIT50}</p>
          <p></p>
          <p></p>
          <p> Histologic Grade (G) (also known as overall grade)</p>
          <p></p>
          <p>GRADING SYSTEM 					GRADE</p>
          <p>                                 </p>
          <p>{FLD:AJCC X} 2 grade system                              {FLD:AJCC X}    Grade I or 1</p>
          <p>{FLD:AJCC X} 3 grade system                              {FLD:AJCC X}    Grade II or 2</p>
          <p>{FLD:AJCC X} 4 grade system                              {FLD:AJCC X}    Grade III or 3</p>
          <p>{FLD:AJCC X} No 2,3,or 4 grade system is available       {FLD:AJCC X}    Grade IV or 4</p>
          <p>                                                {FLD:AJCC X}    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X} Not Applicable</p>
          <p>{FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X} RX  Presence of residual tumor cannot be assessed.</p>
          <p>{FLD:AJCC X} R0  No residual tumor</p>
          <p>{FLD:AJCC X} R1  Microscopic residual tumor</p>
          <p>{FLD:AJCC X} R2  Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}  Clinical stage was used in the treatment planning (describe):{FLD:AJCC W-P INDENT3}</p>
          <p>{FLD:AJCC X}  National guidelines were used in treatment planning:</p>
          <p>     {FLD:AJCC X}  NCCN</p>
          <p>     {FLD:AJCC X}  Other: {FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Lymphoid Neoplasms Hodgkin and Non-Hodgkin ">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>LYMPHOID NEOPLASMS (HODGKIN AND NON-HODGKIN LYMPHOMA)</p>
          <p>      (Excludes ocular adnexal lymphoma)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p></p>
          <p>ANATOMIC STAGE/PROGNOSTIC GROUPS</p>
          <p>{FLD:AJCC X}    Stage I    Involvement of a single lymphatic site (i.e. nodal </p>
          <p>			    region, Waldeyer's ring, thymus or spleen)(I); or localized</p>
          <p>                  involvement of a single extralymphatic oragan or site in</p>
          <p>                  the absence of any lymph node involvement (IE) (rare in</p>
          <p>                  Hodgkin lymphoma).      </p>
          <p></p>
          <p>{FLD:AJCC X}    Stage II   Involvement of two or more lymph node regions on 	</p>
          <p>			    the same side of the diaphragm (II); or localized 		</p>
          <p>			    involvement of a  single extralymphatic organ or site in 	</p>
          <p>			    association with  regional lymph node involvement with or 	</p>
          <p>			    without involvement of other lymph node regions on the same </p>
          <p>			    side of the diaphgram (IIE). The number of regions involved </p>
          <p>			    may be indicated by a subscript, as in, for example, II3.</p>
          <p></p>
          <p>{FLD:AJCC X}    Stage III  Involvement of lymph node regions on both sides of </p>
          <p>			    the diaphgram (III), which also may be accompanied by</p>
          <p>                  extralymphatic extension in association with adjacent lymph</p>
          <p>                  node involvement (IIIE) or by involvement of the spleen</p>
          <p>                  (IIIS) or both (IIIE,S). Splenic involvement is designated</p>
          <p>                  by the letter S.</p>
          <p></p>
          <p>{FLD:AJCC X}    Stage IV   Diffuse or disseminated involvement of one or more</p>
          <p>                  extralymphatic organs, with or without associated lymph</p>
          <p>                  node involvement; or isolated extralymphatic organ</p>
          <p>                  involvement in the absence of adjacent regional lymph node</p>
          <p>                  involvement, but in conjunction with disease in distant</p>
          <p>                  site(s). Stage IV includes any involvement of the liver or</p>
          <p>                  bone marrow, lungs (other than by direct extension from</p>
          <p>                  another site), or cerebrospinal fluid.</p>
          <p></p>
          <p>{FLD:AJCC X}    Unknown Stage</p>
          <p></p>
          <p>Modifiers of Group:</p>
          <p>{FLD:AJCC X} E Extranodal</p>
          <p>{FLD:AJCC X} S Spleen</p>
          <p></p>
          <p>A &amp; B Classification (Symptoms):</p>
          <p>{FLD:AJCC X} A Asymptomatic</p>
          <p>{FLD:AJCC X} B Symptoms; fevers, night sweats, weight loss</p>
          <p></p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : {FLD:AJCC X}None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p> Associated with HIV/AIDS {FLD:AJCC X}</p>
          <p> Symptoms at diagnosis (B Symptoms): {FLD:AJCC EDIT50}</p>
          <p> International Prognostic Index (IPI) score: {FLD:AJCC EDIT45}</p>
          <p> Follicular Lymphoma Prognostic Index (FLIPI) score: {FLD:AJCC EDIT45}</p>
          <p> International Prognostic Score (IPS): {FLD:AJCC EDIT45}</p>
          <p></p>
          <p></p>
          <p>GRADING SYSTEM</p>
          <p></p>
          <p>{FLD:X BOX} 2 grade system			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 		     {FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 			{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available  {FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been</p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:X BOX}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:X BOX}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:X BOX}Not Applicable</p>
          <p>{FLD:X BOX}Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some</p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:X BOX}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:X BOX}R0 No residual tumor</p>
          <p>{FLD:X BOX}R1 Microscopic residual tumor</p>
          <p>{FLD:X BOX}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:X BOX}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:X BOX}National guidelines were used in treatment planning </p>
          <p>{FLD:X BOX}NCCN </p>
          <p>{FLD:X BOX}Other (describe):{FLD:WP 2}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Lymphoid Neoplasm Ocular Adnexal Lymphoma ">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>OCULAR ADNEXAL LYMPHOMA</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:{FLD:AJCC EDIT45}</p>
          <p>Laterality:</p>
          <p> {FLD:AJCC X} Left</p>
          <p> {FLD:AJCC X} Right</p>
          <p> {FLD:AJCC X} Bilateral</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Lymphoma extent not specified</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of lymphoma</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Lymphoma involving the conjunctiva 	</p>
          <p>				    alone  without orbital involvement.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1a     Bulbar conjunctiva only</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1b     Palpebral conjunctive +/- fornix 	</p>
          <p>				    +/- caruncle </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1c     Extensive conjunctival involvement</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Lymphoma with orbital involvement 	</p>
          <p>				    +/- any conjunctival</p>
          <p>                       involvement.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2a     Anterior orbital involvement (+/- 	</p>
          <p>				    conjunctival involvement</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2b     Anterior orbital involvement (=/- 	</p>
          <p>				    conjunctiva involvement + lacrimal involvement)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2c     Posterior orbital involvement (+/- 	</p>
          <p>			         conjunctival involvement +/- anterior involvement and </p>
          <p>				    +/- any extraocular muscle involvement)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2d      Nasolacrimal drainage system 		</p>
          <p>				    involvement (+/- conjunctival involvement but not 	</p>
          <p>				    including nasopharynx)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3       Lymphoma with pre-septal eyelid 	</p>
          <p>				    involvement (defined above) +/- orbital involvement 	</p>
          <p>				    +/- any conjunctival  involvement.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      Orbital adnexal lymphoma extending 	</p>
          <p>			         beyond orbit to adjacent structures such as bone and 	</p>
          <p>				    brain.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4a     Involvement of nasopharynx</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4b     Osseous involvement (including 	</p>
          <p>				    periosteum)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4c      Involvement of maxillofacial, 	</p>
          <p>				    ethmoidal and /or</p>
          <p>                        frontal sinuses</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4d      Intracranial spread</p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph nodes cannot be 	</p>
          <p>				    assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No evidence of lymph node 			</p>
          <p>				    involvement</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Involvement of ipsilateral regional </p>
          <p>				    lymph nodes*</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2      Involvement of contralateral or 	</p>
          <p>			         bilateral regional lymph nodes*</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N3      Involvement of peripheral lymph 	</p>
          <p>				    nodes not draining</p>
          <p>                       ocular adnexal region</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N4      Involvement of central lymph nodes</p>
          <p>  *The regional lymph nodes included preauricular (parotid), submandibular,</p>
          <p>   and cervical</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}             M0      No evidence of involvement of other 		</p>
          <p>				    extranodal site</p>
          <p>                       (no pathologic M0; use clinical M to complete stage</p>
          <p>                       group) </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1a     Noncontiguous involvement of tissues </p>
          <p>				    or organs external to the ocular adnexa (e.g., parotid </p>
          <p>				    glands,submandibular gland, lung, liver, spleen, 	</p>
          <p>				    kidney, breast etc.)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1b     Lymphomatous involvement of the bone </p>
          <p>				    marrow </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1c     Both M1a and M1b involvement</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>No stage grouping is presently recommended.</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : {FLD:AJCC X}None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p> Tumor cell growth fraction (Ki-67, MIB-1):{FLD:AJCC EDIT50}</p>
          <p> Serum lactate dehydrogenase (LDH) at diagnosis: {FLD:AJCC EDIT50}</p>
          <p> History of rheumatoid arthritis {FLD:AJCC X}</p>
          <p> History of Sjogren's syndrome {FLD:AJCC X}</p>
          <p> History of connective tissue disease {FLD:AJCC X}</p>
          <p> History of recurrent dry eye syndrome (sicca syndrome) {FLD:AJCC X}</p>
          <p> Any evidence of a viral infection (e.g. Hepatitis C or HIV {FLD:AJCC X}</p>
          <p> Any evidence of bacterial infection (e.g. Helicobacter pylori){FLD:AJCC X}</p>
          <p> Any evidence of an infection caused by other micro-organisms (e.g. chlamydia</p>
          <p>  psittaci) {FLD:AJCC X}</p>
          <p></p>
          <p>GRADING SYSTEM</p>
          <p>{FLD:X BOX} 2 grade system			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 		     {FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 			{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available  {FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been</p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:X BOX}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:X BOX}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:X BOX}Not Applicable</p>
          <p>{FLD:X BOX}Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some</p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:X BOX}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:X BOX}R0 No residual tumor</p>
          <p>{FLD:X BOX}R1 Microscopic residual tumor</p>
          <p>{FLD:X BOX}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:X BOX}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:X BOX}National guidelines were used in treatment planning </p>
          <p>{FLD:X BOX}NCCN </p>
          <p>{FLD:X BOX}Other (describe):{FLD:WP 2}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Malignant Melanoma of the Uvea Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>{FLD:AJCC 7TH EDITION HDR}</p>
          <p>AJCC CANCER STAGING 7th EDITION--MALIGNANT MELANOMA OF THE UVEA</p>
          <p></p>
          <p>Type of specimen: {FLD:AJCC EDIT50}</p>
          <p>Histopathologic type: {FLD:AJCC EDIT50}</p>
          <p>Tumor size: {FLD:AJCC EDIT50}</p>
          <p>Laterality: {FLD:X BUTTON1}Bilateral   {FLD:X BUTTON1}Left     {FLD:X </p>
          <p>BUTTON1}Right</p>
          <p></p>
          <p>PRIMARY TUMOR(T):</p>
          <p>{FLD:AJCC 7TH EDITION CLINICAL STAGING TEXT}                          </p>
          <p>{FLD:AJCC 7TH EDITION PATHOLOGIC STAGING TEXT}</p>
          <p></p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p></p>
          <p>{FLD:X BUTTON1} y clinical  -                               {FLD:X BUTTON1} y </p>
          <p>pathologic - </p>
          <p>staging completed                                staging completed</p>
          <p>after neoadjuvant therapy but                    after neoadjuvant therapy</p>
          <p>before subsequent surgery.                       AND subsequent surgery.</p>
          <p></p>
          <p>            ALL UVEA MELANOMAS                                              </p>
          <p> {FLD:X BUTTON1} TX   Primary tumor cannot be assessed               {FLD:X </p>
          <p>BUTTON1} TX</p>
          <p> {FLD:X BUTTON1} T0   No evidence of primary tumor                   {FLD:X </p>
          <p>BUTTON1} T0</p>
          <p></p>
          <p>            IRIS*</p>
          <p> {FLD:X BUTTON1} T1   Tumor limited to the iris                      {FLD:X </p>
          <p>BUTTON1} T1</p>
          <p> {FLD:X BUTTON1} T1a  Tumor limited to the iris not more than 3      {FLD:X </p>
          <p>BUTTON1} T1a</p>
          <p>            clock hours in size</p>
          <p> {FLD:X BUTTON1} T1b  Tumor limited to the iris more than 3 clock    {FLD:X </p>
          <p>BUTTON1} T1b</p>
          <p>            hours in size</p>
          <p> {FLD:X BUTTON1} T1c  Tumor limited to the iris with secondary       {FLD:X </p>
          <p>BUTTON1} T1c</p>
          <p>            glaucoma</p>
          <p> {FLD:X BUTTON1} T2   Tumor confluent with or extending into the     {FLD:X </p>
          <p>BUTTON1} T2</p>
          <p>            ciliary body, choroid or both </p>
          <p> {FLD:X BUTTON1} T2a  Tumor confluent with or extending into the     {FLD:X </p>
          <p>BUTTON1} T2a</p>
          <p>            ciliary body, choroid or both, with </p>
          <p>            secondary glaucoma</p>
          <p> {FLD:X BUTTON1} T3   Tumor confluent with or extending into the     {FLD:X </p>
          <p>BUTTON1} T3</p>
          <p>            ciliary body, choroid or both, with </p>
          <p>            scleral extension</p>
          <p> {FLD:X BUTTON1} T3a  Tumor confluent with or extending into the     {FLD:X </p>
          <p>BUTTON1} T3a</p>
          <p>            ciliary body, choroid or both with </p>
          <p>            scleral extension and secondary glaucoma</p>
          <p> {FLD:X BUTTON1} T4   Tumor with extrascleral extension              {FLD:X </p>
          <p>BUTTON1} T4</p>
          <p> {FLD:X BUTTON1} T4a  Tumor with extrascleral extension less than or {FLD:X </p>
          <p>BUTTON1} T4a</p>
          <p>            5 mm in diameter</p>
          <p> {FLD:X BUTTON1} T4b  Tumor with extrascleral extension more than 5  {FLD:X </p>
          <p>BUTTON1} T4b</p>
          <p>            mm in diameter</p>
          <p></p>
          <p>            *Iris melanomas originate from, and are </p>
          <p>            predominantly located in, this region of</p>
          <p>            the uvea.  If less than half of the tumor</p>
          <p>            volume is located within the iris, the tumor</p>
          <p>            may have originated in the ciliary body and</p>
          <p>            consideration should be given to classifying</p>
          <p>            it accordingly.</p>
          <p></p>
          <p>            CILIARY BODY AND CHOROID (see Figure below)</p>
          <p>            Primary ciliary body and choroidal melanomas</p>
          <p>            are classified according to the four tumor</p>
          <p>            size categories below:</p>
          <p></p>
          <p> {FLD:X BUTTON1} T1   Tumor size category 1                          {FLD:X </p>
          <p>BUTTON1} T1</p>
          <p> {FLD:X BUTTON1} T1a  Tumor size category 1 without ciliary body     {FLD:X </p>
          <p>BUTTON1} T1a</p>
          <p>            involvement and extraocular extension</p>
          <p> {FLD:X BUTTON1} T1b  Tumor size category 1 with ciliary body        {FLD:X </p>
          <p>BUTTON1} T1b</p>
          <p>            involvement</p>
          <p> {FLD:X BUTTON1} T1c  Tumor size category 1 without ciliary body     {FLD:X </p>
          <p>BUTTON1} T1c</p>
          <p>            involvement but with extraocular extension</p>
          <p>            less than or equal to 5 mm in diameter</p>
          <p> {FLD:X BUTTON1} T1d  Tumor size category 1 with ciliary body        {FLD:X </p>
          <p>BUTTON1} T1d</p>
          <p>            involvement and extraocular extension less</p>
          <p>            than or equal to 5 mm in diameter</p>
          <p> {FLD:X BUTTON1} T2   Tumor size category 2                          {FLD:X </p>
          <p>BUTTON1} T2</p>
          <p> {FLD:X BUTTON1} T2a  Tumor size category 2 without ciliary body     {FLD:X </p>
          <p>BUTTON1} T2a</p>
          <p>            involvement and extraocular extension</p>
          <p> {FLD:X BUTTON1} T2b  Tumor size category 2 with ciliary body        {FLD:X </p>
          <p>BUTTON1} T2b</p>
          <p>            involvement</p>
          <p> {FLD:X BUTTON1} T2c  Tumor size category 2 withour ciliary body     {FLD:X </p>
          <p>BUTTON1} T2c</p>
          <p>            involvement but with extraocular extension</p>
          <p>            less than or equal to 5 mm in diameter</p>
          <p> {FLD:X BUTTON1} T2d  Tumor size category 2 without ciliary body     {FLD:X </p>
          <p>BUTTON1} T2d</p>
          <p>            involvement and extraocular extension less</p>
          <p>            than or equal to 5 mm in diameter</p>
          <p> {FLD:X BUTTON1} T3   Tumor size category 3                          {FLD:X </p>
          <p>BUTTON1} T3</p>
          <p> {FLD:X BUTTON1} T3a  Tumor size category 3 without ciliary body     {FLD:X </p>
          <p>BUTTON1} T3a</p>
          <p>            involvement and extraocular extension</p>
          <p> {FLD:X BUTTON1} T3b  Tumor size category 3 with ciliary body        {FLD:X </p>
          <p>BUTTON1} T3b</p>
          <p>            involvement</p>
          <p> {FLD:X BUTTON1} T3c  Tumor size category 3 without ciliary body     {FLD:X </p>
          <p>BUTTON1} T3c</p>
          <p>            involvement but with extraocular extension</p>
          <p>            less than or equal to 5 mm in diameter</p>
          <p> {FLD:X BUTTON1} T3d  Tumor size category 3 with ciliary body        {FLD:X </p>
          <p>BUTTON1} T3d</p>
          <p>            involvement and extraocular exension less</p>
          <p>            than or equal to 5 mm in diameter</p>
          <p> {FLD:X BUTTON1} T4   Tumor size category 4                          {FLD:X </p>
          <p>BUTTON1} T4</p>
          <p> {FLD:X BUTTON1} T4a  Tumor size category 4 without ciliary body     {FLD:X </p>
          <p>BUTTON1} T4a</p>
          <p>            involvement and extraocular extension</p>
          <p> {FLD:X BUTTON1} T4b  Tumor size category 4 with ciliary body        {FLD:X </p>
          <p>BUTTON1} T4b</p>
          <p>            involvement</p>
          <p> {FLD:X BUTTON1} T4c  Tumor size category 4 without ciliary body     {FLD:X </p>
          <p>BUTTON1} T4c</p>
          <p>            involvement but with extraocular extension</p>
          <p>            less than or equal to 5 mm in diameter</p>
          <p> {FLD:X BUTTON1} T4d  Tumor size category 4 with ciliary body        {FLD:X </p>
          <p>BUTTON1} T4d</p>
          <p>            involvement and extraocular extension less</p>
          <p>            than or equal to 5 mm in diameter</p>
          <p> {FLD:X BUTTON1} T4e  Any tumor size category with extraocular       {FLD:X </p>
          <p>BUTTON1} T4e</p>
          <p>            extension more than 5 mm in diameter</p>
          <p></p>
          <p>            * CLINICAL: In clinical practice, the </p>
          <p>            largest tumor basal diameter may be </p>
          <p>            estimated in optic disc diameters (dd,</p>
          <p>            average: 1 dd = 1.5 mm).  Tumor thickness</p>
          <p>            may be estimated in diopters (average:</p>
          <p>            2.5 diopters = 1 mm).  However, techniques</p>
          <p>            such as ultrasonography and fundus </p>
          <p>            photography are used to provide more</p>
          <p>            accurate measurements.  Ciliary body</p>
          <p>            involvement can be evaluated by the slit-</p>
          <p>            lamp, ophthalmoscopy, gonioscopy and </p>
          <p>            transillumination.  However, high</p>
          <p>            frequency ultrasonography (ultrasound</p>
          <p>            biomicroscopy) is used for more accurate</p>
          <p>            assessment.  Extension through the sclera</p>
          <p>            is evaluated visually before and during</p>
          <p>            surgery, and with ultrasonography, computed</p>
          <p>            tomography or magnetic resonance inaging.</p>
          <p></p>
          <p>            **PATHOLOGIC: When histopathologic measure-</p>
          <p>            ments are recorded after fixation, tumor</p>
          <p>            diameters and thickness may be underestimated</p>
          <p>            because of tissue shortage.</p>
          <p></p>
          <p>REGIONAL LYMPH NODES (N):</p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p></p>
          <p> {FLD:X BUTTON1} NX   Regional lymph nodes cannot be assessed.       {FLD:X </p>
          <p>BUTTON1} NX</p>
          <p> {FLD:X BUTTON1} N0   No regional lymph node metastasis.             {FLD:X </p>
          <p>BUTTON1} N0</p>
          <p> {FLD:X BUTTON1} N1   Regional lymph node metastasis                 {FLD:X </p>
          <p>BUTTON1} N1</p>
          <p></p>
          <p>DISTANT METASTASIS(M):</p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p> {FLD:X BUTTON1} M0   No distant metastasis</p>
          <p>      {FLD:AJCC 7TH ED PARANASAL DISTANT METS NOTE}</p>
          <p> {FLD:X BUTTON1} M1   Distant metastasis                             {FLD:X </p>
          <p>BUTTON1} M1</p>
          <p> {FLD:X BUTTON1} M1a  Largest diameter of the largest metastasis     {FLD:X </p>
          <p>BUTTON1} M1a</p>
          <p>            &lt; or = 3 cm</p>
          <p> {FLD:X BUTTON1} M1b  Largest diameter of the largest metastasis     {FLD:X </p>
          <p>BUTTON1} M1b</p>
          <p>            3.1 - 8.0 cm</p>
          <p> {FLD:X BUTTON1} M1c  Largest diameter of the largest metastasis     {FLD:X </p>
          <p>BUTTON1} M1c</p>
          <p>            &gt; or = 8.0 cm</p>
          <p></p>
          <p>  CLASSIFICATION FOR CILIARY BODY AND CHOROID UVEAL MELANOMA BASED ON</p>
          <p>  THICKNESS AND DIAMETER</p>
          <p> </p>
          <p>  Thickness(mm)</p>
          <p> </p>
          <p>  &gt;15.0                                                 4          4        4</p>
          <p>  12.1 - 15.0                                3          3          4        4</p>
          <p>   9.1 - 12.0              3        3        3          3          3        4</p>
          <p>   6.1 - 9.0     2         2        2        2          3          3        4</p>
          <p>   3.1 - 6.0     1         1        1        2          2          3        4</p>
          <p>  &lt; or = 3.0     1         1        1        1          2          2        4</p>
          <p>           </p>
          <p>___________________________________________________________________</p>
          <p>          &lt; or = 3.0   3.1-6.0  6.1-9.0  9.1-12.0  12.1-15.0  15.1-18.0  &gt;</p>
          <p>18.0</p>
          <p> </p>
          <p>            Largest basal diameter (mm)</p>
          <p></p>
          <p></p>
          <p>ANATOMIC STAGE PROGNOSTIC GROUPS:</p>
          <p>Clinical Group     T       N       M       Group   Pathologic</p>
          <p>  {FLD:X BUTTON1}      I       T1a     N0      M0      I           {FLD:X </p>
          <p>BUTTON1}</p>
          <p>  {FLD:X BUTTON1}      IIA     T1b-d   N0      M0      IIA         {FLD:X </p>
          <p>BUTTON1}</p>
          <p>                   T2a     N0      M0</p>
          <p>  {FLD:X BUTTON1}      IIB     T2b     N0      M0      IIB         {FLD:X </p>
          <p>BUTTON1}</p>
          <p>                   T3a     N0      M0</p>
          <p>  {FLD:X BUTTON1}      IIIA    T2c-d   N0      M0      IIIA        {FLD:X </p>
          <p>BUTTON1}</p>
          <p>                   T3b-c   N0      M0</p>
          <p>                   T4a     N0      M0</p>
          <p>  {FLD:X BUTTON1}      IIIA    T3d     N0      M0      IIIA        {FLD:X </p>
          <p>BUTTON1}</p>
          <p>                   T4b-c   N0      M0</p>
          <p>  {FLD:X BUTTON1}      IIIB    T4d-e   N0      M0      IIIB        {FLD:X </p>
          <p>BUTTON1}</p>
          <p>  {FLD:X BUTTON1}      IV      Any T   N1      M0      IV          {FLD:X </p>
          <p>BUTTON1}</p>
          <p>                   Any T   Any N   M1a-c</p>
          <p>  {FLD:X BUTTON1}               Stage Unknown                      {FLD:X </p>
          <p>BUTTON1}</p>
          <p></p>
          <p>Prognostic Factors: (Site-Specific Factors)</p>
          <p>Required for Staging: Tumor height and largest diameter</p>
          <p>Clinically Significant Factors:</p>
          <p>  Measured thickness (depth): </p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Chromosomal alterations: </p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Gene expression profile:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Positron emission tomography/computed tomography:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Confocal indocyanine green angiography:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Mitotic count per 40 high power fields (HPF):</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Mean diameter of the ten largest nucleoli (MLN):</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Presence of extravascular matrix patterns:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Microvascular density (MVD):</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Insulin-like growth factor 1 receptor (IGF1-R):</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Tumor-infiltrating lymphocytosis:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Tumor-infiltrating macrophages:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Human Lymphocytes Antigen (HLA) Class 1 expression:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>General Notes:</p>
          <p>For identification of special cases of TNM or pTNM classifications, the "m" </p>
          <p>suffix and "y", "r", and "a" prefixes are used.  Although they do not affect</p>
          <p>the stage grouping, they indicate cases needing separate analysis.</p>
          <p></p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p></p>
          <p> {FLD:X BUTTON1} m   suffix to indicate the presence of primary      {FLD:X </p>
          <p>BUTTON1} m</p>
          <p>           tumors in a single site and is recorded</p>
          <p>           in parenthesis: pT(m)NM.</p>
          <p></p>
          <p> {FLD:X BUTTON1} y   prefix to indicate those cases in which         {FLD:X </p>
          <p>BUTTON1} y</p>
          <p>           classification is performed during or </p>
          <p>           following initial multimodality therapy.</p>
          <p>           The cTNM or pTNM category is identified</p>
          <p>           by a "y" prefix.  The ycTNM or ypTNM </p>
          <p>           categorizes the extent of tumor actually</p>
          <p>           present at the time of that examination.</p>
          <p>           The "y" categorization is not an estimate</p>
          <p>           of tumor prior to multimodality therapy.</p>
          <p></p>
          <p> {FLD:X BUTTON1} r   prefix to indicate a recurrent tumor when       {FLD:X </p>
          <p>BUTTON1} r</p>
          <p>           staged after a disease-free interval and </p>
          <p>           is identified by the "r" prefix: rTNM.</p>
          <p></p>
          <p> {FLD:X BUTTON1} a   prefix to indicate the stage was determined at  {FLD:X </p>
          <p>BUTTON1} a</p>
          <p>           autopsy: aTNM.</p>
          <p></p>
          <p>Surgical margins is data field recorded by registrars describing the surgical </p>
          <p>margins of the resected primary site specimen as determined only by the </p>
          <p>pathology report.</p>
          <p></p>
          <p>Neoadjuvant treatment is radiation therapy or systemic therapy (consisting of</p>
          <p>chemotherapy, hormone therapy, or immunotherapy) administered prior to a </p>
          <p>definitive surgical procedure.  If the surgical procedure is not performed,</p>
          <p>the administered therapy no longer meets the definition of neoadjuvant </p>
          <p>therapy.</p>
          <p></p>
          <p>Histologic Grade (G): (also known as overall grade)</p>
          <p></p>
          <p>Grading System                                Grade</p>
          <p> {FLD:X BUTTON1} 2 grade system                            {FLD:X BUTTON1} </p>
          <p>Grade I or 1</p>
          <p> {FLD:X BUTTON1} 3 grade system                            {FLD:X BUTTON1} </p>
          <p>Grade II or 2</p>
          <p> {FLD:X BUTTON1} 4 grade system                            {FLD:X BUTTON1} </p>
          <p>Grade III or 3</p>
          <p> {FLD:X BUTTON1} No 2, 3, or 4 grade system is available   {FLD:X BUTTON1} </p>
          <p>Grade IV or 4</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p></p>
          <p>Lypmhatic Vessel Invasion (L) and Venous Invasion (V) have been combined </p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.  The </p>
          <p>College of American Pathologists' (CAP) Checklist should be used as the </p>
          <p>primary </p>
          <p>source.  Other sources may be used in the absence of a Checklist.  Priority </p>
          <p>is </p>
          <p>given to positive results.</p>
          <p></p>
          <p>  {FLD:X BUTTON1} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>  {FLD:X BUTTON1} Lymph-Vascular Invasion Present/Identified</p>
          <p>  {FLD:X BUTTON1} Not Applicable</p>
          <p>  {FLD:X BUTTON1} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p></p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be residual </p>
          <p>tumor at the primary site after treatment because of incomplete resection or </p>
          <p>local and regional disease that extends beyond the limit of ability of </p>
          <p>resection.</p>
          <p></p>
          <p>  {FLD:X BUTTON1} RX   Presence of residual tumor cannot be assessed</p>
          <p>  {FLD:X BUTTON1} R0   No Residual Tumor</p>
          <p>  {FLD:X BUTTON1} R1   Microscopic residual tumor</p>
          <p>  {FLD:X BUTTON1} R2   Macroscopic residual tumor</p>
          <p></p>
          <p>Additional Information:</p>
          <p></p>
          <p> {FLD:X BUTTON1}Yes {FLD:X BUTTON1}No Clinical stage was used in treatment </p>
          <p>planning </p>
          <p>(describe):</p>
          <p>{FLD:WORD PROCESSING 1 LINE N/R HDB}</p>
          <p></p>
          <p> {FLD:X BUTTON1}Yes {FLD:X BUTTON1}No National guidelines were used in </p>
          <p>treatment </p>
          <p>planning: </p>
          <p>          {FLD:X BUTTON1}National Comprehensive Cancer Network (NCCN)</p>
          <p>          {FLD:X BUTTON1}Other (describe):</p>
          <p>{FLD:WORD PROCESSING 1 LINE N/R HDB}</p>
          <p></p>
          <p>{FLD:AJCC 7TH EDITION STAGING ILLUSTRATIONS}</p>
          <p> {FLD:X BUTTON1}Yes {FLD:X BUTTON1}No Have you completed the illustration </p>
          <p>page for </p>
          <p>this AJCC Staging form?</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Melanoma of Conjunctiva Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>MALIGNANT MELANOMA OF THE CONJUNCTIVA</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:{FLD:AJCC EDIT45}</p>
          <p>Laterality:</p>
          <p> {FLD:AJCC X} Left</p>
          <p> {FLD:AJCC X} Right</p>
          <p> {FLD:AJCC X} Bilateral</p>
          <p></p>
          <p>CLINICAL            PRIMARY TUMOR (T)</p>
          <p>*Quadrants are defined by clock hours, starting at the limbus (e.g.</p>
          <p>      6,9,12,3)extending from the central cornea to and beyond the eyelid</p>
          <p>      margins. This will bisect the caruncle.</p>
          <p></p>
          <p>{FLD:AJCC X}         TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}         T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}         Tis     Melanoma confined to the conjunctival epithelium</p>
          <p>{FLD:AJCC X}         T1      Malignant conjunctival melanoma of the bulbar 	</p>
          <p>				 conjunctiva</p>
          <p>{FLD:AJCC X}         T1a     Less than or equal to 1 quadrant*</p>
          <p>{FLD:AJCC X}         T1b     More than 1 but less than or equal to 2 		</p>
          <p>				 quadrants</p>
          <p>{FLD:AJCC X}         T1c     More than 2 but less than or equal to 3 		</p>
          <p>				  quadrants</p>
          <p>{FLD:AJCC X}         T1d     Greater than 3 quadrants</p>
          <p>{FLD:AJCC X}         T2      Malignant conjunctival melanoma of the non-	</p>
          <p>				 bulbar (palpebral, forniceal, caruncular)</p>
          <p>{FLD:AJCC X}         T2a     Non-caruncular, less than or equal to 1 quadrant</p>
          <p>{FLD:AJCC X}         T2b     Non-caruncular, greater than 1 quadrant</p>
          <p>{FLD:AJCC X}         T2c     Any caruncular, less than or equal to 1 quadrant</p>
          <p>{FLD:AJCC X}         T2d     Any caruncular, greater than 1 quadrant</p>
          <p>{FLD:AJCC X}         T3      Any malignant conjunctival melanoma with local 	</p>
          <p>				 invasion</p>
          <p>{FLD:AJCC X}         T3a     Globe</p>
          <p>{FLD:AJCC X}         T3b     Eyelid</p>
          <p>{FLD:AJCC X}         T3c     Orbit</p>
          <p>{FLD:AJCC X}         T3d     Sinus</p>
          <p>{FLD:AJCC X}         T4      Tumor invades the central nervous system</p>
          <p></p>
          <p>PATHOLOGIC          PRIMARY TUMOR (pT)</p>
          <p>{FLD:AJCC X}        pTX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}        pT0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}        pTis     Melanoma confined to the conjunctival epithelium</p>
          <p>{FLD:AJCC X}        pT1a     Melanoma of the bulbar conjunctiva not more than </p>
          <p>				 0.5mm inthickness with invasion of the substantia propria</p>
          <p>{FLD:AJCC X}        pT1b     Melanoma of the bulbar conjunctiva more than 	</p>
          <p>				 0.5mm butnot more than 1.5mm in thickness with invasion 	</p>
          <p>				 of thesubstantia propria</p>
          <p>{FLD:AJCC X}        pT1c     Melanoma of the bulbar conjunctiva greater than </p>
          <p>				 1.5mm inthickness with invasion of the substantia propria</p>
          <p>{FLD:AJCC X}        pT2a     Melanoma of the palpebral, forniceal or 		</p>
          <p>				 caruncular conjunctiva not more than 0.5mm in thickness 	</p>
          <p>				 withinvasion of the substantia propria</p>
          <p>{FLD:AJCC X}        pT2b     Melanoma more than 0.5 but not greater than 	</p>
          <p>				 1.5mm inthickness with invasion of the substantia propria</p>
          <p>{FLD:AJCC X}        pT2c     Melanoma of the palpebral, forniceal or 		</p>
          <p>				 caruncular conjunctiva greater than 1.5mm in thickness 	</p>
          <p>				 with invasion of the substantia propria.</p>
          <p>{FLD:AJCC X}        pT3      Melanoma invades the eye, eyelid, nasolacrimal 	</p>
          <p>				 system or Orbit</p>
          <p>{FLD:AJCC X}        pT4      Melanoma invades the central nervous system</p>
          <p></p>
          <p>CLINICAL             REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}         NX       Regional lymph nodes cannot be assessed</p>
          <p>{FLD:AJCC X}         N0a      No regional lymph node metastasis, biopsy 	</p>
          <p>				  performed</p>
          <p>{FLD:AJCC X}         N0b      No regional lymph node metastasis, biopsy not 	</p>
          <p>				  performed</p>
          <p>{FLD:AJCC X}         N1       Regional lymph node metastasis</p>
          <p></p>
          <p>PATHOLOGIC           REGIONAL LYMPH NODES (pN)</p>
          <p>{FLD:AJCC X}        pNx       Regional lymph nodes cannot be assessed</p>
          <p>{FLD:AJCC X}        pN0       No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}        pN1       Regional lymph node metastasis present</p>
          <p> </p>
          <p> </p>
          <p>DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}             M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis</p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>No stage grouping is presently recommended</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>Measured thickness (depth):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>GRADING SYSTEM</p>
          <p>{FLD:X BOX} 2 grade system				{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 		        {FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 			{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available  {FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been</p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:X BOX}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:X BOX}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:X BOX}Not Applicable</p>
          <p>{FLD:X BOX}Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some</p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:X BOX}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:X BOX}R0 No residual tumor</p>
          <p>{FLD:X BOX}R1 Microscopic residual tumor</p>
          <p>{FLD:X BOX}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:X BOX}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:X BOX}National guidelines were used in treatment planning </p>
          <p>{FLD:X BOX}NCCN </p>
          <p>{FLD:X BOX}Other (describe):{FLD:WP 2}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Melanoma of Skin Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>MELANOMA OF THE SKIN</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p> </p>
          <p>Tumor size:{FLD:AJCC EDIT50}  </p>
          <p></p>
          <p>Laterality</p>
          <p></p>
          <p>{FLD:AJCC X} Left</p>
          <p>{FLD:AJCC X} Right</p>
          <p>{FLD:AJCC X} Bilateral</p>
          <p></p>
          <p></p>
          <p></p>
          <p>CLIN   PATH           PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX     Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0     No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis    Melanoma in situ</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1     Melanoma ?1.0 mm in thickness </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1a    without ulceration and mitosis ,1/mm2</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1b    with ulceration and mitosis, ?1/mm2</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2     Melanoma 1.01-2.0 mm</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2a    without ulceration</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2b    with ulceration</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3     Melanoma 2.01-4.0 mm</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3a    without ulceration</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3b    with ulceration</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4     Tumor &gt; 4.0 mm </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4a    without ulceration</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4b    with ulceration</p>
          <p></p>
          <p>                       REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph nodes cannot be </p>
          <p>assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      1 lymph node</p>
          <p>        {FLD:AJCC X}     N1a     micrometastasis*</p>
          <p>        {FLD:AJCC X}     N1b     macrometastasis**</p>
          <p>        {FLD:AJCC X}     N2      2-3 nodes</p>
          <p>        {FLD:AJCC X}     N2a     micrometastasis*</p>
          <p>        {FLD:AJCC X}     N2b     macrometastasis**</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2c     in-transit met(s) without metastatic </p>
          <p>nodes </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N3      Clinical:?1 node with in transit met</p>
          <p>(s)/</p>
          <p>                       satellite(s) pathologic 4 or more metastastic</p>
          <p>                       nodes, or matted nodes, or in transit met(s)</p>
          <p>                       satellite(s) with metastastic node(s).</p>
          <p></p>
          <p>     *Micrometastases are diagnosed after sentinel lymph node biopsy</p>
          <p>      and completion lymphadenectomy (if performed).</p>
          <p>    **Macrometastases are defined as clinically detectable nodal</p>
          <p>      Metastases confirmed by therapeutic lymphadenectomy or when nodal</p>
          <p>      Metastasis exhibits gross extracapsular extension.</p>
          <p></p>
          <p>                       DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M0      No distant metastasis (no pathologic </p>
          <p>M;  use </p>
          <p>                       Clinical M to complete stage group)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1a     Metastasis to skin, subcutaneous </p>
          <p>tissue or distant </p>
          <p>                       lymph nodes</p>
          <p>{FLD:AJCC X}     M1b     Metastasis to lung</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1c     Metastasis to all other visceral </p>
          <p>sites or distant </p>
          <p>                       metastasis at any site combined with an elevated </p>
          <p>                       serum (LDH)</p>
          <p></p>
          <p></p>
          <p>CLINICAL STAGE GROUPING</p>
          <p>CLIN</p>
          <p>{FLD:AJCC X}    0     Tis     N0         M0</p>
          <p>{FLD:AJCC X}    IA    T1a     N0         M0</p>
          <p>{FLD:AJCC X}    IB    T1b     N0         M0</p>
          <p>{FLD:AJCC X}          T2A     N0         M0</p>
          <p>{FLD:AJCC X}    IIA   T2b     N0         M0</p>
          <p>{FLD:AJCC X}          T3a     N0         M0</p>
          <p>{FLD:AJCC X}    IIB   T3b     N0         M0</p>
          <p>{FLD:AJCC X}          T4a     N0         M0</p>
          <p>{FLD:AJCC X}    IIC   T4b     N0         M0</p>
          <p>{FLD:AJCC X}    III   Any T   Any N&gt;N1   M0</p>
          <p>{FLD:AJCC X}    IV    Any T   Any N      M1</p>
          <p>{FLD:AJCC X}    Stage Unknown</p>
          <p></p>
          <p>     *Clinical staging includes microstaging of the primary melanoma</p>
          <p>      and clinical/radiologic evaluation for metastases.  By convention</p>
          <p>      it should be used after complete excision of the primary melanoma</p>
          <p>      with clinical assessment for regional and distant metastases.</p>
          <p></p>
          <p></p>
          <p></p>
          <p>PATHOLOGIC STAGING</p>
          <p></p>
          <p>PATH</p>
          <p>{FLD:AJCC X}     0      Tis     N0     M0</p>
          <p>{FLD:AJCC X}     IA     T1a     N0     M0</p>
          <p>{FLD:AJCC X}     IB     T1b     N0     M0</p>
          <p>{FLD:AJCC X}            T2a     N0     M0</p>
          <p>{FLD:AJCC X}     IIA    T2b     N0     M0</p>
          <p>{FLD:AJCC X}            T3a     N0     M0</p>
          <p>{FLD:AJCC X}     IIB    T3b     N0     M0</p>
          <p>{FLD:AJCC X}            T4a     N0     M0</p>
          <p>{FLD:AJCC X}     IIC    T4b     N0     M0</p>
          <p>{FLD:AJCC X}     IIIA   T1-4a   N1a    M0</p>
          <p>{FLD:AJCC X}            T1-4a   N2a    M0</p>
          <p>{FLD:AJCC X}     IIIB   T1-4b   N1a    M0</p>
          <p>{FLD:AJCC X}            T1-4b   N2a    M0</p>
          <p>{FLD:AJCC X}            T1-4a   N1b    M0</p>
          <p>{FLD:AJCC X}            T1-4a   N2b    M0</p>
          <p>{FLD:AJCC X}            T1-4a/b N2c    M0</p>
          <p>{FLD:AJCC X}     IIIC   T1-4b   N1b    M0</p>
          <p>{FLD:AJCC X}            T1-4b   N2b    M0</p>
          <p>{FLD:AJCC X}            T1-4b   N2c    M0</p>
          <p>{FLD:AJCC X}            Any T   N3     M0</p>
          <p>{FLD:AJCC X}     IV     Any T   Any N  M1</p>
          <p></p>
          <p>    *Pathologic staging includes microstaging of the primary melanoma</p>
          <p>     and pathologic information about the regional lymph nodes after</p>
          <p>     partial or complete lymphadenectomy.  Pathologic Stage 0 or Stage</p>
          <p>     IA patients are the exception, they do not require pathologic</p>
          <p>     evaluation of their lymph nodes.</p>
          <p></p>
          <p>{FLD:AJCC X}  Stage Unknown</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING:  None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>   Measured thickness (depth):{FLD:AJCC EDIT50}</p>
          <p>   Ulceration:{FLD:AJCC EDIT50}</p>
          <p>   Serum lactate dehydrogenase (LDH){FLD:AJCC EDIT50}</p>
          <p>   Mitotic Rate:{FLD:AJCC EDIT50}</p>
          <p>   Tumor infiltrating lymphocytes (TIL):{FLD:AJCC EDIT50}</p>
          <p>   Level of invasion:{FLD:AJCC EDIT50}</p>
          <p>   Vertical growth plate:{FLD:AJCC EDIT50}</p>
          <p>   Regression:{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Histologic Grade (G) (also known as overall grade)</p>
          <p>Histologic grading is not used in the staging of Melanoma.</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X}Not Applicable</p>
          <p>{FLD:AJCC X}Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:AJCC X}R0 No residual tumor</p>
          <p>{FLD:AJCC X}R1 Microscopic residual tumor</p>
          <p>{FLD:AJCC X}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:AJCC X}National guidelines were used in treatment planning </p>
          <p>   {FLD:AJCC X}NCCN </p>
          <p>   {FLD:AJCC X}Other (describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Merkel Cell Carcinoma Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>MERKEL CELL CARCINOMA</p>
          <p>(Staging for Merkel Cell of the eyelid is not included in this chapter; see </p>
          <p>Carcinoma of the Eyelid form)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>{FLD:AJCC X} y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X} y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size: {FLD:AJCC EDIT45}</p>
          <p>Laterality:</p>
          <p> {FLD:AJCC X} Left</p>
          <p> {FLD:AJCC X} Right</p>
          <p> {FLD:AJCC X} Bilateral</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor (e.g., nodal/metastatic</p>
          <p>                       presentation without associated primary)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis     In situ primary tumor </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Less than or equal to 2 cm maximum tumor dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Greater than 2 cm but not more than 5 cm maximum tumor</p>
          <p>                       dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Over 5 cm maximum tumor dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      Primary tumor invades bone, muscle, fascia or</p>
          <p>                       cartilage</p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}            NX      Regional lymph nodes cannot be assessed</p>
          <p>{FLD:AJCC X}            N0      No regional lymph node metastasis</p>
          <p>                        Nodes negative by clinical exam* (no pathologic node</p>
          <p>                        exam performed)</p>
          <p>       {FLD:AJCC X}              Nodes negative by pathologic exam</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Metastasis in regional lymph nodes(s)</p>
          <p>       {FLD:AJCC X}     N1a     Micrometastasis **</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1b     Macrometastasis***</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2      In transit Metastasis****</p>
          <p></p>
          <p>   *Clinical detection of nodal disease may be via inspection, palpation</p>
          <p>      and/or imaging.</p>
          <p>  **Micrometastases are diagnosed after sentinel or elective lymphadenectomy.</p>
          <p> ***Macrometastases are defined as clinically detectable nodal metastases</p>
          <p>      confirmed by therapeutic lymphadenectomy or needle biopsy.</p>
          <p>****In transit metastasis: a tumor distinct from the primary lesion and</p>
          <p>      located either 1)between the primary lesion and the draining regional</p>
          <p>      lymph nodes or 2) distal to the primary lesion. </p>
          <p></p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Metastasis beyond regional lymph nodes</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1a     Metastasis to skin, subcutaneous issues or distant</p>
          <p>                        lymph nodes</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1b     Metastasis to lung</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1c     Metastasis to all other visceral sites</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p></p>
          <p>Clinical</p>
          <p>{FLD:AJCC X}         0       Tis     N0      M0</p>
          <p>{FLD:AJCC X}         IB      T1      N0      M0</p>
          <p>{FLD:AJCC X}         IIB     T2/T3   N0      M0</p>
          <p>{FLD:AJCC X}         IIC     T4      N0      M0</p>
          <p>{FLD:AJCC X}         IIIB    Any T   N1b/N2  M0</p>
          <p>{FLD:AJCC X}         IV      Any T   Any N   M1</p>
          <p>{FLD:AJCC X} STAGE UNKNOWN</p>
          <p></p>
          <p>Pathologic</p>
          <p>{FLD:AJCC X}         0       Tis     N0      M0</p>
          <p>{FLD:AJCC X}         IA      T1      pN0     M0</p>
          <p>{FLD:AJCC X}         IB      T1      cN0     M0</p>
          <p>{FLD:AJCC X}         IIA     T2/T3   pN0     M0</p>
          <p>{FLD:AJCC X}         IIB     T2/T3   cN0     M0</p>
          <p>{FLD:AJCC X}         IIC     T4      N0      M0</p>
          <p>{FLD:AJCC X}         IIIA    Any T   N1a     M0</p>
          <p>{FLD:AJCC X}         IIIB    Any T   N1b/N2  M0</p>
          <p>{FLD:AJCC X}         IV      Any T   Any N   M1</p>
          <p>{FLD:AJCC X}  STAGE UNKNOWN</p>
          <p></p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>Measured thickness (depth): {FLD:AJCC EDIT50}</p>
          <p>Tumor Base Transection Status: {FLD:AJCC EDIT50}</p>
          <p>Profound Immune Suppression: {FLD:AJCC EDIT50}</p>
          <p>Tumor Infiltrating Lymphocytes in the Primary tumor (TIL): {FLD:AJCC EDIT50}</p>
          <p>Growth Pattern of Primary Tumor: {FLD:AJCC EDIT50}</p>
          <p>Size of tumor nests in regional lymph nodes: {FLD:AJCC EDIT50}</p>
          <p>Clinical Status of Regional Lymph nodes: {FLD:AJCC EDIT50}</p>
          <p>Regional Lymph nodes Pathological Extracapsular extension: {FLD:AJCC EDIT50}</p>
          <p>Isolated Tumor cell in Regional lymph nodes: {FLD:AJCC EDIT50}</p>
          <p></p>
          <p>GRADING SYSTEM</p>
          <p>Histologic grade is not used in staging of Merkel cell carcinoma.</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X} Not Applicable</p>
          <p>{FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X} RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:AJCC X} R0 No residual tumor</p>
          <p>{FLD:AJCC X} R1 Microscopic residual tumor</p>
          <p>{FLD:AJCC X} R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X} Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:AJCC X} National guidelines were used in treatment planning </p>
          <p>      {FLD:AJCC X} NCCN </p>
          <p>      {FLD:AJCC X} Other (describe): {FLD:AJCC W-P2LINES}</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Mucosal Melanoma of the Head and Neck Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>{FLD:AJCC 7TH EDITION HDR}</p>
          <p>AJCC CANCER STAGING 7th EDITION--MUCOSAL MELANOMA OF THE HEAD AND NECK</p>
          <p></p>
          <p>Type of specimen: {FLD:AJCC EDIT50}</p>
          <p>Histopathologic type: {FLD:AJCC EDIT50}</p>
          <p>Tumor size: {FLD:AJCC EDIT50}</p>
          <p>Laterality: {FLD:AJCC X}Bilateral   {FLD:AJCC X}Left     {FLD:AJCC X}Right</p>
          <p></p>
          <p>PRIMARY TUMOR(T):</p>
          <p>{FLD:AJCC 7TH EDITION CLINICAL STAGING TEXT}                          </p>
          <p>{FLD:AJCC 7TH EDITION PATHOLOGIC STAGING TEXT}</p>
          <p></p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p></p>
          <p>{FLD:AJCC X} y clinical  -                               {FLD:AJCC X} y </p>
          <p>pathologic - </p>
          <p>staging completed                                staging completed</p>
          <p>after neoadjuvant therapy but                    after neoadjuvant therapy</p>
          <p>before subsequent surgery.                       AND subsequent surgery.</p>
          <p>                                              </p>
          <p> {FLD:AJCC X} T3   Mucosal disease                                {FLD:AJCC </p>
          <p>X} T3</p>
          <p> {FLD:AJCC X} T4a  Moderately advanced disease.                   {FLD:AJCC </p>
          <p>X} T4a</p>
          <p>            Tumor invades deep soft tissue, cartilage,</p>
          <p>            bone, or overlying skin.</p>
          <p> {FLD:AJCC X} T4b  Very advanced disease.                         {FLD:AJCC </p>
          <p>X} T4b</p>
          <p>            Tumor involving brain, dura, skull base,  </p>
          <p>            lower cranial nerves (IX, X, XI, XII),</p>
          <p>            masticator space, carotid artery, </p>
          <p>            prevertebral space, or mediastinal structures </p>
          <p></p>
          <p>REGIONAL LYMPH NODES (N):</p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p></p>
          <p> {FLD:AJCC X} NX   Regional lymph nodes cannot be assessed.       {FLD:AJCC </p>
          <p>X} NX</p>
          <p> {FLD:AJCC X} N0   No regional lymph node metastasis.             {FLD:AJCC </p>
          <p>X} N0</p>
          <p> {FLD:AJCC X} N1   Regional lymph n ode metastasis present        {FLD:AJCC </p>
          <p>X} N1</p>
          <p></p>
          <p>DISTANT METASTASIS(M):</p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p> {FLD:AJCC X} M0   No distant metastasis</p>
          <p>      {FLD:AJCC 7TH ED PARANASAL DISTANT METS NOTE}</p>
          <p> {FLD:AJCC X} M1   Distant metastasis                             {FLD:AJCC </p>
          <p>X} M1</p>
          <p></p>
          <p>ANATOMIC STAGE PROGNOSTIC GROUPS:</p>
          <p>Clinical Group     T       N       M       Group   Pathologic</p>
          <p>  {FLD:AJCC X}      III     T3      N0      M0      III         {FLD:AJCC X}</p>
          <p>  {FLD:AJCC X}      IVA     T4a     N0      M0      IVA         {FLD:AJCC X}</p>
          <p>                   T3-T4a  N1      M0                  </p>
          <p>  {FLD:AJCC X}      IVB     T4b     Any N   M0      IVB         {FLD:AJCC X}</p>
          <p>  {FLD:AJCC X}      IVC     Any T   Any N   M1      IVC         {FLD:AJCC X}</p>
          <p>  {FLD:AJCC X}               Stage Unknown                      {FLD:AJCC X}</p>
          <p></p>
          <p>Prognostic Factors: (Site-Specific Factors)</p>
          <p>Required for Staging: NONE</p>
          <p>Clinically Significant Factors:</p>
          <p>  Size of Lymph Nodes: </p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Extracapsular Extension from Lymph Nodes for Head &amp; Neck: </p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Head &amp; Neck Lymph Nodes Levels I - III:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Head &amp; Neck Lymph Nodes Levels IV - V:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Head &amp; Neck Lymph Nodes Levels VI - VII:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Other Lymph Nodes Group:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Clinical Location of cervical nodes:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Extracapsular spread (ECS) Clinical:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Extracapsular spread (ECS) Pathologic:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Human Papillomavirus (HPV) Status:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Tumor Thickness:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>General Notes:</p>
          <p>For identification of special cases of TNM or pTNM classifications, the "m" </p>
          <p>suffix and "y", "r", and "a" prefixes are used.  Although they do not affect</p>
          <p>the stage grouping, they indicate cases needing separate analysis.</p>
          <p></p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p></p>
          <p> {FLD:AJCC X} m   suffix to indicate the presence of primary      {FLD:AJCC </p>
          <p>X} m</p>
          <p>           tumors in a single site and is recorded</p>
          <p>           in parenthesis: pT(m)NM.</p>
          <p></p>
          <p> {FLD:AJCC X} y   prefix to indicate those cases in which         {FLD:AJCC </p>
          <p>X} y</p>
          <p>           classification is performed during or </p>
          <p>           following initial multimodality therapy.</p>
          <p>           The cTNM or pTNM category is identified</p>
          <p>           by a "y" prefix.  The ycTNM or ypTNM </p>
          <p>           categorizes the extent of tumor actually</p>
          <p>           present at the time of that examination.</p>
          <p>           The "y" categorization is not an estimate</p>
          <p>           of tumor prior to multimodality therapy.</p>
          <p></p>
          <p> {FLD:AJCC X} r   prefix to indicate a recurrent tumor when       {FLD:AJCC </p>
          <p>X} r</p>
          <p>           staged after a disease-free interval and </p>
          <p>           is identified by the "r" prefix: rTNM.</p>
          <p></p>
          <p> {FLD:AJCC X} a   prefix to indicate the stage was determined at  {FLD:AJCC </p>
          <p>X} a</p>
          <p>           autopsy: aTNM.</p>
          <p></p>
          <p>Surgical margins is data field recorded by registrars describing the surgical </p>
          <p>margins of the resected primary site specimen as determined only by the </p>
          <p>pathology report.</p>
          <p></p>
          <p>Neoadjuvant treatment is radiation therapy or systemic therapy (consisting of</p>
          <p>chemotherapy, hormone therapy, or immunotherapy) administered prior to a </p>
          <p>definitive surgical procedure.  If the surgical procedure is not performed,</p>
          <p>the administered therapy no longer meets the definition of neoadjuvant </p>
          <p>therapy.</p>
          <p></p>
          <p>Histologic Grade (G): (also known as overall grade)</p>
          <p></p>
          <p>Grading System                                Grade</p>
          <p> {FLD:AJCC X} 2 grade system                            {FLD:AJCC X} Grade I </p>
          <p>or 1</p>
          <p> {FLD:AJCC X} 3 grade system                            {FLD:AJCC X} Grade II </p>
          <p>or 2</p>
          <p> {FLD:AJCC X} 4 grade system                            {FLD:AJCC X} Grade </p>
          <p>III or 3</p>
          <p> {FLD:AJCC X} No 2, 3, or 4 grade system is available   {FLD:AJCC X} Grade IV </p>
          <p>or 4</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p></p>
          <p>Lypmhatic Vessel Invasion (L) and Venous Invasion (V) have been combined </p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.  The </p>
          <p>College of American Pathologists' (CAP) Checklist should be used as the </p>
          <p>primary </p>
          <p>source.  Other sources may be used in the absence of a Checklist.  Priority </p>
          <p>is </p>
          <p>given to positive results.</p>
          <p></p>
          <p>  {FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>  {FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>  {FLD:AJCC X} Not Applicable</p>
          <p>  {FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p></p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be residual </p>
          <p>tumor at the primary site after treatment because of incomplete resection or </p>
          <p>local and regional disease that extends beyond the limit of ability of </p>
          <p>resection.</p>
          <p></p>
          <p>  {FLD:AJCC X} RX   Presence of residual tumor cannot be assessed</p>
          <p>  {FLD:AJCC X} R0   No Residual Tumor</p>
          <p>  {FLD:AJCC X} R1   Microscopic residual tumor</p>
          <p>  {FLD:AJCC X} R2   Macroscopic residual tumor</p>
          <p></p>
          <p>Additional Information:</p>
          <p></p>
          <p> {FLD:AJCC X}Yes {FLD:AJCC X}No Clinical stage was used in treatment planning </p>
          <p>(describe):</p>
          <p>{FLD:WORD PROCESSING 1 LINE N/R HDB}</p>
          <p></p>
          <p> {FLD:AJCC X}Yes {FLD:AJCC X}No National guidelines were used in treatment </p>
          <p>planning: </p>
          <p>          {FLD:AJCC X}National Comprehensive Cancer Network (NCCN)</p>
          <p>          {FLD:AJCC X}Other (describe):</p>
          <p>{FLD:WORD PROCESSING 1 LINE N/R HDB}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Nasal Cavity and Paranasal Sinuses Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <INDENT_ITEMS>1</INDENT_ITEMS>
        <BOILERPLATE_TEXT>
          <p>{FLD:AJCC 7TH EDITION HDR}</p>
          <p>AJCC CANCER STAGING 7th EDITION--NASAL CAVITY &amp; PARANASAL SINUSES</p>
          <p></p>
          <p>Type of specimen: {FLD:AJCC EDIT50}</p>
          <p>Histopathologic type: {FLD:AJCC EDIT50}</p>
          <p>Tumor size: {FLD:AJCC EDIT50}</p>
          <p>Laterality: {FLD:AJCC X}Bilateral   {FLD:AJCC X}Left     {FLD:AJCC X}Right</p>
          <p></p>
          <p>PRIMARY TUMOR(T):</p>
          <p>{FLD:AJCC 7TH EDITION CLINICAL STAGING TEXT}                          </p>
          <p>{FLD:AJCC 7TH EDITION PATHOLOGIC STAGING TEXT}</p>
          <p></p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p></p>
          <p>{FLD:AJCC X} y clinical  -                               {FLD:AJCC X} y </p>
          <p>pathologic - </p>
          <p>staging completed                                staging completed</p>
          <p>after neoadjuvant therapy but                    after neoadjuvant therapy</p>
          <p>before subsequent surgery.                       AND subsequent surgery.</p>
          <p>                                              </p>
          <p> {FLD:AJCC X} TX   Primary tumor cannot be assessed               {FLD:AJCC </p>
          <p>X} TX</p>
          <p> {FLD:AJCC X} T0   No evidence of primary tumor                   {FLD:AJCC </p>
          <p>X} T0</p>
          <p> {FLD:AJCC X} Tis  Tis Carcinoma in situ                          {FLD:AJCC </p>
          <p>X} Tis</p>
          <p></p>
          <p>            Maxillary Sinus</p>
          <p> {FLD:AJCC X} T1   Tumor limited to maxillary sinus mucosa        {FLD:AJCC </p>
          <p>X} T1</p>
          <p>            with no erosion or destruction of bone.</p>
          <p> {FLD:AJCC X} T2   Tumor causing bone erosion or destruction      {FLD:AJCC </p>
          <p>X} T2</p>
          <p>            including extension into the hard palate</p>
          <p>            and/or middle nasal meatus, except </p>
          <p>            extension to posterior wall of maxillary </p>
          <p>            sinus and pterygoid plates.</p>
          <p> {FLD:AJCC X} T3   Tumor invades any of the following: bone       {FLD:AJCC </p>
          <p>X} T3</p>
          <p>            of the posterior wall of maxillary sinus,</p>
          <p>            subcutaneous tissues, floor or medial wall</p>
          <p>            of orbit, pterygoid fossa, ethmoid sinuses.</p>
          <p> {FLD:AJCC X} T4a  Moderately advanced local disease.             {FLD:AJCC </p>
          <p>X} T4a</p>
          <p>            Tumor invades anterior orbital contents,</p>
          <p>            skin of cheek, pterygoid plates, infra-</p>
          <p>            temporal fossa, cribriform plate, sphenoid</p>
          <p>            or frontal sinuses.</p>
          <p> {FLD:AJCC X} T4b  Very advanced local disease.                   {FLD:AJCC </p>
          <p>X} T4b</p>
          <p>            Tumor invades any of the following: orbital </p>
          <p>            apex, brain, middle cranial fossa, cranial</p>
          <p>            nerves other than maxillary division of </p>
          <p>            trigeminal nerve (V2), nasopharynx, or </p>
          <p>            clivus.</p>
          <p></p>
          <p>            Nasal Cavity and Ethmoid Sinus</p>
          <p> {FLD:AJCC X} T1   Tumor restricted to any one subsite,           {FLD:AJCC </p>
          <p>X} T1</p>
          <p>            with or without bony invasion.</p>
          <p> {FLD:AJCC X} T2   Tumor invading two subsites in a single        {FLD:AJCC </p>
          <p>X} T2</p>
          <p>            region or extending to involve an adjacent</p>
          <p>            region within the nasoethmoidal complex, </p>
          <p>            with or without bony invasion.</p>
          <p> {FLD:AJCC X} T3   Tumor extends to invade the medial wall        {FLD:AJCC </p>
          <p>X} T3</p>
          <p>            or floor of the orbit, maxillary sinus,</p>
          <p>            palate, or cribriform plate.</p>
          <p> {FLD:AJCC X} T4a  Moderately advanced local disease.             {FLD:AJCC </p>
          <p>X} T4a</p>
          <p>            Tumor invades any of the following: anterior</p>
          <p>            orbital contents, skin of nose or cheek,</p>
          <p>            minimal extension to anterior cranial </p>
          <p>            fossa, pterygoid plates, sphenoid or</p>
          <p>            frontal sinuses.</p>
          <p> {FLD:AJCC X} T4b  Very advanced local disease.                   {FLD:AJCC </p>
          <p>X} T4b</p>
          <p>            Tumor invades any of the following: orbital </p>
          <p>            apex, dura, brain, middle cranial fossa,</p>
          <p>            cranial nerves other than (V2), nasopharynx,</p>
          <p>            or clivus.</p>
          <p></p>
          <p>REGIONAL LYMPH NODES (N):</p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p></p>
          <p> {FLD:AJCC X} NX   Regional lymph nodes cannot be assessed.       {FLD:AJCC </p>
          <p>X} NX</p>
          <p> {FLD:AJCC X} N0   No regional lymph node metastasis.             {FLD:AJCC </p>
          <p>X} N0</p>
          <p> {FLD:AJCC X} N1   Metastasis in a single ipsilateral lymph node, {FLD:AJCC </p>
          <p>X} N1</p>
          <p>            3 cm or less in greatest dimension.</p>
          <p> {FLD:AJCC X} N2   Metastasis in a single ipsilateral lymph node, {FLD:AJCC </p>
          <p>X} N2</p>
          <p>            more than 3 cm but not more than 6 cm in</p>
          <p>            greatest dimension, or in multiple </p>
          <p>            ipsilateral lymph nodes, none more</p>
          <p>            than 6 cm in greatest dimension, or</p>
          <p>            in bilateral or contralateral lymph</p>
          <p>            nodes, none more than 6 cm in greatest</p>
          <p>            dimension.</p>
          <p> {FLD:AJCC X} N2a  Metastasis in a single ipsilateral lymph node, {FLD:AJCC </p>
          <p>X} N2a</p>
          <p>            more than 3 cm but not more than 6 cm in</p>
          <p>            greatest dimension.</p>
          <p> {FLD:AJCC X} N2b  Metastasis in multiple ipsilateral lymph       {FLD:AJCC </p>
          <p>X} N2b</p>
          <p>            nodes, none more than 6 cm in greatest</p>
          <p>            dimension.</p>
          <p> {FLD:AJCC X} N2c  Metastasis in bilateral or contralateral lymph {FLD:AJCC </p>
          <p>X} N2c</p>
          <p>            nodes, none more than 6 cm in greatest</p>
          <p>            dimension.</p>
          <p> {FLD:AJCC X} N3   Metastasis in a lymph node, more than 6 cm in  {FLD:AJCC </p>
          <p>X} N3</p>
          <p>            greatest dimension.</p>
          <p></p>
          <p>DISTANT METASTASIS(M):</p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p> {FLD:AJCC X} M0   No distant metastasis</p>
          <p>      {FLD:AJCC 7TH ED PARANASAL DISTANT METS NOTE}</p>
          <p> {FLD:AJCC X} M1   Distant metastasis                             {FLD:AJCC </p>
          <p>X} M1</p>
          <p></p>
          <p>ANATOMIC STAGE PROGNOSTIC GROUPS:</p>
          <p>Clinical Group     T       N       M       Group   Pathologic</p>
          <p>  {FLD:AJCC X}      0       Tis     N0      M0      0           {FLD:AJCC X}</p>
          <p>  {FLD:AJCC X}      I       T1      N0      M0      I           {FLD:AJCC X}</p>
          <p>  {FLD:AJCC X}      II      T2      N0      M0      II          {FLD:AJCC X}</p>
          <p>  {FLD:AJCC X}      III     T3      N0      M0      III         {FLD:AJCC X}</p>
          <p>                   T1      N1      M0</p>
          <p>                   T2      N1      M0</p>
          <p>                   T3      N1      M0</p>
          <p>  {FLD:AJCC X}      IVA     T4a     N0      M0      IVA         {FLD:AJCC X}</p>
          <p>                   T4a     N1      M0</p>
          <p>                   T1      N2      M0</p>
          <p>                   T2      N2      M0</p>
          <p>                   T3      N2      M0</p>
          <p>                   T4a     N2      M0</p>
          <p>  {FLD:AJCC X}      IVB     T4b     Any N   M0      IVB         {FLD:AJCC X}</p>
          <p>                   Any T   N3      M0</p>
          <p>  {FLD:AJCC X}      IVC     Any T   Any N   M1      IVC         {FLD:AJCC X}</p>
          <p>  {FLD:AJCC X}               Stage Unknown                      {FLD:AJCC X}</p>
          <p></p>
          <p>Prognostic Factors: (Site-Specific Factors)</p>
          <p>Required for Staging: NONE</p>
          <p>Clinically Significant Factors:</p>
          <p>  Size of Lymph Nodes: </p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Extracapsular Extension from Lymph Nodes for Head &amp; Neck: </p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Head &amp; Neck Lymph Nodes Levels I - III:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Head &amp; Neck Lymph Nodes Levels IV - V:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Head &amp; Neck Lymph Nodes Levels VI - VII:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Other Lymph Nodes Group:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Clinical Location of cervical nodes:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Extracapsular spread (ECS) Clinical:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Extracapsular spread (ECS) Pathologic:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Human Papillomavirus (HPV) Status:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Tumor Thickness:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>General Notes:</p>
          <p>For identification of special cases of TNM or pTNM classifications, the "m" </p>
          <p>suffix and "y", "r", and "a" prefixes are used.  Although they do not affect</p>
          <p>the stage grouping, they indicate cases needing separate analysis.</p>
          <p></p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p></p>
          <p> {FLD:AJCC X} m   suffix to indicate the presence of primary      {FLD:AJCC </p>
          <p>X} m</p>
          <p>           tumors in a single site and is recorded</p>
          <p>           in parenthesis: pT(m)NM.</p>
          <p></p>
          <p> {FLD:AJCC X} y   prefix to indicate those cases in which         {FLD:AJCC </p>
          <p>X} y</p>
          <p>           classification is performed during or </p>
          <p>           following initial multimodality therapy.</p>
          <p>           The cTNM or pTNM category is identified</p>
          <p>           by a "y" prefix.  The ycTNM or ypTNM </p>
          <p>           categorizes the extent of tumor actually</p>
          <p>           present at the time of that examination.</p>
          <p>           The "y" categorization is not an estimate</p>
          <p>           of tumor prior to multimodality therapy.</p>
          <p></p>
          <p> {FLD:AJCC X} r   prefix to indicate a recurrent tumor when       {FLD:AJCC </p>
          <p>X} r</p>
          <p>           staged after a disease-free interval and </p>
          <p>           is identified by the "r" prefix: rTNM.</p>
          <p></p>
          <p> {FLD:AJCC X} a   prefix to indicate the stage was determined at  {FLD:AJCC </p>
          <p>X} a</p>
          <p>           autopsy: aTNM.</p>
          <p></p>
          <p>Surgical margins is data field recorded by registrars describing the surgical </p>
          <p>margins of the resected primary site specimen as determined only by the </p>
          <p>pathology report.</p>
          <p></p>
          <p>Neoadjuvant treatment is radiation therapy or systemic therapy (consisting of</p>
          <p>chemotherapy, hormone therapy, or immunotherapy) administered prior to a </p>
          <p>definitive surgical procedure.  If the surgical procedure is not performed,</p>
          <p>the administered therapy no longer meets the definition of neoadjuvant </p>
          <p>therapy.</p>
          <p></p>
          <p>Histologic Grade (G): (also known as overall grade)</p>
          <p></p>
          <p>Grading System                                Grade</p>
          <p> {FLD:AJCC X} 2 grade system                            {FLD:AJCC X} Grade I </p>
          <p>or 1</p>
          <p> {FLD:AJCC X} 3 grade system                            {FLD:AJCC X} Grade II </p>
          <p>or 2</p>
          <p> {FLD:AJCC X} 4 grade system                            {FLD:AJCC X} Grade </p>
          <p>III or 3</p>
          <p> {FLD:AJCC X} No 2, 3, or 4 grade system is available   {FLD:AJCC X} Grade IV </p>
          <p>or 4</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p></p>
          <p>Lypmhatic Vessel Invasion (L) and Venous Invasion (V) have been combined </p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.  The </p>
          <p>College of American Pathologists' (CAP) Checklist should be used as the </p>
          <p>primary </p>
          <p>source.  Other sources may be used in the absence of a Checklist.  Priority </p>
          <p>is </p>
          <p>given to positive results.</p>
          <p></p>
          <p>  {FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>  {FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>  {FLD:AJCC X} Not Applicable</p>
          <p>  {FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p></p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be residual </p>
          <p>tumor at the primary site after treatment because of incomplete resection or </p>
          <p>local and regional disease that extends beyond the limit of ability of </p>
          <p>resection.</p>
          <p></p>
          <p>  {FLD:AJCC X} RX   Presence of residual tumor cannot be assessed</p>
          <p>  {FLD:AJCC X} R0   No Residual Tumor</p>
          <p>  {FLD:AJCC X} R1   Microscopic residual tumor</p>
          <p>  {FLD:AJCC X} R2   Macroscopic residual tumor</p>
          <p></p>
          <p>Additional Information:</p>
          <p></p>
          <p> {FLD:AJCC X}Yes {FLD:AJCC X}No Clinical stage was used in treatment planning </p>
          <p>(describe):</p>
          <p>{FLD:WORD PROCESSING 1 LINE N/R HDB}</p>
          <p></p>
          <p> {FLD:AJCC X}Yes {FLD:AJCC X}No National guidelines were used in treatment </p>
          <p>planning: </p>
          <p>          {FLD:X BUTTON1}National Comprehensive Cancer Network (NCCN)</p>
          <p>          {FLD:X BUTTON1}Other (describe):</p>
          <p>{FLD:WORD PROCESSING 1 LINE N/R HDB}</p>
          <p></p>
          <p>{FLD:AJCC 7TH EDITION STAGING ILLUSTRATIONS}</p>
          <p> {FLD:AJCC X}Yes {FLD:AJCC X}No Have you completed the illustration page for </p>
          <p>this AJCC Staging form?</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Neuroendocrine Tumor Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>NEUROENDOCRINE TUMOR </p>
          <p>Gastric, small bowel, colonic, rectal and ampulla of vater carcinoid tumors</p>
          <p>(well differentiated neuroendocrine tumors and well differentiated neuro </p>
          <p>endocrine carcinomas); carcinoid tumors of the appendix (see Chap. 13) and </p>
          <p>neuroendocrine tumor of the pancreas (see Chap. 24) are not included. </p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:AJCC X} y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X} y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size: {FLD:AJCC EDIT45}</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p> Stomach</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis     Carcinoma in situ/dysplasia (tumor size &lt;0.5mm)</p>
          <p>                       confined to  mucosa</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor invades lamina propria or submucosa and size </p>
          <p>                       &lt;/= 1cm in size</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor invades muscularis propria or &gt; 1cm in size</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Tumor penetrates subserosa</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      Tumor invades visceral peritoneum (serosa) or other</p>
          <p>                       organs of adjacent structures.</p>
          <p></p>
          <p>For any T, add (m) for multiple tumors</p>
          <p></p>
          <p> Duodenum/Ampulla/Jejunum/Ileum</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor invades lamina propria or submucosa and size</p>
          <p>                       &lt;/= 1cm (small intestinal tumors); tumor &lt;/= 1 cm </p>
          <p>                       (ampullary tumors)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor invades muscularis propria or size &gt; 1cm</p>
          <p>                       (small intestinal tumors); tumor &gt; 1cm </p>
          <p>                       (ampullary tumors)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Tumor invades through the muscularis propria into</p>
          <p>                       subserosal tissue without penetration of overlying</p>
          <p>                       serosa (jejunal or ileal tumors) or invades pancreas</p>
          <p>                       or retroperitoneum (ampullary or duodenal tumors) or</p>
          <p>                       into nonperitonealized tissues.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      Tumor invades visceral peritoneum (serosa) or invades </p>
          <p>			  other organs.</p>
          <p></p>
          <p>For any T, add (m) for multiple tumors</p>
          <p>*Tumor limited to ampulla of Vater for ampullary gangliocytic paraganglioma</p>
          <p></p>
          <p> Colon or Rectum</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor invades lamina propria or submucosa and &lt;/= 2 cm</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1a     Tumor size &lt; 1 cm in greatest dimension </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1b     Tumor size 1 to 2 cm in greatest dimension </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor invades muscularis propria or size &gt; 2 cm</p>
          <p>                       with invasion of lamina propria of submucosa</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Tumor invades through the muscularis propria into the</p>
          <p>                       subserosa, or into non-peritonealized pericolic or</p>
          <p>                       perirectal tissues</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      Tumor invades peritoneum of other organs </p>
          <p></p>
          <p>For any T, add (m) for multiple tumors</p>
          <p></p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p> Stomach; Duodenum/Ampulla/Jejunum/Ileum; Colon or Rectum</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph nodes cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Regional lymph node metastasis</p>
          <p></p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>Stomach; Duodenum/Ampulla/Jejunum/Ileum; Colon or Rectum</p>
          <p>{FLD:AJCC X}            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0       Tis*     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     I       T1       N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIA     T2       N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIB     T3       N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIA    T4       N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIB    Any T    N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IV      Any T    Any N   M1</p>
          <p></p>
          <p>{FLD:AJCC X}            UNKNOWN STAGE</p>
          <p>*Note: Tis applies only to stomach</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>Pre-operative plasma chromogranin A level (CgA): {FLD:AJCC EDIT50}</p>
          <p>Urinary 5-hydroxyindolacetic acid (5-HIAA) level: {FLD:AJCC EDIT50}</p>
          <p>Mitotic count {FLD:AJCC EDIT50}</p>
          <p></p>
          <p>GRADING SYSTEM					GRADE</p>
          <p>{FLD:AJCC X} 2 grade system                            {FLD:AJCC X} Grade I or 1     </p>
          <p>{FLD:AJCC X} 3 grade system                            {FLD:AJCC X} Grade II or 2 </p>
          <p>{FLD:AJCC X} No 2 or 3 grade system is available       {FLD:AJCC X} Grade III or 3</p>
          <p></p>
          <p>HISTOLOGIC GRADE</p>
          <p>                       Mitotic count (10 HPF)*    Ki-67 index (%)**</p>
          <p>{FLD:AJCC X}   Grade 1:         less than 2                less than or equal to 2</p>
          <p>{FLD:AJCC X}   Grade 2:         2-20                       3-20</p>
          <p>{FLD:AJCC X}   Grade 3:         greater than 20            greater than 20</p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X} Not Applicable</p>
          <p>{FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X} RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:AJCC X} R0 No residual tumor</p>
          <p>{FLD:AJCC X} R1 Microscopic residual tumor</p>
          <p>{FLD:AJCC X} R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X} Clinical stage was used in treatment planning (describe): {FLD:AJCC W-P2LINES}</p>
          <p>{FLD:AJCC X} National guidelines were used in treatment planning </p>
          <p>   {FLD:AJCC X} NCCN </p>
          <p>   {FLD:AJCC X} Other (describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Orbit Sarcoma Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>Sarcoma of the Orbit</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:{FLD:AJCC EDIT45}</p>
          <p>Laterality:</p>
          <p> {FLD:AJCC X} Left</p>
          <p> {FLD:AJCC X} Right</p>
          <p> {FLD:AJCC X} Bilateral</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor 15 mm or less in greatest 	</p>
          <p>				    dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor more than 15 mm in greatest 	</p>
          <p>				    dimension without  invasion of the globe or bony wall</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Tumor of any size with invasion of 	</p>
          <p>				    orbital tissues</p>
          <p>                       and/or bony walls.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      Tumor invasion of globe or 		</p>
          <p>				    periorbital structure, such</p>
          <p>                       as eyelids, temporal fossa, nasal cavity and paranasal</p>
          <p>                       sinuses, and/or central nervous system.</p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph nodes cannot be 	</p>
          <p>				    assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Regional lymph node metastasis</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}             M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis</p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>No stage grouping is presently recommended</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : {FLD:AJCC X}None</p>
          <p>CLINICALLY SIGNIFICANT : {FLD:AJCC X}None</p>
          <p></p>
          <p>GRADING SYSTEM</p>
          <p></p>
          <p>{FLD:X BOX} 2 grade system			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 		     {FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 			{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available  {FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been</p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:X BOX}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:X BOX}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:X BOX}Not Applicable</p>
          <p>{FLD:X BOX}Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some</p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:X BOX}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:X BOX}R0 No residual tumor</p>
          <p>{FLD:X BOX}R1 Microscopic residual tumor</p>
          <p>{FLD:X BOX}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:X BOX}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:X BOX}National guidelines were used in treatment planning </p>
          <p>{FLD:X BOX}NCCN </p>
          <p>{FLD:X BOX}Other (describe):{FLD:WP 2}</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Ovary Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>OVARY AND PRIMARY PERITONEAL CARCINOMA</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>Tumor size:  {FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Laterality</p>
          <p></p>
          <p>{FLD:AJCC X} Left</p>
          <p>{FLD:AJCC X} Right</p>
          <p>{FLD:AJCC X} Bilateral</p>
          <p></p>
          <p> </p>
          <p>CLIN   PATH    FIGO    TNM     PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             TX      Primary tumor cannot be </p>
          <p>				   	       assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     I       T1      Tumor limited to ovaries </p>
          <p>						  (one or both)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IA      T1a     Tumor limited to one ovary; </p>
          <p>						  capsule intact,no tumor on ovarian surface. No</p>
          <p>                               malignant cells in ascites or peritoneal</p>
          <p>                               washings.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IB      T1b     Tumor limited to both </p>
          <p>						  ovaries capsules Intact, no tumor on ovarian 	</p>
          <p>						  surface.  No Malignant cells in ascites or 	</p>
          <p>						  peritoneal washings</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IC      T1c     Tumor limited to 1 or both </p>
          <p>						  ovaries with any of the following: capsule 	</p>
          <p>						  ruptured,tumor on ovarian surface, malignant</p>
          <p>                               cells in ascites or peritoneal washings</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     II      T2      Tumor involves one or both </p>
          <p>						  ovaries with pelvic extension and/or implants.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIA     T2a     Extension and/or implants on </p>
          <p>						  uterus and tubes. No malignant cells in 		</p>
          <p>					       ascites or peritoneal washings.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIB     T2b     Extension to and/or implants </p>
          <p>						  on other pelvic tissues. No malignant cells in</p>
          <p>                               ascites or peritoneal washings.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIC     T2c     Pelvic extension and/or </p>
          <p>						  implants 2a or 2b) with malignant cells in 	</p>
          <p>						  ascites or peritoneal washings.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     III     T3      Tumor involves 1 or both </p>
          <p>						  ovaries, with microscopically confirmed 		</p>
          <p>						  peritoneal mets outside pelvis.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIA    T3a     Microscopic peritoneal </p>
          <p>						  metastasis beyond pelvis (no macroscopic 		</p>
          <p>						  tumor)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIB    T3b     Macroscopic peritoneal </p>
          <p>						  metastasis beyond pelvis 2 cm or less in 		</p>
          <p>						  greatest dimension.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIC    T3c     Peritoneal metastasis beyond </p>
          <p>						  pelvis &gt;2 cm and/or regional lymph node 		</p>
          <p>						  metastasis</p>
          <p></p>
          <p>    Note:  Liver capsule metastasis T3/Stage III:  liver parenchymal</p>
          <p>    metastasis M1/Stage IV.  Pleural effusion must have positive </p>
          <p>    cytology for M1/Stage IV.</p>
          <p> </p>
          <p>                               REGIONAL LYMPH NODES (N)</p>
          <p>CLIN   PATH    FIGO   TNM</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}            NX       Regional lymph nodes cannot </p>
          <p>					  	  be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}            N0       No regional lymph node </p>
          <p>						  metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIC   N1       Regional lymph node </p>
          <p>						  metastasis</p>
          <p> </p>
          <p>                               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}            M0       No distant metastasis (no </p>
          <p>						  pathologic M0;</p>
          <p>                               use clinical M to complete stage group)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IV     M1       Distant metastasis</p>
          <p> </p>
          <p></p>
          <p>STAGE GROUPING</p>
          <p>CLIN   PATH</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     I       T1      N0      M0      Stage I</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IA      T1a     N0      M0      Stage IA</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IB      T1b     N0      M0      Stage IB</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IC      T1c     N0      M0      Stage IC</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     II      T2      N0      M0      Stage II</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIA     T2a     N0      M0      Stage IIA</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIB     T2b     N0      M0      Stage IIB</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIC     T2c     N0      M0      Stage IIC</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}    III     T3      N0      M0      Stage III</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIA    T3a     N0      M0      Stage IIIA</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIB    T3b     N0      M0      Stage IIIB</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIC    T3c     N0      M0      Stage IIIC</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Any T   N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IV      Any T   Any N   M1      Stage IV</p>
          <p>{FLD:AJCC X}    Stage Unknown</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>FIGO:{FLD:AJCC EDIT50}</p>
          <p>Gross residual tumor after primary cyto-reductive surgery:{FLD:AJCC EDIT50}</p>
          <p>(present, absent, unknow, "y"</p>
          <p>   meaning patient received chemotherapy prior to surgery)</p>
          <p>Residual tumor volume after primary cyto-reductive surgery:{FLD:AJCC EDIT45}</p>
          <p>(no gross, ?1cm, &gt;1cm, unknown, "y" meaning patient</p>
          <p>   received chemotherapy prior to surgery)</p>
          <p>Residual tumor location following primary cyto-reductive</p>
          <p>   Surgery:{FLD:AJCC EDIT45}("y" indicates patient received chemotherapy</p>
          <p>   Prior to surgery)</p>
          <p>Malignant ascites volume:{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Histologic Grade (G)</p>
          <p>Grading system</p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>checklist.</p>
          <p>Priority is given to positive results.</p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X}Not Applicable</p>
          <p>{FLD:AJCC X}Unknown/Indeterminate</p>
          <p></p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:AJCC X}R0 No residual tumor</p>
          <p>{FLD:AJCC X}R1 Microscopic residual tumor</p>
          <p>{FLD:AJCC X}R2 Macroscopic residual tumor</p>
          <p></p>
          <p></p>
          <p>{FLD:AJCC X}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:AJCC X}National guidelines were used in treatment planning </p>
          <p>   {FLD:AJCC X}NCCN </p>
          <p>   {FLD:AJCC X}Other (describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Pancreas-Exocrine and Endocrine staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>PANCREAS</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:X BOX}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:X BOX}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:{FLD:AJCC EDIT45}</p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis     Carcinoma in situ*</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor limited to pancreas, 2 cm or </p>
          <p>less in greatest</p>
          <p>                       dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor limited to pancreas, more than </p>
          <p>2 cm in greatest</p>
          <p>                       dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Tumor extends beyond the pancreas </p>
          <p>but without </p>
          <p>                       involvement of the celiac axis or the superior </p>
          <p>                       mesenteric artery</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      Tumor involves the celiac axis or </p>
          <p>the superior</p>
          <p>                       mesenteric artery (unresectable primary tumor)</p>
          <p></p>
          <p>   *This also includes the "PanInIII" classification</p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph nodes cannot be </p>
          <p>assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Regional lymph node metastasis</p>
          <p> </p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}             M0      No distant metastasis (no pathologic M0;</p>
          <p>                       use clinical M to complete stage group) </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis</p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0       Tis     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IA      T1      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IB      T2      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIA     T3      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIB     T1      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     III     T4      Any N   M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IV      Any T   Any N   M1</p>
          <p>{FLD:AJCC X}            UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : {FLD:AJCC X}None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>   Preoperative CA 19-9: {FLD:AJCC EDIT45}</p>
          <p>   Preoperative Carcinoemic antigen (CEA): {FLD:AJCC EDIT45}</p>
          <p>   Preoperative plasma chromaranin A level (CgA) (endocrine pancreas):</p>
          <p>{FLD:AJCC EDIT45}</p>
          <p>   Mitotic count (endocrine pancreas): {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>GRADING SYSTEM</p>
          <p></p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>Checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X} Not Applicable</p>
          <p>{FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X} RX  Presence of residual tumor cannot be assessed.</p>
          <p>{FLD:AJCC X} R0  No residual tumor</p>
          <p>{FLD:AJCC X} R1  Microscopic residual tumor</p>
          <p>{FLD:AJCC X} R2  Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}  Clinical stage was used in the treatment planning (describe):</p>
          <p>{FLD:AJCC EDIT45}</p>
          <p>{FLD:AJCC X}  National guidelines were used in treatment planning</p>
          <p>     {FLD:AJCC X} NCCN</p>
          <p>     {FLD:AJCC X} Other(describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Penis Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>PENIS</p>
          <p>(Primary urethral cardinomas and melanomas are not included)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:AJCC X} y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X} y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size: {FLD:AJCC EDIT45}</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH            PRIMARY TUMOR</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis     Carcinoma in situ</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Ta      Noninvasive verrucous carcinoma*</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1a     Tumor invades subepithelial connective tissue </p>
          <p>                       without lymph vascular invasion and is not </p>
          <p>                       poorly differentiated (i.e., grade 3-4)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1b     Tumor invades subepithelial connective tissue </p>
          <p>                       with LVI or is poorly differentiated</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor invades corpus spongiosum or cavernosum</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Tumor invades urethra</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      Tumor invades other adjacent structures</p>
          <p></p>
          <p>*Note: Broad pushing penetration (invasion) is permitted - destructive invasion </p>
          <p>is against this diagnosis</p>
          <p> </p>
          <p>                       REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph nodes cannot be assessed*</p>
          <p>{FLD:AJCC X}            N0      No palpable or visibly enlarged inguinal </p>
          <p>                       lymph nodes*</p>
          <p>       {FLD:AJCC X}     N0      No regional lymph node metastasis**</p>
          <p>{FLD:AJCC X}            N1      Palpable mobile unilateral inguinal node*</p>
          <p>       {FLD:AJCC X}     N1      Metastasis in a single inguinal lymph node**</p>
          <p>{FLD:AJCC X}            N2      Palpable mobile multiple or bilateral </p>
          <p>                       inguinal lymph nodes *</p>
          <p>       {FLD:AJCC X}     N2      Metastasis in multiple or bilateral inguinal </p>
          <p>                       lymph nodes**</p>
          <p>{FLD:AJCC X}            N3      Palpable fixed inguinal nodal mass or pelvic </p>
          <p>                       lymphadenopathy unilateral or bilateral*</p>
          <p>       {FLD:AJCC X}     N3      Extranodal extension of lymph node metastasis </p>
          <p>                       or pelvic lymph node(s)unilateral or </p>
          <p>                       bilateral**</p>
          <p>                * Based upon palpation, imaging</p>
          <p>                **Based upon biopsy, or surgical excision</p>
          <p></p>
          <p>              DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis*</p>
          <p></p>
          <p>            *Note: Lymph node metastasis outside of the true pelvis </p>
          <p>             in addition to visceral or bone sites.</p>
          <p></p>
          <p></p>
          <p>       STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0       Tis     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Ta      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     I       T1a     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     II      T1b     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIA    T1-3    N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIB    T1-3    N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IV      T4      Any N   M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Any T   N3      M0</p>
          <p>                       Any T   Any N   M1</p>
          <p>{FLD:AJCC X}            Unknown Stage</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Involvement of corpus spongiosum: {FLD:AJCC EDIT50}</p>
          <p>Involvement of corpus cavernosum: {FLD:AJCC EDIT50}</p>
          <p>Percent of tumor that is poorly differentiated: {FLD:AJCC EDIT50}</p>
          <p>Verrucous carcinoma depth of invasion: {FLD:AJCC EDIT50}</p>
          <p>Size of largest lymph node metastasis: {FLD:AJCC EDIT50}</p>
          <p>Extranodal/extracapsular extension: {FLD:AJCC EDIT50}</p>
          <p>HPV Status: {FLD:AJCC EDIT50}</p>
          <p></p>
          <p>GRADING SYSTEM       </p>
          <p>{FLD:AJCC X} 2 grade system                          {FLD:AJCC X} Grade I or 1</p>
          <p>{FLD:AJCC X} 3 grade system                          {FLD:AJCC X} Grade II or 2</p>
          <p>{FLD:AJCC X} 4 grade system                          {FLD:AJCC X} Grade III or 3</p>
          <p>{FLD:AJCC X} No 2,3,or 4 grade system is available   {FLD:AJCC X} Grade IV or 4</p>
          <p>                           </p>
          <p></p>
          <p></p>
          <p>Lypmhatic Vessel Invasion (L) and Venous Invasion (V) have been combined </p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.  The </p>
          <p>College of American Pathologists' (CAP) Checklist should be used as the primary </p>
          <p>source.  Other sources may be used in the absence of a Checklist.  Priority is </p>
          <p>given to positive results.</p>
          <p></p>
          <p>  {FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>  {FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>  {FLD:AJCC X} Not Applicable</p>
          <p>  {FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p></p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be residual </p>
          <p>tumor at the primary site after treatment because of incomplete resection or </p>
          <p>local and regional disease that extends beyond the limit of ability of resection.</p>
          <p></p>
          <p>  {FLD:AJCC X} RX   Presence of residual tumor cannot be assessed</p>
          <p>  {FLD:AJCC X} R0   No Residual Tumor</p>
          <p>  {FLD:AJCC X} R1   Microscopic residual tumor</p>
          <p>  {FLD:AJCC X} R2   Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X} Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:AJCC X} National guidelines were used in treatment planning </p>
          <p>{FLD:AJCC X}  NCCN </p>
          <p>{FLD:AJCC X}  Other (describe):{FLD:AJCC W-P2LINES}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Pharynx Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>PHARYNX</p>
          <p>(Nonepithelial tumors such as those of lymphoid tissue, soft tissue, </p>
          <p>bone, and cartilage are not included.  Staging of mucosal melanoma of </p>
          <p>the pharynx is not included)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:AJCC X} y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X} y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size: {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>CLIN   PATH            PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis     Carcinoma in situ</p>
          <p> </p>
          <p>               *****NASOPHARYNX*****</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor confined to the nasopharynx, or extends to </p>
          <p>                       oropharynx and/or nasal cavity without parapharyngeal </p>
          <p>                       extension* </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor with parapharyngeal extension* </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Tumor involves bony structures of skull base </p>
          <p>                       and/or paranasal sinuses </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      Tumor with intracranial extension and/or involvement </p>
          <p>                       of cranial nerves, hypopharynx, orbit, or with extension</p>
          <p>                       to the infratemporal fossa/masticator space.</p>
          <p></p>
          <p>* Parapharyngeal extension denotes posterolateral infiltration of tumor.</p>
          <p>                       </p>
          <p>               *****OROPHARYNX*****</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor 2 cm or less in greatest dimension.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor more than 2 cm but not more than 4 cm in </p>
          <p>                       greatest dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Tumor &gt;4 cm in greatest dimension or extention</p>
          <p>                       to lingual surface of epiglottis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4a     Moderately advanced local disease.</p>
          <p>                         Tumor invades the larynx, extrinsic muscle of </p>
          <p>                         tongue, medial pterygoid, hard palate, or </p>
          <p>                         mandible* </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4b     Very advanced local disease.</p>
          <p>                         Tumor invades lateral pterygoid muscle, </p>
          <p>                         pterygoid plates, lateral nasopharynx, or skull</p>
          <p>                         base or encases carotid artery.</p>
          <p></p>
          <p>* Mucosal extension to lingual surface of epiglottis from primary tumors of </p>
          <p>the base of the tongue and vallecula does not constitute invasion of larynx.</p>
          <p>                       </p>
          <p>               *****HYPOPHARYNX*****</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor limited to 1 subsite of hypopharynx and/or </p>
          <p>                       2 cm or less in greatest dimension.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor invades more than 1 subsite of hypopharynx or</p>
          <p>                       an adjacent site, or measures &gt;2 cm but not &gt;4 cm </p>
          <p>                       in greatest dimension without fixation of hemilarynx.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Tumor &gt;4 cm in greatest dimension or with fixation of </p>
          <p>                       hemilarynx or extension to esophagus.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4a     Moderately advanced local disease.</p>
          <p>                         Tumor invades thyroid/cricoid cartilage, hyoid </p>
          <p>                         bone, thyroid gland, or central compartment soft</p>
          <p>                         tissue* </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4b     Very advanced local disease.</p>
          <p>                         Tumor invades prevertebral fascia, encases </p>
          <p>                         carotid artery, or involves mediastinal</p>
          <p>                         structures.</p>
          <p>* Central compartment soft tissue includes prelaryngeal strap muscles and</p>
          <p>subcutaneous fat.                       </p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)   NASOPHARYNX</p>
          <p>The distribution and the prognostic impact of regional lymph node spread </p>
          <p>from nasopharynx cancer, particularly of the undifferentiated type, are </p>
          <p>different from those of other head and neck mucosal cancers and justify </p>
          <p>the use of a different N classification scheme.</p>
          <p></p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph node cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Unilateral metastasis in lymph node(s) 6 cm or less </p>
          <p>                         in greatest dimension, above the supraclavicular </p>
          <p>                         fossa and/or unilateral or bilateral, retropharyngeal </p>
          <p>                         lymph nodes, 6 cm or less in greatest dimension*</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2      Bilateral metastasis in lymph node(s) 6 cm or less in </p>
          <p>                         greatest dimension, above the supraclavicular fossa*</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N3      Metastasis in a lymph node(s)* &gt;6 cm and/or extention to </p>
          <p>                       supraclivicular fossa </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N3a     Greater than 6 cm in dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N3b     Extension to the supraclavicular fossa**</p>
          <p> </p>
          <p>* Note: Midline nodes are considered ipsilateral nodes.</p>
          <p>**Supraclavicular zone or fossa is relevant to the staging of </p>
          <p>nasopharyngeal carcinoma and is the triangular region originally described</p>
          <p>by Ho. It is defined by three points: </p>
          <p>       (1) the superior margin of the sternal end of the clavicle, </p>
          <p>       (2) the superior margin of the lateral end of the clavicle, </p>
          <p>       (3) the point where the neck meets the shoulder; </p>
          <p>   Note that this would include caudal portions of Levels IV and VB.</p>
          <p>   All cases with lymph nodes (whole or part) in the fossa are considered N3b. </p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N) OROPHARYNX and HYPOPHARYNX</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph node cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Metastasis in a single ipsilateral node, 3 cm or less</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2      Metastasis in single ipsilat node, &gt;3 cm but not &gt;6 cm </p>
          <p>                       or in multiple ipsilateral nodes, none &gt;6 cm  </p>
          <p>                       or in bilateral or contralateral lymph nodes, none &gt;6 cm  </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2a     Metastasis in single ipsilateral lymph node &gt;3 cm, </p>
          <p>                       but not &gt;6 cm  </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2b     Metastasis in multiple ipsilateral lymph nodes, </p>
          <p>                       none &gt;6 cm  </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2c     Metastasis in bilateral or contralateral lymph nodes, </p>
          <p>                       none &gt;6 cm  </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N3      Metastasis in lymph node &gt;6 cm in greatest dimension</p>
          <p></p>
          <p>* Metastases at Level VII are considered regional lymph node metastases.</p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}            M0      No distant metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis</p>
          <p> </p>
          <p>CLIN   PATH    NASOPHARYNX STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0       Tis     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     I       T1      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     II      T1      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     III     T1      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVA     T4      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T4      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T4      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVB     Any T   N3      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVC     Any T   Any N   M1</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     UNKNOWN STAGE</p>
          <p> </p>
          <p>               OROPHARYNX AND HYPOPHARYNX STAGE GROUPING </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0       TIS     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     I       T1      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     II      T2      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     III     T3      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVA     T4a     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T4a     N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T4a     N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVB     T4b     AnyN    M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             AnyT    N3      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVC     Any T   Any N   M1</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Size of Lymph Nodes: {FLD:AJCC EDIT50}</p>
          <p>Extracapsular Extension from Lymph Nodes for Head &amp; Neck: {FLD:AJCC EDIT50}</p>
          <p>Head &amp; Neck Lymph Nodes Levels I-III: {FLD:AJCC EDIT50}</p>
          <p>Head &amp; Neck Lymph Nodes Levels IV-V: {FLD:AJCC EDIT50}</p>
          <p>Head &amp; Neck Lymph Nodes Levels VI-VII: {FLD:AJCC EDIT50}</p>
          <p>Other Lymph Node Group: {FLD:AJCC EDIT50}</p>
          <p>Clinical Location of cervical nodes: {FLD:AJCC EDIT50}</p>
          <p>Extracapsular spread (ECS) Clinical: {FLD:AJCC EDIT50}</p>
          <p>Extracapsular spread (ECS) Pathologic: {FLD:AJCC EDIT50}</p>
          <p>Human Papillomavirus (HPV) Status: {FLD:AJCC EDIT50}</p>
          <p>Tumor Thickness: {FLD:AJCC EDIT50}</p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>{FLD:AJCC X} 2 grade system                              {FLD:AJCC X}    Grade I or 1</p>
          <p>{FLD:AJCC X} 3 grade system                              {FLD:AJCC X}    Grade II or 2</p>
          <p>{FLD:AJCC X} 4 grade system                              {FLD:AJCC X}    Grade III or 3</p>
          <p>{FLD:AJCC X} No 2,3,or 4 grade system is available       {FLD:AJCC X}    Grade IV or 4</p>
          <p>                                                {FLD:AJCC X}    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X} Not Applicable</p>
          <p>{FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X} RX  Presence of residual tumor cannot be assessed.</p>
          <p>{FLD:AJCC X} R0  No residual tumor</p>
          <p>{FLD:AJCC X} R1  Microscopic residual tumor</p>
          <p>{FLD:AJCC X} R2  Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}  Clinical stage was used in the treatment planning (describe):{FLD:AJCC W-P INDENT3}</p>
          <p>{FLD:AJCC X}  National guidelines were used in treatment planning:</p>
          <p>     {FLD:AJCC X}  NCCN</p>
          <p>     {FLD:AJCC X}  Other: {FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Pleural Mesothelioma Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>PLEURAL MESOTHELIOMA</p>
          <p></p>
          <p> 7th edition AJCC Cancer Staging Manual</p>
          <p>{FLD:AJCC X} y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X} y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:{FLD:AJCC EDIT45}</p>
          <p></p>
          <p>Laterality:</p>
          <p>          {FLD:AJCC X} Left</p>
          <p>          {FLD:AJCC X} Right</p>
          <p>          {FLD:AJCC X} Bilateral</p>
          <p></p>
          <p>CLIN   PATH            PRIMARY TUMOR (T)</p>
          <p>                       IMIG Staging System for Diffuse Malignant </p>
          <p>                       Pleural Mesothelioma (MPM)</p>
          <p> </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor limited to the ipsilateral parietal </p>
          <p>                       pleura, with or without focal mediastinal </p>
          <p>                       pleura and with or without diaphragmatic </p>
          <p>                       pleural involvement</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1a     No involvement of the visceral pleura</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1b     Tumor also involving the visceral pleura</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor involving each of the ipsilateral </p>
          <p>                       pleural surfaces (parietal, mediastinal, </p>
          <p>                       diaphragmatic and visceral pleura) with</p>
          <p>                       at least one of the following features:</p>
          <p>                       -invasion of diaphragmatic muscle</p>
          <p>                       -extension of tumor from visceral pleura</p>
          <p>                       into the underlying pulmonary parenchyma</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Locally advanced but potentially resectable</p>
          <p>                       tumor. Tumor involving all of the ipsilateral </p>
          <p>                       pleural surfaces, with at least 1 of the </p>
          <p>                       following features:</p>
          <p>                       -involvement of the endothroacic fascia</p>
          <p>                       -extension into mediastinal fat</p>
          <p>                       -solitary, completely resectable focus</p>
          <p>                        of tumor extending into the soft tissues </p>
          <p>                        of the chest wall</p>
          <p>                       -non-transmural involvement of the pericardium</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      Locally advanced technically unresectable tumor</p>
          <p>                       Tumor involving all of the ipsilateral pleural </p>
          <p>                       surfaces, with at least one of the following:</p>
          <p>                       -diffuse extension or multifocal masses of </p>
          <p>                        tumor in the chest wall, with or without </p>
          <p>                        associated rib destruction </p>
          <p>                       -direct transdiaphragmatic extension of tumor</p>
          <p>                        to the peritoneum</p>
          <p>                       -direct extension of tumor to the contralateral</p>
          <p>                        pleura</p>
          <p>                       -direct extension of tumor to mediastinal </p>
          <p>                        organ(s)</p>
          <p>                       -direct extension of tumor into the spine</p>
          <p>                       -tumor extending through to the internal </p>
          <p>                        surface of the pericardium with or without</p>
          <p>                        a pericardial effusion, or tumor involving</p>
          <p>                        the myocardium                                                                                                                                                   </p>
          <p>                        </p>
          <p>                       REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph nodes cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Metastasis in the ipsilateral bronchopulmonary </p>
          <p>                       or hilar lymph node(s)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2      Metastasis in the subcarinal or the ipsilateral</p>
          <p>                       mediastinal lymph node(s) including the </p>
          <p>                       ipsilateral internal mammary and </p>
          <p>                       peridiaphragmatic nodes </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N3      Metastasis in contralateral mediastinal,</p>
          <p>                       contralateral internal mammary, ipsilateral or</p>
          <p>                       contralateral supraclavicular lymph node(s)</p>
          <p>                       </p>
          <p>                       DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}            M0      No distant metastasis (no pathologic M0; use</p>
          <p>                       clinical M to complete stage group).</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis</p>
          <p>                                           </p>
          <p> </p>
          <p>               STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     I       T1      N0       M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IA      T1a     N0       M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IB      T1b     N0       M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     II      T2      N0       M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     III     T1,T2   N1       M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1,T2   N2       M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N0,N1,N2 M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IV      T4      Any N    M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Any T   N3       M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Any T   Any N    M1</p>
          <p>{FLD:AJCC X}            Stage Unknown</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING:  None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Histological subtype:  {FLD:AJCC X} epithelioid  {FLD:AJCC X} mixed or biphasic</p>
          <p>                       {FLD:AJCC X} sarcomatoid  {FLD:AJCC X} desmoplastic</p>
          <p></p>
          <p>History of asbestosis exposure:  {FLD:AJCC Y/N}</p>
          <p>Presence or absence of chest pain:  {FLD:AJCC PRESENT/ABSENT}</p>
          <p></p>
          <p>FDG-PET SUV: {FLD:AJCC EDIT50} </p>
          <p></p>
          <p>Histologic Grade (G) (also known as overall grade)</p>
          <p></p>
          <p>GRADING SYSTEM 					GRADE</p>
          <p>                                 </p>
          <p>{FLD:AJCC X} 2 grade system                              {FLD:AJCC X}    Grade I or 1</p>
          <p>{FLD:AJCC X} 3 grade system                              {FLD:AJCC X}    Grade II or 2</p>
          <p>{FLD:AJCC X} 4 grade system                              {FLD:AJCC X}    Grade III or 3</p>
          <p>{FLD:AJCC X} No 2,3,or 4 grade system is available       {FLD:AJCC X}    Grade IV or 4</p>
          <p>                                                {FLD:AJCC X}    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X} Not Applicable</p>
          <p>{FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X} RX  Presence of residual tumor cannot be assessed.</p>
          <p>{FLD:AJCC X} R0  No residual tumor</p>
          <p>{FLD:AJCC X} R1  Microscopic residual tumor</p>
          <p>{FLD:AJCC X} R2  Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}  Clinical stage was used in the treatment planning (describe):{FLD:AJCC W-P INDENT3}</p>
          <p>{FLD:AJCC X}  National guidelines were used in treatment planning:</p>
          <p>     {FLD:AJCC X}  NCCN</p>
          <p>     {FLD:AJCC X}  Other: {FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Primary Cutaneous Lymphomas Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>PRIMARY CUTANEOUS LYMPHOMA</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>{FLD:AJCC X} y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X} y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)SKIN</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Limited patches*, papules, and/or plaques** covering</p>
          <p>                       &lt;10% of the skin surface. May further stratify into</p>
          <p>                       T1a (patch only) vs T1b (plaque +/- patch). </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Patches, papules or plaques covering 10% or greater of</p>
          <p>                       the skin surface. May further stratify into T2a (patch</p>
          <p>                       only) vs T2b (plaque +/- patch).</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      One or more tumors***(size 1cm or less in diameter)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      Confluence of erythema covering 80% or greater body</p>
          <p>                       surface area</p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Clinically abnormal peripheral lymph nodes; no</p>
          <p>                       histologic confirmation</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No clinically abnormal peripheral lymph nodes^;</p>
          <p>                       biopsy not required.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Clinically abnormal peripheral lymph nodes;</p>
          <p>                       histopathology Dutch grade 1 or NCI LN0-2.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1a     Clone negative#</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1b     Clone positive#</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2      Clinically abnormal peripheral lymph nodes;</p>
          <p>                       histopathology Dutch grade 2 or NCI LN3.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2a     Clone negative#</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2b     Clone positive#</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N3      Clinically abnormal peripheral lymph nodes;</p>
          <p>                       histopathology Dutch grade 3-4 or NCI LN4; clone</p>
          <p>                       positive or negative</p>
          <p></p>
          <p>                DISTANT METASTASIS (M) VISCERAL</p>
          <p>{FLD:AJCC X}            M0      No visceral organ involvement (no pathologic M; use</p>
          <p>                       clinical M to complete stage group)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Visceral involvement (must have pathology</p>
          <p>                       confirmation^^ and organ involved should be specified)</p>
          <p></p>
          <p>                PERIPHERAL BLOOD INVOLVEMENT (B)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     B0      Absence of significant blood involvement; &lt; or = %5 of</p>
          <p>                       peripheral blood lymphocytes are atypical(Sezary)</p>
          <p>                       cells ^^</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     B0a     Clone negative#</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     B0b     Clone positive#</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     B1      Low blood tumor burden: &gt;5% of peripheral blood</p>
          <p>                       lymphocytes are atypical (Sezary) cells but does not</p>
          <p>                       meet the criteria of B2.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     B2      High blood tumor burden: greater than or equal to</p>
          <p>                       100/uL Sezary cells^^^ with positive clone# </p>
          <p></p>
          <p>Notes:</p>
          <p></p>
          <p>  * For skin, patch indicates any size skin lesion without significant</p>
          <p>    elevation or induration. Presence/absence of hypo-or hyperpigmentation,</p>
          <p>    scale, crusting, and/or poikiloderma should be noted.</p>
          <p></p>
          <p> ** For skin, plaque indicates any size skin lesion that is elevated or</p>
          <p>    indurated. Presence or absence of scale, crusting, and/or poikiloderma</p>
          <p>    should be noted. Histologic features such as folliculotropism or large-</p>
          <p>    cell transformation (&gt;25% large cells), CD30+ or CD30-, and clinical</p>
          <p>    features such as ulceration are important to document.</p>
          <p></p>
          <p>*** For skin, tumor indicates at least one 1cm diameter solid or nodular</p>
          <p>    lesion with evidence of depth and/or vertical growth.  Note total number</p>
          <p>    of lesions, total volume of lesions, largest size lesion, and region of</p>
          <p>    body involved. Also note if histologic evidence of large-cell</p>
          <p>    transformation has occurred. Phenotyping for CD30 is encouraged.</p>
          <p></p>
          <p>  ^ For node, abnormal peripheral lymph node(s) indicates any palpable</p>
          <p>    peripheral node that on physical examination is firm, irregular,</p>
          <p>    clustered, fixed or 1.5cm or larger in diameter. Node groups examined on</p>
          <p>    physical examination include cervical, supraclavicular, epitrochlear,</p>
          <p>    axillary and inguinal. Central nodes, which are not generally amenable to</p>
          <p>    pathologic assessment, are not currently considered in nodal</p>
          <p>    classification unless used to establish N3 histopathologically.</p>
          <p></p>
          <p> ^^ For viscera, spleen and liver may be diagnosed by imaging criteria.</p>
          <p></p>
          <p>^^^ For blood, Sezary cells are defined as lymphocytes with hyperconvoluted</p>
          <p>    cerebriform nuclei. If Sezary cells are not able to be used to determine</p>
          <p>    tumor burden for B2, then one of the following modified ISCL criteria</p>
          <p>    along with a positive clonal rearrangement of the TCR may be used</p>
          <p>    instead: (1) expanded CD4+ or CD3+ cells with CD4/CD8 ratio of 10 or</p>
          <p>    more. (2) expanded CD4+ cells with abnormal immunophenotype including loss</p>
          <p>    of CD7 or CD26.</p>
          <p>  # A T-cell clone is defined by PCR or Southern blot analysis of the T-cell</p>
          <p>    receptor gene.</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IA      T1      N0      M0      B0,1</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IB      T2      N0      M0      B0,1</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIA     T1,2    N1,2    M0      B0,1</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIB     T3      N0-2    M0      B0,1</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     III     T4      N0-2    M0      B0,1</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIA    T4      N0-2    M0      B0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIB    T4      N0-2    M0      B1</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVA1    T1-4    N0-2    M0      B2</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVA2    T1-4    N3      M0      B0-2</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVB     T1-4    N0-3    M1      B0-2</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     STAGE UNKNOWN</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: Peripheral blood involvement: {FLD:AJCC EDIT50}</p>
          <p>CLINICALLY SIGNIFICANT: None</p>
          <p></p>
          <p>GRADING </p>
          <p>{FLD:AJCC X} T-Cell</p>
          <p>{FLD:AJCC X} B-cell (pre B, B precursor)</p>
          <p>{FLD:AJCC X} Null cell (non T-non B)</p>
          <p>{FLD:AJCC X} NK cell (natural killer cell)</p>
          <p>{FLD:AJCC X} Cell type not determined, not stated or not applicable. </p>
          <p></p>
          <p></p>
          <p>Lypmhatic Vessel Invasion (L) and Venous Invasion (V) have been combined </p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.  The </p>
          <p>College of American Pathologists' (CAP) Checklist should be used as the primary </p>
          <p>source.  Other sources may be used in the absence of a Checklist.  Priority is </p>
          <p>given to positive results.</p>
          <p></p>
          <p>  {FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>  {FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>  {FLD:AJCC X} Not Applicable</p>
          <p>  {FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p></p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be residual </p>
          <p>tumor at the primary site after treatment because of incomplete resection or </p>
          <p>local and regional disease that extends beyond the limit of ability of resection.</p>
          <p></p>
          <p>  {FLD:AJCC X} RX   Presence of residual tumor cannot be assessed</p>
          <p>  {FLD:AJCC X} R0   No Residual Tumor</p>
          <p>  {FLD:AJCC X} R1   Microscopic residual tumor</p>
          <p>  {FLD:AJCC X} R2   Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X} Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:AJCC X} National guidelines were used in treatment planning </p>
          <p>{FLD:AJCC X}  NCCN </p>
          <p>{FLD:AJCC X}  Other (describe):{FLD:AJCC W-P2LINES}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Prostate Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>PROSTATE</p>
          <p>(Sarcomas and transitional cell carcinomas are excluded.</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:{FLD:FREE TEXT}</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}            T1      Clinically inapparent, neither palpable nor </p>
          <p>                       visible by imaging</p>
          <p>{FLD:AJCC X}            T1a     Incidental finding in 5% or less of resected </p>
          <p>                       tissue</p>
          <p>{FLD:AJCC X}            T1b     Incidental finding in more than 5% resected </p>
          <p>                       tissue</p>
          <p>{FLD:AJCC X}            T1c     Tumor identified by needle biopsy (e.g., </p>
          <p>                       because of elevated PSA)</p>
          <p>{FLD:AJCC X}            T2      Tumor confined within prostate*</p>
          <p>        {FLD:AJCC X}    pT2      Organ confined </p>
          <p>{FLD:AJCC X}            T2a     Tumor involves one half of one lobe or less</p>
          <p>        {FLD:AJCC X}    pT2a     Unilateral, one-half of one side or less</p>
          <p>{FLD:AJCC X}            T2b     Tumor involves more than one-half of one </p>
          <p>                       lobe but not both lobes</p>
          <p>        {FLD:AJCC X}    pT2b     Unilateral, involving more than one-half of </p>
          <p>                       side but not both sides</p>
          <p>{FLD:AJCC X}            T2c     Tumor involves both lobes</p>
          <p>        {FLD:AJCC X}    pT2c     Bilateral Disease</p>
          <p>{FLD:AJCC X}            T3      Tumor extends through the prostatic</p>
          <p>                       capsule**</p>
          <p>        {FLD:AJCC X}    pT3      Extraprostatic extension</p>
          <p>{FLD:AJCC X}            T3a     Extracapsular extension (unilateral or </p>
          <p>                       bilateral)</p>
          <p>        {FLD:AJCC X}    pT3a     Extraprostatic extension or microscopic </p>
          <p>                       invasion of bladder neck ***</p>
          <p>{FLD:AJCC X}            T3b     Tumor invades seminal vesicle(s)</p>
          <p>        {FLD:AJCC X}    pT3b     Seminal vesicle invasion</p>
          <p>{FLD:AJCC X}            T4      Tumor is fixed or invades adjacent  	</p>
          <p>					structures other than seminal vesicles: such as </p>
          <p>					external sphincter, rectum, bladder, levator 	</p>
          <p>					muscles, and/or pelvic wall</p>
          <p>        {FLD:AJCC X}    pT4      Invasion of rectum, levator muscles and/or </p>
          <p>                       pelvic wall</p>
          <p></p>
          <p>            Note: There is no pathologic T1 classification.</p>
          <p>           *Note: Tumor found in one or both lobes by needle biopsy, </p>
          <p>                  but not palpable or reliably visible by imaging, is </p>
          <p>                  classified as T1c.</p>
          <p>          **Note: Invasion into the prostatic apex or into (but not </p>
          <p>                  beyond) the prostatic capsule is classified not as T3 </p>
          <p>                  but as T2.</p>
          <p>         ***Note: Positive surgical margin should be indicated by an </p>
          <p>                  R1 descriptor (residual microscopic disease).</p>
          <p></p>
          <p></p>
          <p>CLIN  PATH    REGIONAL LYMPH NODES  (N)</p>
          <p>{FLD:AJCC X}            NX      Regional lymph were not assessed</p>
          <p>        {FLD:AJCC X}    pNX      Regional nodes not sampled</p>
          <p>{FLD:AJCC X}            N0      No regional lymph node metastasis</p>
          <p>        {FLD:AJCC X}    pN0      No positive regional lymph nodes</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    pN1      Metastasis in regional node(s)</p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M0      No distant metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1a     Non-regional lymph nodes</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1b     Bone(s)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1c     Other sites (with or without bone </p>
          <p>										disease)</p>
          <p> </p>
          <p>      *Note: When more than one site of metastasis is present, the </p>
          <p>             most advanced category is used. pM1c is most advanced</p>
          <p></p>
          <p>CLIN   PATH    STAGE GROUPING     PSA             GLEASON</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}      T1a-c  N0   M0   PSA&lt;10          GL &lt;or =6</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}      T2     N0   M0   PSA&lt;10          GL &lt;or =6</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}      T1-2a  N0   M0   PSA X           GL  X</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}      IIA    T1a-c  N0   M0   PSA&lt;20      GL  7</p>
          <p>                       T1a-c  N0   M0   PSA &gt;or =10+&lt;20 GL &lt; or =6</p>
          <p>                       T2a    N0   M0   PSA &lt; 20        GL &lt; or =7</p>
          <p>                       T2b    N0   M0   PSA &lt; 20        GL &lt; or =7</p>
          <p>                       T2b    N0   M0   PSA X           GL X</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}  IIB     T2c    N0   M0   Any PSA     Any </p>
          <p>Gleason</p>
          <p>                       T1-2   N0   M0   PSA &gt; or =20    Any Gleason</p>
          <p>                       T1-2   N0   M0   Any PSA         GL &gt; or =8</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     III     T3a-b  N0   M0   Any PSA         </p>
          <p>Any Gleason</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IV      T4     N0   M0   Any PSA         </p>
          <p>Any Gleason</p>
          <p>                       Any T  N1   M0   Any PSA         Any Gleason</p>
          <p>                       Any T  Any NM1   Any PSA         Any Gleason</p>
          <p>{FLD:AJCC X}            Unknown Stage</p>
          <p></p>
          <p>*When either PSA or Gleason is not available, grouping should be determined </p>
          <p>by T </p>
          <p> stage and/or either PSA or Gleason as available.</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: Prostate Specific Antigen</p>
          <p>Gleason score</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Gleason primary and secondary patterns:{FLD:FREE TEXT}</p>
          <p>Gleason Tertiary Pattern: {FLD:FREE TEXT}</p>
          <p>Clinical Staging procedures performed:{FLD:FREE TEXT}</p>
          <p>Number of biopsy cores examined:{FLD:FREE TEXT}</p>
          <p>Number of biopsy cores positive for cancer:{FLD:FREE TEXT}</p>
          <p></p>
          <p>Histologic Grade (G)</p>
          <p>Grading system</p>
          <p>{FLD:AJCC X} Gleason X Gleason score cannot be processed</p>
          <p>{FLD:AJCC X} Gleason &lt; OR = 6 Well differentiated (slight anaplasia)</p>
          <p>{FLD:AJCC X} Gleason 7 Moderately differentiated (moderate anaplasia)</p>
          <p>{FLD:AJCC X} Gleason 8-10 Poorly differentiated/undifferentiated (marked </p>
          <p>anaplasia)</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X}Not Applicable</p>
          <p>{FLD:AJCC X}Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:AJCC X}R0 No residual tumor</p>
          <p>{FLD:AJCC X}R1 Microscopic residual tumor</p>
          <p>{FLD:AJCC X}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:AJCC X}National guidelines were used in treatment planning </p>
          <p>{FLD:AJCC X}NCCN </p>
          <p>{FLD:AJCC X}Other (describe):{FLD:FREE TEXT}</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Renal Pelvis and Ureter">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>RENAL PELVIS AND URETER</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:AJCC X} y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X} y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p></p>
          <p>Tumor Size:{FLD:AJCC EDIT50}</p>
          <p>Laterality:</p>
          <p> {FLD:AJCC X} Left</p>
          <p> {FLD:AJCC X} Right</p>
          <p> {FLD:AJCC X} Bilateral</p>
          <p></p>
          <p> </p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Ta      Papillary noninvasive carcinoma</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis     Carcinoma in situ</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor invades subepithelial connective tissue</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor invades muscularis </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      (For Renal Pelvis only) Tumor invades beyond</p>
          <p>                       muscularis into peripelvic fat or renal </p>
          <p>                       parenchyma </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      (For Ureter only) Tumor invades beyond </p>
          <p>                       muscularis into periureteric fat</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      Tumor invades adjacent organs or through the </p>
          <p>                       kidney into perinephric fat</p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)*</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph nodes cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Mets in single LN, 2 cm or less in greatest</p>
          <p>                       dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2      Mets in single LN more than 2 cm but less </p>
          <p>                       than 5 cm or multiple lymph nodes, none more </p>
          <p>                       than 5 cm</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N3      Metastasis in lymph node more 5 cm in </p>
          <p>                       greatest dimension</p>
          <p> </p>
          <p>             *Note: Laterality does not affect the N classification</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0a      Ta      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0is     Tis     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     I       T1      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     II      T2      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     III     T3      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IV      T4      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Any T   N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Any T   N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Any T   N3      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Any T   Any N   M1</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Unknown Stage</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Renal parenchymal invasion: {FLD:AJCC EDIT50}</p>
          <p>World Health Organization/International Society of Urologic Pathology (WHO/ISUP) </p>
          <p>grade: {FLD:AJCC EDIT50}</p>
          <p></p>
          <p>HISTOLOGIC GRADE: WHO/ISUP</p>
          <p>{FLD:AJCC X} LOW GRADE</p>
          <p>{FLD:AJCC X} HIGH GRADE</p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>{FLD:AJCC X} 2 grade system                              {FLD:AJCC X}    Grade I or 1</p>
          <p>{FLD:AJCC X} 3 grade system                              {FLD:AJCC X}    Grade II or 2</p>
          <p>{FLD:AJCC X} 4 grade system                              {FLD:AJCC X}    Grade III or 3</p>
          <p>{FLD:AJCC X} No 2,3,or 4 grade system is available       {FLD:AJCC X}    Grade IV or 4</p>
          <p>                                                {FLD:AJCC X}    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X} Not Applicable</p>
          <p>{FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X} RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:AJCC X} R0 No residual tumor</p>
          <p>{FLD:AJCC X} R1 Microscopic residual tumor</p>
          <p>{FLD:AJCC X} R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X} Clinical stage was used in treatment planning (describe): {FLD:AJCC W-P INDENT3}</p>
          <p>{FLD:AJCC X}National guidelines were used in treatment planning </p>
          <p>   {FLD:AJCC X} NCCN </p>
          <p>   {FLD:AJCC X} Other (describe): {FLD:AJCC W-P INDENT3}</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Retinoblastoma Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>RETINOBLASTOMA</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:{FLD:AJCC EDIT45}</p>
          <p>Laterality:</p>
          <p> {FLD:AJCC X} Left</p>
          <p> {FLD:AJCC X} Right</p>
          <p> {FLD:AJCC X} Bilateral</p>
          <p></p>
          <p></p>
          <p></p>
          <p></p>
          <p></p>
          <p>CLINICAL            PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}         TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}         T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}         T1      Tumor no more than 2/3 the volume of the eye 	</p>
          <p>				  with no vitreous or subretinal seeding.</p>
          <p>{FLD:AJCC X}         T1a     No tumor in either eye is greater than 3mm in 	</p>
          <p>				  largest dimension or located closer than 1.5mm to the 	</p>
          <p>				 optic nerve or fovea.</p>
          <p>{FLD:AJCC X}         T1b     At least one tumor is greater than 3mm in 		</p>
          <p>				 largest dimension or located closer than 1.5mm to the 	</p>
          <p>				 optic nerve or fovea. No retinal detachment or subretinal  </p>
          <p>				 fluid beyond 5mm from the base of the tumor.</p>
          <p>{FLD:AJCC X}         T1c     At least one tumor is greater than 3mm in 		</p>
          <p>				 largest </p>
          <p>                    dimension or located closer than 1.5mm to the optic nerve</p>
          <p>                    or fovea. With retinal detachment of subretinal fluid</p>
          <p>                    beyond 5mm from the base of the tumor.</p>
          <p>{FLD:AJCC X}         T2      Tumor no more than 2/3 the volume of the eye 	</p>
          <p>				 with Vitreous or subretinal seeding. Can have retinal</p>
          <p>                    detachment.</p>
          <p>{FLD:AJCC X}         T2a     Focal vitreous and/or subretinal seeding of fine</p>
          <p>                    aggregates of tumor cells is present, but no large clumps</p>
          <p>                    or "snowballs" of tumor cells. </p>
          <p>{FLD:AJCC X}         T2b     Massive vitreous and/or subretinal seeding is 	</p>
          <p>				 present,defined as diffuse clumps or "snowballs" of tumor </p>
          <p>				 cells</p>
          <p>{FLD:AJCC X}         T3      Severe intraocular disease</p>
          <p>{FLD:AJCC X}         T3a     Tumor fills more than 2/3 of the eye</p>
          <p>{FLD:AJCC X}         T3b     One or more complications present, which may 	</p>
          <p>				 include tumor-associated neovascular or angle closure 	</p>
          <p>				 glaucoma,tumor extension into the anterior segment, 	</p>
          <p>				 hyphema, vitreous hemorrhage or orbital cellulitis.</p>
          <p>{FLD:AJCC X}         T4      Extraocular disease detected by imaging studies</p>
          <p>{FLD:AJCC X}         T4a     Invasion of optic nerve</p>
          <p>{FLD:AJCC X}         T4b     Invasion into the orbit</p>
          <p>{FLD:AJCC X}         T4c     Intracranial extension not past chiasm</p>
          <p>{FLD:AJCC X}         T4d     Intracranial extension past chiasm</p>
          <p></p>
          <p>PATHOLOGIC          PRIMARY TUMOR (pT)</p>
          <p>[{FLD:AJCC X}       pTX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}        pT0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}        pT1      Tumor confined to eye with no optic nerve or 	</p>
          <p>				 choroidal Invasion.</p>
          <p>{FLD:AJCC X}        pT2      Tumor with minimal optic nerve and/or choroidal </p>
          <p>				 invasion.</p>
          <p>{FLD:AJCC X}        pT2a     Tumor superficially invades optic nerve head but </p>
          <p>				 does not  extend past lamina cribrosa or tumor exhibits 	</p>
          <p>				 focal choroidal invasion.</p>
          <p>{FLD:AJCC X}        pT2b     Tumor superficially invades optic nerve head but </p>
          <p>				 does not extend past lamina cribrosa and exhibits focal 	</p>
          <p>				 choroidal invasion</p>
          <p>{FLD:AJCC X}        pT3      Tumor with significant optic nerve and/or 		</p>
          <p>				 choroidal invasion</p>
          <p>{FLD:AJCC X}        pT3a     Tumor invades optic nerve past lamina cribrosa 	</p>
          <p>				 but not to surgical resection line or tumor exhibits 	</p>
          <p>				 massive choroidal invasion</p>
          <p>{FLD:AJCC X}        pT3b     One or more complications present, which may 	</p>
          <p>				 include tumor-associated neovascular or angle closure 	</p>
          <p>				 glaucoma,a tumor extension into the anterior segment, 	</p>
          <p>				 hyphema, vitreous hemorrhage or orbital cellulitis.</p>
          <p>{FLD:AJCC X}        pT4      Tumor invades optic nerve to resection line or 	</p>
          <p>				 exhibits  extraocular extension elsewhere</p>
          <p>{FLD:AJCC X}        pT4a     Tumor invades optic nerve to resection line but </p>
          <p>				 no extraocular extension identified</p>
          <p>{FLD:AJCC X}        pT4b     Tumor invades optic nerve to resection line and</p>
          <p>                    extraocular extension identified</p>
          <p></p>
          <p>Clin   Path    REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX   Regional lymph nodes cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0   No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1   Regional lymph node involvement 		</p>
          <p>				(preauricular,cervical, submandibular)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2   Distant lymph node involvement</p>
          <p></p>
          <p> </p>
          <p>CLINICAL            DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}         M0      No distant metastasis (no pathologic M0; use </p>
          <p>{FLD:AJCC X}                 clinical M to complete stage group) </p>
          <p>{FLD:AJCC X}         M1      Systemic metastasis</p>
          <p>{FLD:AJCC X}         M1a     Single lesions to sites other than CNS</p>
          <p>{FLD:AJCC X}         M1b     Multiple lesions to sites other than CNS</p>
          <p>{FLD:AJCC X}         M1c     Prechiasmatic CNS lesion(s)</p>
          <p>{FLD:AJCC X}         M1d     Postchiasmatic CNS lesions(s)</p>
          <p>{FLD:AJCC X}         M1e     Leptomeningeal and/or CSF involvement</p>
          <p></p>
          <p>PATHOLOGIC          DISTANT METASTASIS (pM)</p>
          <p>{FLD:AJCC X}        pM1      Metastasis to sites other than CNS</p>
          <p>{FLD:AJCC X}        pM1a     Single lesion</p>
          <p>{FLD:AJCC X}        pM1b     Multiple lesions</p>
          <p>{FLD:AJCC X}        pM1c     CNS metastasis</p>
          <p>{FLD:AJCC X}        pM1d     Discrete mass(es) without leptomeningeal and/or </p>
          <p>				 CSF  Involvement</p>
          <p>{FLD:AJCC X}        pM1e     Leptomeningeal and/or CSF involvement</p>
          <p></p>
          <p>STAGE GROUPING:</p>
          <p>No stage grouping is presently recommended</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>{FLD:AJCC X} Extension evaluated at enucleation</p>
          <p>{FLD:AJCC X} RB gene mutation </p>
          <p>{FLD:AJCC X} Positive family history of retinoblastoma</p>
          <p>{FLD:AJCC X} Greater linear extent of choroid involved by choroidal tumor </p>
          <p>invasion</p>
          <p></p>
          <p>GRADING SYSTEM</p>
          <p></p>
          <p>{FLD:X BOX} 2 grade system				{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 		        {FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 			{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available  {FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been</p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:X BOX}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:X BOX}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:X BOX}Not Applicable</p>
          <p>{FLD:X BOX}Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some</p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:X BOX}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:X BOX}R0 No residual tumor</p>
          <p>{FLD:X BOX}R1 Microscopic residual tumor</p>
          <p>{FLD:X BOX}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:X BOX}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:X BOX}National guidelines were used in treatment planning </p>
          <p>{FLD:X BOX}NCCN </p>
          <p>{FLD:X BOX}Other (describe):{FLD:WP 2}</p>
          <p></p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Salivary Glands Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>{FLD:AJCC 7TH EDITION HDR}</p>
          <p>AJCC CANCER STAGING 7th EDITION--MAJOR SALIVARY GLANDS</p>
          <p></p>
          <p>Type of specimen: {FLD:AJCC EDIT50}</p>
          <p>Histopathologic type: {FLD:AJCC EDIT50}</p>
          <p>Tumor size: {FLD:AJCC EDIT50}</p>
          <p>Laterality: {FLD:X BUTTON1}Bilateral   {FLD:X BUTTON1}Left     {FLD:X </p>
          <p>BUTTON1}Right</p>
          <p></p>
          <p>PRIMARY TUMOR(T):</p>
          <p>{FLD:AJCC 7TH EDITION CLINICAL STAGING TEXT}                          </p>
          <p>{FLD:AJCC 7TH EDITION PATHOLOGIC STAGING TEXT}</p>
          <p></p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p></p>
          <p>{FLD:X BUTTON1} y clinical  -                               {FLD:X BUTTON1} y </p>
          <p>pathologic - </p>
          <p>staging completed                                staging completed</p>
          <p>after neoadjuvant therapy but                    after neoadjuvant therapy</p>
          <p>before subsequent surgery.                       AND subsequent surgery.</p>
          <p>                                              </p>
          <p> {FLD:X BUTTON1} TX   Primary tumor cannot be assessed               {FLD:X </p>
          <p>BUTTON1} TX</p>
          <p> {FLD:X BUTTON1} T0   No evidence of primary tumor                   {FLD:X </p>
          <p>BUTTON1} T0</p>
          <p> {FLD:X BUTTON1} T1   Tumor 2 cm or less in greatest dimension       {FLD:X </p>
          <p>BUTTON1} T1</p>
          <p>            without extraparenchymal extension*</p>
          <p> {FLD:X BUTTON1} T2   Tumor more than 2 cm but not more than 4 cm    {FLD:X </p>
          <p>BUTTON1} T2</p>
          <p>            in greatest dimension without extraparenchymal</p>
          <p>            extension.*</p>
          <p> {FLD:X BUTTON1} T3   Tumor more than 4 cm and/or tumor having       {FLD:X </p>
          <p>BUTTON1} T3</p>
          <p>            extraparenchymal extension*</p>
          <p> {FLD:X BUTTON1} T4a  Moderately advanced disease.                   {FLD:X </p>
          <p>BUTTON1} T4a</p>
          <p>            Tumor invades skin, mandible, ear canal,</p>
          <p>            and/or facial nerve</p>
          <p> {FLD:X BUTTON1} T4b  Very advanced disease.                         {FLD:X </p>
          <p>BUTTON1} T4b</p>
          <p>            Tumor invades skull base and/or pterygoid </p>
          <p>            plates and/or encases carotid artery.</p>
          <p>     *NOTE: Extraparenchymal extension is clinical or macroscopic</p>
          <p>            evidence of invasion of soft tissues.  Microscopic </p>
          <p>            evidence alone does not constitute extraparenchymal</p>
          <p>            extension for classification purposes.</p>
          <p></p>
          <p>REGIONAL LYMPH NODES (N):</p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p></p>
          <p> {FLD:X BUTTON1} NX   Regional lymph nodes cannot be assessed.       {FLD:X </p>
          <p>BUTTON1} NX</p>
          <p> {FLD:X BUTTON1} N0   No regional lymph node metastasis.             {FLD:X </p>
          <p>BUTTON1} N0</p>
          <p> {FLD:X BUTTON1} N1   Metastasis in a single ipsilateral lymph node, {FLD:X </p>
          <p>BUTTON1} N1</p>
          <p>            3 cm or less in greatest dimension.</p>
          <p> {FLD:X BUTTON1} N2   Metastasis in a single ipsilateral lymph node, {FLD:X </p>
          <p>BUTTON1} N2</p>
          <p>            more than 3 cm but not more than 6 cm in</p>
          <p>            greatest dimension, or in multiple </p>
          <p>            ipsilateral lymph nodes, none more</p>
          <p>            than 6 cm in greatest dimension, or</p>
          <p>            in bilateral or contralateral lymph</p>
          <p>            nodes, none more than 6 cm in greatest</p>
          <p>            dimension.</p>
          <p> {FLD:X BUTTON1} N2a  Metastasis in a single ipsilateral lymph node, {FLD:X </p>
          <p>BUTTON1} N2a</p>
          <p>            more than 3 cm but not more than 6 cm in</p>
          <p>            greatest dimension.</p>
          <p> {FLD:X BUTTON1} N2b  Metastasis in multiple ipsilateral lymph       {FLD:X </p>
          <p>BUTTON1} N2b</p>
          <p>            nodes, none more than 6 cm in greatest</p>
          <p>            dimension.</p>
          <p> {FLD:X BUTTON1} N2c  Metastasis in bilateral or contralateral lymph {FLD:X </p>
          <p>BUTTON1} N2c</p>
          <p>            nodes, none more than 6 cm in greatest</p>
          <p>            dimension.</p>
          <p> {FLD:X BUTTON1} N3   Metastasis in a lymph node, more than 6 cm in  {FLD:X </p>
          <p>BUTTON1} N3</p>
          <p>            greatest dimension.</p>
          <p></p>
          <p>DISTANT METASTASIS(M):</p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p> {FLD:X BUTTON1} M0   No distant metastasis</p>
          <p>      {FLD:AJCC 7TH ED PARANASAL DISTANT METS NOTE}</p>
          <p> {FLD:X BUTTON1} M1   Distant metastasis                             {FLD:X </p>
          <p>BUTTON1} M1</p>
          <p></p>
          <p>STAGE GROUPING:</p>
          <p>Clinical Group     T       N       M       Group   Pathologic</p>
          <p>  {FLD:X BUTTON1}      I       T1      N0      M0      I           {FLD:X </p>
          <p>BUTTON1}</p>
          <p>  {FLD:X BUTTON1}      II      T2      N0      M0      II          {FLD:X </p>
          <p>BUTTON1}</p>
          <p>  {FLD:X BUTTON1}      III     T3      N0      M0      III         {FLD:X </p>
          <p>BUTTON1}</p>
          <p>                   T1      N1      M0</p>
          <p>                   T2      N1      M0</p>
          <p>                   T3      N1      M0</p>
          <p>  {FLD:X BUTTON1}      IVA     T4a     N0      M0      IVA         {FLD:X </p>
          <p>BUTTON1}</p>
          <p>                   T4a     N1      M0 </p>
          <p>                   T1      N2      M0 </p>
          <p>                   T2      N2      M0 </p>
          <p>                   T3      N2      M0                  </p>
          <p>                   T4a     N2      M0                  </p>
          <p>  {FLD:X BUTTON1}      IVB     T4b     Any N   M0      IVB         {FLD:X </p>
          <p>BUTTON1}</p>
          <p>                   Any T   N3      M0                  </p>
          <p>  {FLD:X BUTTON1}      IVC     Any T   Any N   M1      IVC         {FLD:X </p>
          <p>BUTTON1}</p>
          <p>  {FLD:X BUTTON1}               Stage Unknown                      {FLD:X </p>
          <p>BUTTON1}</p>
          <p></p>
          <p>Prognostic Factors: (Site-Specific Factors)</p>
          <p>Required for Staging: NONE</p>
          <p>Clinically Significant Factors:</p>
          <p>  Size of Lymph Nodes: </p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Extracapsular Extension from Lymph Nodes for Head &amp; Neck: </p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Head &amp; Neck Lymph Nodes Levels I - III:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Head &amp; Neck Lymph Nodes Levels IV - V:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Head &amp; Neck Lymph Nodes Levels VI - VII:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Other Lymph Nodes Group:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Clinical Location of cervical nodes:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Extracapsular spread (ECS) Clinical:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Extracapsular spread (ECS) Pathologic:</p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>General Notes:</p>
          <p>For identification of special cases of TNM or pTNM classifications, the "m" </p>
          <p>suffix and "y", "r", and "a" prefixes are used.  Although they do not affect</p>
          <p>the stage grouping, they indicate cases needing separate analysis.</p>
          <p>  </p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p></p>
          <p> {FLD:X BUTTON1} m   suffix to indicate the presence of primary      {FLD:X </p>
          <p>BUTTON1} m</p>
          <p>           tumors in a single site and is recorded</p>
          <p>           in parenthesis: pT(m)NM.</p>
          <p></p>
          <p> {FLD:X BUTTON1} y   prefix to indicate those cases in which         {FLD:X </p>
          <p>BUTTON1} y</p>
          <p>           classification is performed during or </p>
          <p>           following initial multimodality therapy.</p>
          <p>           The cTNM or pTNM category is identified</p>
          <p>           by a "y" prefix.  The ycTNM or ypTNM </p>
          <p>           categorizes the extent of tumor actually</p>
          <p>           present at the time of that examination.</p>
          <p>           The "y" categorization is not an estimate</p>
          <p>           of tumor prior to multimodality therapy.</p>
          <p></p>
          <p> {FLD:X BUTTON1} r   prefix to indicate a recurrent tumor when       {FLD:X </p>
          <p>BUTTON1} r</p>
          <p>           staged after a disease-free interval and </p>
          <p>           is identified by the "r" prefix: rTNM.</p>
          <p></p>
          <p> {FLD:X BUTTON1} a   prefix to indicate the stage was determined at  {FLD:X </p>
          <p>BUTTON1} a</p>
          <p>           autopsy: aTNM.</p>
          <p></p>
          <p>Surgical margins is data field recorded by registrars describing the surgical </p>
          <p>margins of the resected primary site specimen as determined only by the </p>
          <p>pathology report.</p>
          <p></p>
          <p>Neoadjuvant treatment is radiation therapy or systemic therapy (consisting of</p>
          <p>chemotherapy, hormone therapy, or immunotherapy) administered prior to a </p>
          <p>definitive surgical procedure.  If the surgical procedure is not performed,</p>
          <p>the administered therapy no longer meets the definition of neoadjuvant </p>
          <p>therapy.</p>
          <p></p>
          <p>Histologic Grade (G): (also known as overall grade)</p>
          <p></p>
          <p>Grading System                                Grade</p>
          <p> {FLD:X BUTTON1} 2 grade system                            {FLD:X BUTTON1} </p>
          <p>Grade I or 1</p>
          <p> {FLD:X BUTTON1} 3 grade system                            {FLD:X BUTTON1} </p>
          <p>Grade II or 2</p>
          <p> {FLD:X BUTTON1} 4 grade system                            {FLD:X BUTTON1} </p>
          <p>Grade III or 3</p>
          <p> {FLD:X BUTTON1} No 2, 3, or 4 grade system is available   {FLD:X BUTTON1} </p>
          <p>Grade IV or 4</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p></p>
          <p>Lypmhatic Vessel Invasion (L) and Venous Invasion (V) have been combined </p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.  The </p>
          <p>College of American Pathologists' (CAP) Checklist should be used as the </p>
          <p>primary </p>
          <p>source.  Other sources may be used in the absence of a Checklist.  Priority </p>
          <p>is </p>
          <p>given to positive results.</p>
          <p></p>
          <p>  {FLD:X BUTTON1} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>  {FLD:X BUTTON1} Lymph-Vascular Invasion Present/Identified</p>
          <p>  {FLD:X BUTTON1} Not Applicable</p>
          <p>  {FLD:X BUTTON1} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p></p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be residual </p>
          <p>tumor at the primary site after treatment because of incomplete resection or </p>
          <p>local and regional disease that extends beyond the limit of ability of </p>
          <p>resection.</p>
          <p></p>
          <p>  {FLD:X BUTTON1} RX   Presence of residual tumor cannot be assessed</p>
          <p>  {FLD:X BUTTON1} R0   No Residual Tumor</p>
          <p>  {FLD:X BUTTON1} R1   Microscopic residual tumor</p>
          <p>  {FLD:X BUTTON1} R2   Macroscopic residual tumor</p>
          <p></p>
          <p>Additional Information:</p>
          <p></p>
          <p> {FLD:X BUTTON1}Yes {FLD:X BUTTON1}No Clinical stage was used in treatment </p>
          <p>planning </p>
          <p>(describe):</p>
          <p>{FLD:WORD PROCESSING 1 LINE N/R HDB}</p>
          <p></p>
          <p> {FLD:X BUTTON1}Yes {FLD:X BUTTON1}No National guidelines were used in </p>
          <p>treatment </p>
          <p>planning: </p>
          <p>          {FLD:X BUTTON1}National Comprehensive Cancer Network (NCCN)</p>
          <p>          {FLD:X BUTTON1}Other (describe):</p>
          <p>{FLD:WORD PROCESSING 1 LINE N/R HDB}</p>
          <p></p>
          <p>{FLD:AJCC 7TH EDITION STAGING ILLUSTRATIONS}</p>
          <p> {FLD:X BUTTON1}Yes {FLD:X BUTTON1}No Have you completed the illustration </p>
          <p>page for </p>
          <p>this AJCC Staging form?</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Small Intestine Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>SMALL INTESTINE</p>
          <p>(Lymphomas, carcinoid tumors, and visceral sarcomas are not included)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:{FLD:AJCC EDIT45}</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis     Carcinoma in situ</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1a     Tumor invades lamina propria</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1b     Tumor invades submucosa</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor invades muscularis propria</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Tumor invades through the muscularis </p>
          <p>propria into the</p>
          <p>                       subserosa or into the nonperitonealized perimuscular</p>
          <p>                       tissue (mesentery or retroperitoneum) with extention </p>
          <p>                       2 cm or less*</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      Tumor perforates the visceral </p>
          <p>peritoneum or directly</p>
          <p>                       invades other organs or structures (includes other</p>
          <p>                       loops of small intestine, mesentery, or </p>
          <p>                       retroperitoneum more than 2 cm, and abdominal wall by </p>
          <p>                       way of serosa; for duodenum only, invasion of pancreas</p>
          <p>                       or bile duct</p>
          <p>  *The nonperitonealized perimuscular tissue is, for jejunum and ileum, part</p>
          <p>  of the mesentery and, for duodenum in areas where serosa is lacking, part </p>
          <p>  of the interface with the pancreas.</p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph nodes cannot be </p>
          <p>assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Metastasis in 1 to 3 regional lymph </p>
          <p>nodes </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2      Metastasis in 4 or more regional </p>
          <p>lymph nodes</p>
          <p></p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}             M0      No distant metastasis (no pathologic M0;</p>
          <p>                       use clinical M to complete stage group) </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0       Tis     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     I       T1      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIA     T3      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIB     T4      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIA    Any T   N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIB    Any T   N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IV      Any T   Any N   M1</p>
          <p>{FLD:AJCC X} UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : {FLD:AJCC X}None</p>
          <p>CLINICALLY SIGNIFICANT :{FLD:AJCC EDIT50}</p>
          <p>Pre-surgical carcinoembryonic antigen (CEA):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Microsatellite instatbility (MSI): {FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Presence of Crohn's Disease: {FLD:AJCC EDIT50}</p>
          <p></p>
          <p></p>
          <p>GRADING SYSTEM</p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>Checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X} Not Applicable</p>
          <p>{FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X} RX  Presence of residual tumor cannot be assessed.</p>
          <p>{FLD:AJCC X} R0  No residual tumor</p>
          <p>{FLD:AJCC X} R1  Microscopic residual tumor</p>
          <p>{FLD:AJCC X} R2  Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}  Clinical stage was used in the treatment planning (describe):</p>
          <p>{FLD:AJCC EDIT45}</p>
          <p>{FLD:AJCC X}  National guidelines were used in treatment planning</p>
          <p>     {FLD:AJCC X} NCCN</p>
          <p>     {FLD:AJCC X} Other(describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Soft Tissue Sarcoma Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>SOFT TISSUE SARCOMA</p>
          <p></p>
          <p>(Kaposi's sarcoma, fibromatosis [desmoid tumor], and sarcoma </p>
          <p>arising from the dura mater, brain, parenchymatous organs or hollow viscera </p>
          <p>are not included.)</p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:AJCC X} y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X} y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size: {FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Laterality:</p>
          <p>          {FLD:AJCC X} Left</p>
          <p>          {FLD:AJCC X} Right</p>
          <p>          {FLD:AJCC X} Bilateral</p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor 5 cm or less in greatest dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1a       Superficial tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1b       Deep tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor more than 5 cm in greatest dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2a       Superficial tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2b       Deep tumor</p>
          <p> </p>
          <p>Note:  Superficial tumor is located exclusively above the superficial</p>
          <p>fascia without invasion of the fascia; deep tumor is located either</p>
          <p>exclusively beneath the superficial fascia, or superficial to the fascia</p>
          <p>with invasion of or through the fascia, or superficial and beneath the</p>
          <p>fascia.   </p>
          <p>               REGIONAL LYMPH NODE (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph nodes cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1*     Regional lymph node metastasis</p>
          <p></p>
          <p>*Note:  Presence of positive nodes (N1) or M0 tumors is considered</p>
          <p> Stage III.</p>
          <p> </p>
          <p>               DISTANT METASTASIS </p>
          <p>{FLD:AJCC X}            M0      No distant metastasis (no pathologic M0; use</p>
          <p>                       Clinical M to complete stage group)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis</p>
          <p> </p>
          <p>STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IA      T1a     N0    M0    G1,GX     </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1b     N0    M0    G1,GX     </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IB      T2a     N0    M0    G1,GX    </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2b     N0    M0    G1,GX     </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIA     T1a     N0    M0    G2,G3  </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1b     N0    M0    G2,G3   </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIB     T2a     N0    M0    G2           </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2b     N0    M0    G2           </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     III     T2a,T2b N0    M0    G3           </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Any T   N1    M0    Any G        </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IV      Any T   Any N M1    Any G      </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Stage Unknown</p>
          <p>                       </p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING:  None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>    Neurovascular invasion as determined by pathology: {FLD:AJCC EDIT50}</p>
          <p>    Bone invasion as determined by imaging: {FLD:AJCC EDIT50}</p>
          <p>    If pM1, source of pathologic metastatic specimen: {FLD:AJCC EDIT50} </p>
          <p></p>
          <p>Histologic Grade (G) (also known as overall grade)</p>
          <p></p>
          <p>GRADING SYSTEM 					GRADE</p>
          <p>                                 </p>
          <p>{FLD:AJCC X} 2 grade system                              {FLD:AJCC X}    Grade I or 1</p>
          <p>{FLD:AJCC X} 3 grade system                              {FLD:AJCC X}    Grade II or 2</p>
          <p>{FLD:AJCC X} 4 grade system                              {FLD:AJCC X}    Grade III or 3</p>
          <p>{FLD:AJCC X} No 2,3,or 4 grade system is available       {FLD:AJCC X}    Grade IV or 4</p>
          <p>                                                {FLD:AJCC X}    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X} Not Applicable</p>
          <p>{FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X} RX  Presence of residual tumor cannot be assessed.</p>
          <p>{FLD:AJCC X} R0  No residual tumor</p>
          <p>{FLD:AJCC X} R1  Microscopic residual tumor</p>
          <p>{FLD:AJCC X} R2  Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}  Clinical stage was used in the treatment planning (describe):{FLD:AJCC W-P INDENT3}</p>
          <p>{FLD:AJCC X}  National guidelines were used in treatment planning:</p>
          <p>     {FLD:AJCC X}  NCCN</p>
          <p>     {FLD:AJCC X}  Other: {FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Squamous Cell and Other Cutaneous CA Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>CUTANEOUS SQUAMOUS CELL CARCINOMAS AND OTHER CUTANEOUS CARCINOMAS</p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:AJCC X} y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X} y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size: {FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Laterality:</p>
          <p>          {FLD:AJCC X} Left</p>
          <p>          {FLD:AJCC X} Right</p>
          <p>          {FLD:AJCC X} Midline</p>
          <p>          {FLD:AJCC X} Bilateral</p>
          <p></p>
          <p>CLIN   PATH            PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis     Tis Carcinoma in situ</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor 2 cm or less in greatest dimension</p>
          <p>                       with less than two high risk features**</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor greater than 2 cm in greatest</p>
          <p>                       dimension or Tumor any size with two or </p>
          <p>                       more high risk features*</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Tumor with invasion of maxilla, orbit or</p>
          <p>                       temporal bone </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      Tumor with invasion of skeleton (axial or </p>
          <p>                       appendicular) or perineural invasion of skull base</p>
          <p></p>
          <p>* Excludes cSCC of the eyelid</p>
          <p>**  High Risk Features for the Primary Tumor (T) Staging:</p>
          <p>      Depth/Invasion:  &gt;2 mm thickness, Clark level &gt; or = IV,</p>
          <p>        Perineural invasion</p>
          <p>      Anatomic Location: Primary site ear, Primary site hair-</p>
          <p>        bearing lip</p>
          <p>      Differentiation: Poorly differentiated or undifferentiated</p>
          <p> </p>
          <p>                       REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph nodes cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Metastasis in a single ipsilateral lymph </p>
          <p>                       node, 3 cm or less in greatest dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2      Metastasis in a single ipsilateral lymph node,</p>
          <p>                       more than 3 cm but not more than 6 cm in</p>
          <p>                       greatest dimension; or in multiple ipsilateral</p>
          <p>                       lymph nodes, none more than 6 cm in greatest</p>
          <p>                       dimension; or in bilateral or contralateral</p>
          <p>                       lymph nodes, none more than 6 cm in greatest</p>
          <p>                       dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2a     Metastasis in a single ipsilateral lymph node,</p>
          <p>                       more than 3 cm but not more than 6 cm in </p>
          <p>                       greatest dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2b     Metastasis in multiple ipsilateral lymph nodes,</p>
          <p>                       none more than 6 cm in greatest dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2c     Metastasis in bilateral or contralateral lymph</p>
          <p>                       nodes, none more than 6 cm in greatest dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N3      Metastasis in a lymph node, nore than 6 cm in </p>
          <p>                       greatest dimension</p>
          <p> </p>
          <p> </p>
          <p>                       DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}                     M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p> </p>
          <p>CLIN   PATH    STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0       Tis     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     I       T1      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     II      T2      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     III     T3      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IV      T1      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T Any   N3      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T4      N Any   M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T Any   N Any   M1</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Stage Unknown</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING:  None</p>
          <p>Tumor Thickness: {FLD:AJCC EDIT50}</p>
          <p>Clark's Level: {FLD:AJCC EDIT50}</p>
          <p>Presence/Absence of perineural invasion: {FLD:AJCC EDIT50}</p>
          <p>Primary site location on ear or hair-bearing lip: {FLD:AJCC EDIT50}</p>
          <p>Histologic Grade: {FLD:AJCC EDIT50}</p>
          <p>Size of largest lymph node metastasis: {FLD:AJCC EDIT50}</p>
          <p>CLINICALLY SIGNIFICANT: No additional factors.</p>
          <p></p>
          <p> Histologic Grade (G) (also known as overall grade)</p>
          <p></p>
          <p>GRADING SYSTEM 					GRADE</p>
          <p>                                 </p>
          <p>{FLD:AJCC X} 2 grade system                              {FLD:AJCC X}    Grade I or 1</p>
          <p>{FLD:AJCC X} 3 grade system                              {FLD:AJCC X}    Grade II or 2</p>
          <p>{FLD:AJCC X} 4 grade system                              {FLD:AJCC X}    Grade III or 3</p>
          <p>{FLD:AJCC X} No 2,3,or 4 grade system is available       {FLD:AJCC X}    Grade IV or 4</p>
          <p>                                                {FLD:AJCC X}    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X} Not Applicable</p>
          <p>{FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X} RX  Presence of residual tumor cannot be assessed.</p>
          <p>{FLD:AJCC X} R0  No residual tumor</p>
          <p>{FLD:AJCC X} R1  Microscopic residual tumor</p>
          <p>{FLD:AJCC X} R2  Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}  Clinical stage was used in the treatment planning (describe):{FLD:AJCC W-P INDENT3}</p>
          <p>{FLD:AJCC X}  National guidelines were used in treatment planning:</p>
          <p>     {FLD:AJCC X}  NCCN</p>
          <p>     {FLD:AJCC X}  Other: {FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Stomach Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>STOMACH</p>
          <p>(Lymphomas, sarcomas and carcinoid tumors [low-grade neuroendocrine </p>
          <p> tumors] are not included)</p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis     Carcinoma in situ: intraepithelial </p>
          <p>tumor without</p>
          <p>                       invasion of lamina propria</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor invades lamina propria, </p>
          <p>muscularis </p>
          <p>                       mucosae, or submucosa</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1a     Tumor invades lamina propria or </p>
          <p>muscularis </p>
          <p>                       mucosae</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor invades submucosa</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor invades muscularis propria or </p>
          <p>subserosa*</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Tumor penetrates subserosal </p>
          <p>connective tissue </p>
          <p>                       without invasion of visceral peritoneum or </p>
          <p>                       adjacent structures*,**,*** </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      Tumor invades serosa (visceral </p>
          <p>peritoneum) or </p>
          <p>                       adjacent structures**,***</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4a     Tumor invades serosa (visceral </p>
          <p>peritoneum)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4b     Tumor invades adjacent structures</p>
          <p></p>
          <p>*A tumor may penetrate the muscularis propria with extension into the </p>
          <p>gastrocolic or gastrohepatic ligaments, or into the greater or lesser </p>
          <p>omentum, without perforation of the visceral peritoneum covering these </p>
          <p>structures. In this case, the tumor is classified T3. If there is </p>
          <p>perforation of the visceral peritoneum covering the gastric ligaments </p>
          <p>or the omentum, the tumor should be classified T4.</p>
          <p></p>
          <p>**The adjacent structures of the stomach include the spleen, transverse </p>
          <p>colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, </p>
          <p>kidney, small intestine, and retroperitoneum.</p>
          <p></p>
          <p>***Intramural extension to the duodenum or esophagus is classified by </p>
          <p>the depth of the greatest invasion in any of these sites, including the </p>
          <p>stomach.  </p>
          <p></p>
          <p>               LYMPH NODE (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph nodes(s) cannot be </p>
          <p>assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Mets in 1 to 2 regional lymph nodes</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2      Mets in 3 to 6 region lymph nodes</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N3      Mets in 7 or more region lymph nodes</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N3a     Mets in 7 to 15 lymph nodes</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N3b     Mets in 16 or more region lymph </p>
          <p>nodes</p>
          <p></p>
          <p>* A designation of pN0 should be used if all examined lymph nodes are </p>
          <p>negative, regardless of the total number removed and examined.</p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}             M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0       Tis     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IA      T1      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IB      T2      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIA     T3      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIB     T4a     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      N3      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIA    T4a     N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      N3      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIB    T4b     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4b     N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4a     N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      N3      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIC    T4b     N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4b     N3      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4a     N3      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IV      AnyT    AnyN    M1</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>  Tumor location: {FLD:AJCC EDIT50}</p>
          <p>  Serum carcinoembryonic antigen: {FLD:AJCC EDIT50}</p>
          <p>  Serum CA19.9: {FLD:AJCC EDIT50}</p>
          <p></p>
          <p></p>
          <p>GRADING SYSTEM       </p>
          <p>                           </p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X}Not Applicable</p>
          <p>{FLD:AJCC X}Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:AJCC X}R0 No residual tumor</p>
          <p>{FLD:AJCC X}R1 Microscopic residual tumor</p>
          <p>{FLD:AJCC X}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:AJCC X}National guidelines were used in treatment planning </p>
          <p>   {FLD:AJCC X}NCCN </p>
          <p>   {FLD:AJCC X}Other (describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Testis Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>TESTIS</p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>The extent of primary tumor is usually classified after radical orchiectomy </p>
          <p>and, </p>
          <p>for this reason, a pathologic stage is assigned.</p>
          <p></p>
          <p>CLIN   PATH</p>
          <p>               PRIMARY TUMOR (T)</p>
          <p>               </p>
          <p>{FLD:AJCC X}     pTX     Primary tumor cannot be assessed (If no </p>
          <p>{FLD:AJCC X}     pT0     No evidence of primary tumor (e.g. histologic scar</p>
          <p>                in testis)</p>
          <p>{FLD:AJCC X}     pTis    Intratubular germ cell neoplasia (carcinoma in Situ)</p>
          <p>{FLD:AJCC X}     pT1     Tumor limited to testis and epididymis w/o</p>
          <p>                  vascular/lymphatic invasion; tumor may invade into</p>
          <p>                  the tunica albuginea but not the tunica vaginalis</p>
          <p>{FLD:AJCC X}     pT2     Tumor limited to testis and epididymis with</p>
          <p>                vascular/lymphatic invasion, or tumor extending</p>
          <p>                through the tunica albuginea with involvement of</p>
          <p>                the tunica vaginalis</p>
          <p>{FLD:AJCC X}     pT3     Tumor invades spermatic cord with or without</p>
          <p>                vascular/lymphatic invasion.</p>
          <p>{FLD:AJCC X}     pT4     Tumor invades the scrotum with or without</p>
          <p>                vascular/lymphatic invasion.</p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>               CLINICAL</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph nodes cannot be </p>
          <p>assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Mets with a lymph node mass 2cm or </p>
          <p>less or</p>
          <p>                       multiple lymph nodes none more than 2cm</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     pN1     Mets with a lymph node mass 2cm or </p>
          <p>less and</p>
          <p>                       less than or equal to 5 nodes positive, none </p>
          <p>                       more that 2cm in greatest dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2      Metastasis with a lymph nodes mass &gt;</p>
          <p>2cm but </p>
          <p>                       not more than 5cm or multiple lymph nodes,</p>
          <p>                       any one mass greater than 2cm but not more </p>
          <p>                       than 5cm in greatest dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     pN2     Metastasis with a lymph nodes mass &gt;</p>
          <p>2cm but </p>
          <p>                       not more than 5cm or more than 5 nodes </p>
          <p>                       positive, none more than 5cm; or evidence of </p>
          <p>                       extranodal extension of tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N3      Metastasis with a lymph node mass </p>
          <p>over 5cm</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     pN3     Metastasis with a lymph node mass </p>
          <p>over 5cm</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}             M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1a     No regional nodal or pulmonary mets</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1b     Distant mets other than to non-</p>
          <p>regional lymph</p>
          <p>                       nodes and lungs</p>
          <p>  </p>
          <p>       STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0       pTis         N0      M0      S0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     I       pT1-4        N0      M0      SX</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IA      pT1          N0      M0      S0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IB      pT2          N0      M0      S0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             pT3          N0      M0      S0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             pT4          N0      M0      S0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IS      Any pT/Tx    N0      M0      S1-3</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     II      Any pT/Tx    N1-3    M0      SX</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIA     Any pT/Tx    N1      M0      S0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Any pT/Tx    N1      M0      S1</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIB     Any pT/Tx    N2      M0      S0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Any pT/Tx    N2      M0      S1</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIC     Any pT/Tx    N3      M0      S0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Any pT/Tx    N3      M0      S1</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     III     Any pT/Tx    Any N   M1      SX</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIA    Any pT/Tx    Any N   M1a     S0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Any pT/Tx    Any N   M1a     S1</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIB    Any pT/Tx    N1-3    M0      S2</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Any pT/Tx    Any N   M1a     S2</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIC    Any pT/Tx    N1-3    M0      S3</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Any pT/Tx    Any N   M1a     S3</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Any pT/Tx    Any N   M1b     Any S</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     UNKNOWN STAGE</p>
          <p></p>
          <p>REQUIRED FOR STAGING:  Serum Tumor Markers (S)</p>
          <p>SX     Marker studies unavailable or not performed</p>
          <p>S0     Marker study levels within normal limits</p>
          <p>S1     LDH &lt;1.5 x N* AND hCG(mlu/ml) &lt;5000 AND AFP &lt;1000</p>
          <p>S2     LDH 1.5-10x N OR hCG(mlu/ml)5000-50,000 OR AFP 1000-10,000</p>
          <p>S3     LDH&gt; 10 x N OR hCG (mlu/ml) &gt;50,000 OR AFP &gt; 10,000</p>
          <p> </p>
          <p>*N indicates the upper limit of normal for the LDH assay</p>
          <p></p>
          <p>Serum tumor maker levels should be measured prior to orchiectomy for </p>
          <p>assignment </p>
          <p>of S category. The only exception is for stage grouping classification of </p>
          <p>Stage </p>
          <p>IS in which persistent elevation of serum tumor markers following orchiectomy </p>
          <p>is </p>
          <p>required.</p>
          <p></p>
          <p>The Serum Tumor Markers (S) category is comprised of the following:</p>
          <p>  Alpha Fetoprotein (AFP)</p>
          <p>  Human Chorionic Gonadotropin (hCG)</p>
          <p>  Lactate Dehydrogenase (LDH)</p>
          <p></p>
          <p>CLINICALLY SIGNIFICANT</p>
          <p>  Size of Largest Metastases in Lymph Nodes {FLD:AJCC EDIT50}</p>
          <p>  Radical Orchiectomy performed {FLD:AJCC X}</p>
          <p></p>
          <p>GRADING SYSTEM	</p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>Checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X} Not Applicable</p>
          <p>{FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X} RX  Presence of residual tumor cannot be assessed.</p>
          <p>{FLD:AJCC X} R0  No residual tumor</p>
          <p>{FLD:AJCC X} R1  Microscopic residual tumor</p>
          <p>{FLD:AJCC X} R2  Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}  Clinical stage was used in the treatment planning (describe):</p>
          <p>{FLD:AJCC EDIT45}</p>
          <p>{FLD:AJCC X}  National guidelines were used in treatment planning</p>
          <p>     {FLD:AJCC X} NCCN</p>
          <p>     {FLD:AJCC X} Other:{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Thyroid Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>{FLD:AJCC 7TH EDITION HDR}</p>
          <p>AJCC CANCER STAGING 7th EDITION--THYROID</p>
          <p></p>
          <p>Type of specimen: {FLD:AJCC EDIT50}</p>
          <p>Histopathologic type: {FLD:AJCC EDIT50}</p>
          <p>Tumor size: {FLD:AJCC EDIT50}</p>
          <p>Laterality: {FLD:AJCC X}Bilateral   {FLD:AJCC X}Left     {FLD:AJCC X}Right</p>
          <p></p>
          <p>PRIMARY TUMOR(T):</p>
          <p>{FLD:AJCC 7TH EDITION CLINICAL STAGING TEXT}                          </p>
          <p>{FLD:AJCC 7TH EDITION PATHOLOGIC STAGING TEXT}</p>
          <p></p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p></p>
          <p>{FLD:AJCC X} y clinical  -                               {FLD:AJCC X} y </p>
          <p>pathologic - </p>
          <p>staging completed                                staging completed</p>
          <p>after neoadjuvant therapy but                    after neoadjuvant therapy</p>
          <p>before subsequent surgery.                       AND subsequent surgery.</p>
          <p></p>
          <p>          All categories may be subdivided: (s) solitary</p>
          <p>          tumor and (m) multifocal tumor (the largest </p>
          <p>          determines the classification).</p>
          <p></p>
          <p> {FLD:AJCC X} TX   Primary tumor cannot be assessed               {FLD:AJCC </p>
          <p>X} TX</p>
          <p> {FLD:AJCC X} T0   No evidence of primary tumor                   {FLD:AJCC </p>
          <p>X} T0</p>
          <p> {FLD:AJCC X} T1   Tumor 2 cm or less in greatest dimension       {FLD:AJCC </p>
          <p>X} T1</p>
          <p>            limited to the thyroid</p>
          <p> {FLD:AJCC X} T1a  Tumor 1 cm or less, limited to the thyroid     {FLD:AJCC </p>
          <p>X} T1a</p>
          <p> {FLD:AJCC X} T1b  Tumor more than 1 cm but not more than 2 cm in {FLD:AJCC </p>
          <p>X} T1b</p>
          <p>            greatest dimension, limited to the thyroid</p>
          <p> {FLD:AJCC X} T2   Tumor more than 2 cm but not more than 4 cm in {FLD:AJCC </p>
          <p>X} T2</p>
          <p>            greatest dimension, limited to the thyroid</p>
          <p> {FLD:AJCC X} T3   Tumor more than 4 cm in greatest dimension     {FLD:AJCC </p>
          <p>X} T3</p>
          <p>            limited to the thyroid, or any tumor with </p>
          <p>            minimal extrathyroid extension (e.g., </p>
          <p>            extension to sternothyroid muscle or </p>
          <p>            perithyroid soft tissues</p>
          <p> {FLD:AJCC X} T4a  Moderately advanced disease.                   {FLD:AJCC </p>
          <p>X} T4a</p>
          <p>            Tumor of any size extending beyond the</p>
          <p>            thyroid capsule to invade subcutaneous</p>
          <p>            soft tissues, larynx, trachea, esophagus,</p>
          <p>            or recurrent laryngeal nerve</p>
          <p> {FLD:AJCC X} T4b  Very advanced disease.                         {FLD:AJCC </p>
          <p>X} T4b</p>
          <p>            Tumor invades prevertebral fascia or </p>
          <p>            encasescarotid artery or mediastinal </p>
          <p>            vessels</p>
          <p></p>
          <p>            All anaplastic carcinomas are considered T4 tumors</p>
          <p></p>
          <p> {FLD:AJCC X} T4a  Intrathyroidal anaplastic carcinoma            {FLD:AJCC </p>
          <p>X} T4a</p>
          <p> {FLD:AJCC X} T4b  Anaplastic carcinoma with gross extrathyroid   {FLD:AJCC </p>
          <p>X} T4b</p>
          <p>            extension </p>
          <p></p>
          <p>REGIONAL LYMPH NODES (N):</p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p></p>
          <p> {FLD:AJCC X} NX   Regional lymph nodes cannot be assessed.       {FLD:AJCC </p>
          <p>X} NX</p>
          <p> {FLD:AJCC X} N0   No regional lymph node metastasis.             {FLD:AJCC </p>
          <p>X} N0</p>
          <p> {FLD:AJCC X} N1   Regional lymph node metastasis                 {FLD:AJCC </p>
          <p>X} N1</p>
          <p> {FLD:AJCC X} N1a  Metastasis to Level IV (pretracheal,           {FLD:AJCC </p>
          <p>X} N1a</p>
          <p>            paratracheal, and prelaryngeal/Delphian </p>
          <p>            lymph nodes)</p>
          <p> {FLD:AJCC X} N1b  Metastasis to unilateral, bilateral, or        {FLD:AJCC </p>
          <p>X} N1b</p>
          <p>            contralateral cervical (Levels I, II, III, </p>
          <p>            IV, or V) or retropharyngeal or superior</p>
          <p>            mediastinal lymph nodes (Level VII)</p>
          <p></p>
          <p>DISTANT METASTASIS(M):</p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p> {FLD:AJCC X} M0   No distant metastasis</p>
          <p>      {FLD:AJCC 7TH ED PARANASAL DISTANT METS NOTE}</p>
          <p> {FLD:AJCC X} M1   Distant metastasis                             {FLD:AJCC </p>
          <p>X} M1</p>
          <p></p>
          <p>ANATOMIC STAGE PROGNOSTIC GROUPS:</p>
          <p>Separate stage groupings are recommended for papillary or follicular </p>
          <p>(differentiated),</p>
          <p>medullary, and anaplastic (undifferentiated) carcinoma.</p>
          <p></p>
          <p>Papillary or Follicular (Differentiated)</p>
          <p>UNDER 45 YEARS</p>
          <p>Clinical Group     T       N       M       Group   Pathologic</p>
          <p>  {FLD:AJCC X}      I       Any T   Any N   M0      I           {FLD:AJCC X}</p>
          <p>  {FLD:AJCC X}      II      Any T   Any N   M1      II          {FLD:AJCC X}</p>
          <p></p>
          <p>Papillary or Follicular (Differentiated)</p>
          <p>45 YEARS OR OLDER</p>
          <p>Clinical Group     T       N       M       Group   Pathologic</p>
          <p>  {FLD:AJCC X}      I       T1      N0      M0      I           {FLD:AJCC X}</p>
          <p>  {FLD:AJCC X}      II      T2      N0      M0      II          {FLD:AJCC X}</p>
          <p>  {FLD:AJCC X}      III     T3      N0      M0      III         {FLD:AJCC X}</p>
          <p>                   T1      N1a     M0                   </p>
          <p>                   T2      N1a     M0                   </p>
          <p>                   T3      N1a     M0                   </p>
          <p>  {FLD:AJCC X}      IVA     T4a     N0      M0      IVA         {FLD:AJCC X}</p>
          <p>                   T4a     N1a     M0                   </p>
          <p>                   T1      N1b     M0                   </p>
          <p>                   T2      N1b     M0                   </p>
          <p>                   T3      N1b     M0                   </p>
          <p>                   T4a     N1b     M0                   </p>
          <p>  {FLD:AJCC X}      IVB     T4b     Any N   M0      IVB         {FLD:AJCC X}</p>
          <p>  {FLD:AJCC X}      IVC     Any T   Any N   M1      IVC         {FLD:AJCC X}</p>
          <p></p>
          <p>Medullary Carcinoma (All Age Groups)</p>
          <p>45 YEARS OR OLDER</p>
          <p>Clinical Group     T       N       M       Group   Pathologic</p>
          <p>  {FLD:AJCC X}      I       T1      N0      M0      I           {FLD:AJCC X}</p>
          <p>  {FLD:AJCC X}      II      T2      N0      M0      II          {FLD:AJCC X}</p>
          <p>  {FLD:AJCC X}      III     T3      N0      M0      III         {FLD:AJCC X}</p>
          <p>                   T1      N1a     M0                   </p>
          <p>                   T2      N1a     M0                   </p>
          <p>                   T3      N1a     M0                   </p>
          <p>  {FLD:AJCC X}      IVA     T4a     N0      M0      IVA         {FLD:AJCC X}</p>
          <p>                   T4a     N1a     M0                  </p>
          <p>                   T1      N1b     M0                   </p>
          <p>                   T2      N1b     M0                   </p>
          <p>                   T3      N1b     M0                   </p>
          <p>                   T4a     N1b     M0                   </p>
          <p>  {FLD:AJCC X}      IVB     T4b     Any N   M0      IVB         {FLD:AJCC X}</p>
          <p>  {FLD:AJCC X}      IVC     Any T   Any N   M1      IVC         {FLD:AJCC X}</p>
          <p></p>
          <p>Anaplastic Carcinoma</p>
          <p>All anaplastic carcinomas are considered Stage IV</p>
          <p>  {FLD:AJCC X}      IVA     T4a     Any N   M0      IVA         {FLD:AJCC X}  </p>
          <p>  {FLD:AJCC X}      IVB     T4b     Any N   M0      IVB         {FLD:AJCC X}</p>
          <p>  {FLD:AJCC X}      IVC     Any T   Any N   M1      IVC         {FLD:AJCC X}</p>
          <p>  {FLD:AJCC X}               Stage Unknown                      {FLD:AJCC X}</p>
          <p></p>
          <p>Prognostic Factors: (Site-Specific Factors)</p>
          <p>Required for Staging: NONE</p>
          <p>Clinically Significant:</p>
          <p>  Solitary or Multifocal tumors in the primary site: </p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>General Notes:</p>
          <p>For identification of special cases of TNM or pTNM classifications, the "m" </p>
          <p>suffix and "y", "r", and "a" prefixes are used.  Although they do not affect</p>
          <p>the stage grouping, they indicate cases needing separate analysis.</p>
          <p></p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p></p>
          <p> {FLD:AJCC X} m   suffix to indicate the presence of primary      {FLD:AJCC </p>
          <p>X} m</p>
          <p>           tumors in a single site and is recorded</p>
          <p>           in parenthesis: pT(m)NM.</p>
          <p></p>
          <p> {FLD:AJCC X} y   prefix to indicate those cases in which         {FLD:AJCC </p>
          <p>X} y</p>
          <p>           classification is performed during or </p>
          <p>           following initial multimodality therapy.</p>
          <p>           The cTNM or pTNM category is identified</p>
          <p>           by a "y" prefix.  The ycTNM or ypTNM </p>
          <p>           categorizes the extent of tumor actually</p>
          <p>           present at the time of that examination.</p>
          <p>           The "y" categorization is not an estimate</p>
          <p>           of tumor prior to multimodality therapy.</p>
          <p></p>
          <p> {FLD:AJCC X} r   prefix to indicate a recurrent tumor when       {FLD:AJCC </p>
          <p>X} r</p>
          <p>           staged after a disease-free interval and </p>
          <p>           is identified by the "r" prefix: rTNM.</p>
          <p></p>
          <p> {FLD:AJCC X} a   prefix to indicate the stage was determined at  {FLD:AJCC </p>
          <p>X} a</p>
          <p>           autopsy: aTNM.</p>
          <p></p>
          <p>Surgical margins is data field recorded by registrars describing the surgical </p>
          <p>margins of the resected primary site specimen as determined only by the </p>
          <p>pathology report.</p>
          <p></p>
          <p>Neoadjuvant treatment is radiation therapy or systemic therapy (consisting of</p>
          <p>chemotherapy, hormone therapy, or immunotherapy) administered prior to a </p>
          <p>definitive surgical procedure.  If the surgical procedure is not performed,</p>
          <p>the administered therapy no longer meets the definition of neoadjuvant </p>
          <p>therapy.</p>
          <p></p>
          <p>Histologic Grade (G): (also known as overall grade)</p>
          <p></p>
          <p>Grading System                                Grade</p>
          <p> {FLD:AJCC X} 2 grade system                            {FLD:AJCC X} Grade I </p>
          <p>or 1</p>
          <p> {FLD:AJCC X} 3 grade system                            {FLD:AJCC X} Grade II </p>
          <p>or 2</p>
          <p> {FLD:AJCC X} 4 grade system                            {FLD:AJCC X} Grade </p>
          <p>III or 3</p>
          <p> {FLD:AJCC X} No 2, 3, or 4 grade system is available   {FLD:AJCC X} Grade IV </p>
          <p>or 4</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p></p>
          <p>Lypmhatic Vessel Invasion (L) and Venous Invasion (V) have been combined </p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.  The </p>
          <p>College of American Pathologists' (CAP) Checklist should be used as the </p>
          <p>primary </p>
          <p>source.  Other sources may be used in the absence of a Checklist.  Priority </p>
          <p>is </p>
          <p>given to positive results.</p>
          <p></p>
          <p>  {FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>  {FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>  {FLD:AJCC X} Not Applicable</p>
          <p>  {FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p></p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be residual </p>
          <p>tumor at the primary site after treatment because of incomplete resection or </p>
          <p>local and regional disease that extends beyond the limit of ability of </p>
          <p>resection.</p>
          <p></p>
          <p>  {FLD:AJCC X} RX   Presence of residual tumor cannot be assessed</p>
          <p>  {FLD:AJCC X} R0   No Residual Tumor</p>
          <p>  {FLD:AJCC X} R1   Microscopic residual tumor</p>
          <p>  {FLD:AJCC X} R2   Macroscopic residual tumor</p>
          <p></p>
          <p>Additional Information:</p>
          <p></p>
          <p> {FLD:AJCC X}Yes {FLD:AJCC X}No Clinical stage was used in treatment planning </p>
          <p>   (describe):</p>
          <p>{FLD:WORD PROCESSING 1 LINE N/R HDB}</p>
          <p></p>
          <p> {FLD:AJCC X}Yes {FLD:AJCC X}No National guidelines were used in treatment </p>
          <p>planning: </p>
          <p>          {FLD:AJCC X}National Comprehensive Cancer Network (NCCN)</p>
          <p>          {FLD:AJCC X}Other (describe):</p>
          <p>{FLD:WORD PROCESSING 1 LINE N/R HDB}</p>
          <p></p>
          <p>{FLD:AJCC 7TH EDITION STAGING ILLUSTRATIONS}</p>
          <p> {FLD:AJCC X}Yes {FLD:AJCC X}No Have you completed the illustration page for </p>
          <p>this AJCC Staging form?</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Urethra">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>FALLOPIAN TUBE</p>
          <p></p>
          <p>7th Edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH      TNM             PRIMARY TUMOR (T) (male and female)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX             Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0             No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Ta             Non-invasive papillary, polypoid, or verrucous </p>
          <p>                                  carcinoma</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis            Carcinoma in situ</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1             Tumor invades subepithelial connective tissue</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2             Tumor invades any of the following: corpus </p>
          <p>                                  spongiosum, prostate, periurethral muscle</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3             Tumor invades any of the following: corpus </p>
          <p>                                  cavernosum, beyond prostatic capsule,</p>
          <p>                                  anterior vagina, bladder neck</p>
          <p>	 </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4             Tumor invades other adjacent organs </p>
          <p>						 </p>
          <p>                                 UROTHELIAL (Transitional Cell) Carcinoma of the Prostate</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis pu         Carcinoma in situ, involvement of the</p>
          <p>                                  prostatic urethra</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis pd         Carcinoma in situ, involvement of the</p>
          <p>                                  prostatic ducts</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1             Tumor invades urethral subepithelial</p>
          <p>                                  connective tissue</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2             Tumor invades any of the follwoing:</p>
          <p>                                  prostatic stroma, corpus spongiosum,</p>
          <p>                                  periurethral muscle</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3             Tumor invades any of the following: corpus</p>
          <p>                                  cavernosum, beyond prostatic capsule,</p>
          <p>                                  bladder neck (extraprostatic extension)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4             Tumor invades other adjacent organs </p>
          <p>                                  (invasion of the bladder)</p>
          <p></p>
          <p></p>
          <p></p>
          <p></p>
          <p>                              REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX             Regional lymph nodes cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0             No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1             Regional lymph node metastasis</p>
          <p></p>
          <p>                              DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}             M0             No distant metastasis (no pathologic M0; </p>
          <p>                                  use clinical M to complete stage group)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1             Distant metastasis</p>
          <p></p>
          <p>CLIN   PATH   TNM     STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0a     Ta       N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0is    Tis      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}            Tis pu   N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}            Tis pd   N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     I      T1       N0      M0			      </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     II     T2       N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     III    T1       N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}            T2       N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}            T3       N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}            T3       N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IV     T4       N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}            T4       N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}            Any T    N2      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}            Any T    Any N   M1          </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Stage Unknown</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>Required for Staging: NONE</p>
          <p>Clinically Significant Factors:</p>
          <p>  World Health Organization/International Society of Urologic Pathology</p>
          <p>       (WHO/ISUP) grade: </p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>GRADING SYSTEM       </p>
          <p>{FLD:X BOX} 2 grade system                          {FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system                          {FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system                          {FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available   {FLD:X BOX}Grade IV or 4</p>
          <p>                           </p>
          <p></p>
          <p></p>
          <p>Lypmhatic Vessel Invasion (L) and Venous Invasion (V) have been combined </p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.  The </p>
          <p>College of American Pathologists' (CAP) Checklist should be used as the primary </p>
          <p>source.  Other sources may be used in the absence of a Checklist.  Priority is </p>
          <p>given to positive results.</p>
          <p></p>
          <p>  {FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>  {FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>  {FLD:AJCC X} Not Applicable</p>
          <p>  {FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p></p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be residual </p>
          <p>tumor at the primary site after treatment because of incomplete resection or </p>
          <p>local and regional disease that extends beyond the limit of ability of resection.</p>
          <p></p>
          <p>  {FLD:AJCC X} RX   Presence of residual tumor cannot be assessed</p>
          <p>  {FLD:AJCC X} R0   No Residual Tumor</p>
          <p>  {FLD:AJCC X} R1   Microscopic residual tumor</p>
          <p>  {FLD:AJCC X} R2   Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:AJCC X}National guidelines were used in treatment planning </p>
          <p>{FLD:AJCC X} NCCN </p>
          <p>{FLD:AJCC X} Other (describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Urinary Bladder Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>URINARY BLADDER</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:AJCC X} y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X} y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:{FLD:AJCC EDIT45}</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH     PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX      Primary tumor cannot be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0      No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Ta      Non invasive papillary carcinoma</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis     Carcinoma in situ (flat tumor)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      Tumor invades subepithelial connective tissue</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      Tumor invades muscularis propria</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2a     Tumor Invades superficial muscularis </p>
          <p>                       propria (inner half)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2b     Tumor Invades deep muscularis propria (outer </p>
          <p>                       half)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      Tumor invades perivesical tissue</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3a     Microscopically</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3b     Macroscopically (extravesical mass)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      Tumor invades any of the following: prostatic </p>
          <p>                       stroma, seminal vesicles, uterus,vagina, </p>
          <p>                       pelvic wall, abdominal wall</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T4a     Tumor invades prostatic stroma,</p>
          <p>                               uterus, vagina</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T4b     Tumor invades pelvic wall, abdominal </p>
          <p>                               wall</p>
          <p> </p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     NX      Regional lymph node metastasis cannot be </p>
          <p>                       assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0      No regional lymph node metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      Single regional lymph node metastasis in the </p>
          <p>                       true pelvis (hypogastric, obturator,external </p>
          <p>                       iliac or presacral lymph node)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N2      Multiple regional lymph node metastasis in </p>
          <p>                       the true pelvis (hypogastric,obturator, </p>
          <p>                       external iliac or presacral lymph node </p>
          <p>                       metastasis) </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N3      Lymph node metastasis to the common iliac </p>
          <p>                       lymph nodes</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      Distant metastasis</p>
          <p></p>
          <p>STAGE GROUPING                        </p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Oa      Ta      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Ois     Tis     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     I       T1      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     II      T2a     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T2b     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     III     T3a     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T3b     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T4a     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IV      T4b     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Any T   N1-3    M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             Any T   Any N   M1</p>
          <p>{FLD:AJCC X}            Unknown Stage </p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Presence or absence of extranodal extension: {FLD:AJCC EDIT50}</p>
          <p>Size of the largest tumor deposit in the lymph nodes: {FLD:AJCC EDIT50}</p>
          <p>World Health Organization/International Society of Urologic Pathology (WHO/ISUP) </p>
          <p>grade : {FLD:AJCC EDIT50}</p>
          <p></p>
          <p>HISTOLOGIC GRADE: WHO/ISUP</p>
          <p>{FLD:AJCC X} LOW GRADE</p>
          <p>{FLD:AJCC X} HIGH GRADE</p>
          <p></p>
          <p>GRADING SYSTEM       </p>
          <p>{FLD:AJCC X} 2 grade system                          {FLD:AJCC X} Grade I or 1</p>
          <p>{FLD:AJCC X} 3 grade system                          {FLD:AJCC X} Grade II or 2</p>
          <p>{FLD:AJCC X} 4 grade system                          {FLD:AJCC X} Grade III or 3</p>
          <p>{FLD:AJCC X} No 2,3,or 4 grade system is available   {FLD:AJCC X} Grade IV or 4</p>
          <p>                           </p>
          <p></p>
          <p></p>
          <p>Lypmhatic Vessel Invasion (L) and Venous Invasion (V) have been combined </p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.  The </p>
          <p>College of American Pathologists' (CAP) Checklist should be used as the primary </p>
          <p>source.  Other sources may be used in the absence of a Checklist.  Priority is </p>
          <p>given to positive results.</p>
          <p></p>
          <p>  {FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>  {FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>  {FLD:AJCC X} Not Applicable</p>
          <p>  {FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p></p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be residual </p>
          <p>tumor at the primary site after treatment because of incomplete resection or </p>
          <p>local and regional disease that extends beyond the limit of ability of resection.</p>
          <p></p>
          <p>  {FLD:AJCC X} RX   Presence of residual tumor cannot be assessed</p>
          <p>  {FLD:AJCC X} R0   No Residual Tumor</p>
          <p>  {FLD:AJCC X} R1   Microscopic residual tumor</p>
          <p>  {FLD:AJCC X} R2   Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X} Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:AJCC X} National guidelines were used in treatment planning </p>
          <p>{FLD:AJCC X}  NCCN </p>
          <p>{FLD:AJCC X}  Other (describe):{FLD:AJCC W-P2LINES}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Uterus (Corpus Uteri Sarcoma) Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>CORPUS UTERI SARCOMA</p>
          <p>(Carcinosarcomas should be staged as carcinomas)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:{FLD:AJCC EDIT50}</p>
          <p></p>
          <p></p>
          <p>CLIN    PATH    TNM     FIGO    Primary Tumor (T)</p>
          <p>                                Leiomyosarcoma, Endometrial Stromal </p>
          <p>                                Sarcoma</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}     TX              Primary tumor cannot be </p>
          <p>assessed</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}     T0              No evidence of primary </p>
          <p>tumor</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}     T1      I       Tumor limited to the uterus</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    T1a      IA      Tumor 5 cm or less in </p>
          <p>greatest dimension</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    T1b      IB      Tumor more than 5 cm</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    T2       II      Tumor extends beyond the </p>
          <p>uterus, within </p>
          <p>                                the pelvis</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    T2a      IIA     Tumor invades the adnexa</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    T2b      IIB     Tumor involves other pelvic </p>
          <p>tissues</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    T3       III*    Tumor infiltrates abdominal </p>
          <p>tissues</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    T3a      IIIA    One Site</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    T3b      IIIB    More than one site</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    T4       IVA     Tumor invades bladder or </p>
          <p>rectum</p>
          <p></p>
          <p></p>
          <p>                                Adenosarcoma</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    TX               Primary tumor cannot be </p>
          <p>assessed</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    T0               No evidence of primary </p>
          <p>tumor</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    T1       I       Tumor limited to the uterus</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    T1a      IA      Tumor limited to the </p>
          <p>endometrium/</p>
          <p>                                endocervix</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    T1b      IB      Tumor invades to less than </p>
          <p>half of</p>
          <p>                                the myometrium</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    T1c      IC      Tumor invades more than </p>
          <p>half of the </p>
          <p>                                myometrium</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    T2       II      Tumor extends beyond the </p>
          <p>uterus,</p>
          <p>                                within the pelvis</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    T2a      IIA     Tumor involves adnexa</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    T2b      IIB     Tumor involves other pelvic </p>
          <p>tissues</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    T3       III*    Tumor involves abdominal </p>
          <p>tissue</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    T3a      IIIA    One site</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    T3b      IIIB    More than one site</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}    T4       IVA     Tumor invades bladder or </p>
          <p>rectum</p>
          <p>      Note:  Simultaneous tumors of the uterine corpus and ovary/pelvis</p>
          <p>             in association with ovarian/pelvic endometriosis should be </p>
          <p>             classified as independent primary tumors.</p>
          <p>     *In this stage, lesions must infiltrate abdominal tissues and not</p>
          <p>     just protrude into the abdominal cavity.</p>
          <p></p>
          <p></p>
          <p>CLIN    PATH    TNM    FIGO    REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}     NX             Regional lymph nodes cannot </p>
          <p>be assessed</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}     N0             No regional lymph nodes</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}     N1     IIIC    Regional lymph nodes </p>
          <p>metastasis</p>
          <p></p>
          <p></p>
          <p>CLIN    PATH    TNM    FIGO    DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}     M0             No distant metastasis (use </p>
          <p>pathologic M to</p>
          <p>                               complete stage group)</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}     M1     IVB     Distant metastasis </p>
          <p>(excluding adexa,</p>
          <p>                               pelvic, and abdominal tissue)</p>
          <p></p>
          <p>Stage Grouping</p>
          <p></p>
          <p>CLIN      PATH    TNM</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}     I       Tl      NO      MO</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}     IA*     Tla     NO      MO</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}     IB*     Tlb     NO      MO</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}     IC**    Tlc     NO      MO</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}V     II      T2      NO      MO</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}     IIIA    T3a     NO      MO</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}     IIIB    T3b     NO      MO</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}     IIIC    T1-T3   N1      MO</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}     IIIA    T3a     N       MO</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}     IVA     T4      Any N   MO</p>
          <p>{FLD:AJCC X}     {FLD:AJCC X}     IVB     Any T   Any N   Ml</p>
          <p>{FLD:AJCC X}               Stage Unknown</p>
          <p></p>
          <p>    *Note Stages IA and IB differ from those applied for leiomyosarcoma</p>
          <p>     and endometrial stromal sarcoma.</p>
          <p>   **Note: Stage IC does not apply for leiomyosarcoma and endometrial</p>
          <p>     stromal sarcoma.</p>
          <p></p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING:  None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>   FIGO Stage:{FLD:AJCC EDIT50}</p>
          <p>   Peritoneral cytology results:{FLD:AJCC EDIT50}</p>
          <p>   Pelvic nodal dissection with number of nodes positive/examined:</p>
          <p>   {FLD:AJCC EDIT50}</p>
          <p>   Para-aortic nodal dissection with number of nodes positive/examined:</p>
          <p>   {FLD:AJCC EDIT50}</p>
          <p>   Percentage of non-edometriod cell type in mixed histology tumors:</p>
          <p>   {FLD:AJCC EDIT50}</p>
          <p>   Omentectomy performed:{FLD:AJCC EDIT50}</p>
          <p></p>
          <p></p>
          <p>Histologic Grade (G)</p>
          <p></p>
          <p>  Grading system</p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p>Endometroid adenocarcinoma should be graded according to the degree </p>
          <p>of differentiation of the adenocarcinoma as follows:</p>
          <p></p>
          <p> {FLD:AJCC X} G1  5% or less of non-squamous or non-morular solid growth </p>
          <p>pattern</p>
          <p> {FLD:AJCC X} G2  6% to 50% of non-squamous or non-morular solid growth </p>
          <p>pattern</p>
          <p> {FLD:AJCC X} G3  More than 50% of non-squamous or non-morular solid growth </p>
          <p>pattern</p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X}Not Applicable</p>
          <p>{FLD:AJCC X}Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:AJCC X}R0 No residual tumor</p>
          <p>{FLD:AJCC X}R1 Microscopic residual tumor</p>
          <p>{FLD:AJCC X}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:AJCC X}National guidelines were used in treatment planning </p>
          <p>   {FLD:AJCC X}NCCN </p>
          <p>   {FLD:AJCC X}Other (describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Uterus (Corpus Uteri Carcinoma) Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>CORPUS UTERI CARCINOMA STAGING FORM</p>
          <p>(Carcinosarcomas should be staged as carcinomas)</p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:{FLD:AJCC EDIT45}</p>
          <p></p>
          <p></p>
          <p>CLIN    PATH    TNM    FIGO    Primary Tumor (T)</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     TX              Primary tumor cannot be </p>
          <p>assessed</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     TO              No evidence of primary </p>
          <p>tumor</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     Tis     0       Carcinoma in situ </p>
          <p>(preinvasive carcinoma)</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     Tl      I       Tumor confined to corpus </p>
          <p>uteri</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     Tla     IA      Tumor limited to </p>
          <p>endometrium or invades</p>
          <p>                                less than one-half of the myometrium</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     Tlb     IB      Tumor invades less than </p>
          <p>one-half of the</p>
          <p>                                myometrium</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     T2      II      Tumor invades stromal </p>
          <p>connective tissue of</p>
          <p>                                the cervix  but does not extend beyond </p>
          <p>                                the uterus</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     T3a     IIIA    Tumor involves serosa </p>
          <p>and/or adnexa(direct</p>
          <p>                                extension or metastasis)</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     T3b     IIIB    Vaginal involvement </p>
          <p>(direct extension or </p>
          <p>                                metastasis) or parametrial involvement</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     T4      IVA     Tumor invades bladder </p>
          <p>mucosa and/ or bowel</p>
          <p>                                mucosa bullous edema is not sufficient to</p>
          <p>                                classify a tumor as T4)</p>
          <p>    *FIGO staging no longer includes Stage 0 (Tis)</p>
          <p>   **Endocervical glandular involvement only should be considered as stage I</p>
          <p>     and not stage II.</p>
          <p></p>
          <p>CLIN      PATH    TNM   FIGO    Regional Lymph Nodes (N)</p>
          <p></p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     NX            Regional lymph nodes cannot </p>
          <p>be assessed</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     NO            No regional lymph node </p>
          <p>metastasis</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     Nl    IIIC1   Regional lymph node </p>
          <p>metastasis to pelvic</p>
          <p>                                lymph nodes</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     N2    IIIC2   Regional lymph node </p>
          <p>metastasis to para-</p>
          <p>                                aortic lymph nodes, with or without</p>
          <p>                                positive pelvic lymph nodes.</p>
          <p></p>
          <p></p>
          <p>CLIN      PATH    TNM   FIGO   Distant Metastasis (M)</p>
          <p></p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     MO            No distant metastasis (no </p>
          <p>pathologic M;</p>
          <p>                                use clinical M to complete stage group)</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     MI    IVB     Distant metastasis </p>
          <p>(includes metastasis</p>
          <p>                                to inguinal lymph nodes intraperitoneal</p>
          <p>                                disease, or lung, liver or bone.  It</p>
          <p>                                excludes metastasis to vagina, pelvic</p>
          <p>                                serosa, or adnexa</p>
          <p></p>
          <p>Stage Grouping </p>
          <p></p>
          <p>CLIN      PATH    TNM</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     0*      Tis     NO      MO</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     I       Tl      NO      MO</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     IA      Tla     NO      MO</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     IB      Tlb     NO      MO</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     II      T2      NO      MO</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     III     T3      NO      MO</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     IlIA    T3a     N       MO</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     IIIB    T3b     NO      MO</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     IIIC1   Tl-T3   Nl      MO</p>
          <p>                  IIIC2   T1-T3   N2      MO</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}     IVA     T4      AnyN    MO</p>
          <p>{FLD:AJCC X}       {FLD:AJCC X}    IVB     AnyT    AnyN    Ml</p>
          <p></p>
          <p>Histologic Grade (G)</p>
          <p>  Grading system</p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING:  None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>   FIGO Stage:{FLD:AJCC EDIT50}</p>
          <p>   Peritoneral cytology results:{FLD:AJCC EDIT50}</p>
          <p>   Pelvic nodal dissection with number of nodes positive/examined:</p>
          <p>{FLD:AJCC EDIT50}</p>
          <p>   Para-aortic nodal dissection with number of nodes positive/examined:</p>
          <p>   {FLD:AJCC EDIT50}</p>
          <p>   Percentage of non-edometriod cell type in mixed histology tumors:</p>
          <p>{FLD:AJCC EDIT45}</p>
          <p>   Omentectomy performed:{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>Checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X}Not Applicable</p>
          <p>{FLD:AJCC X}Unknown/Indeterminate</p>
          <p></p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:AJCC X}R0 No residual tumor</p>
          <p>{FLD:AJCC X}R1 Microscopic residual tumor</p>
          <p>{FLD:AJCC X}R2 Macroscopic residual tumor</p>
          <p></p>
          <p></p>
          <p>{FLD:AJCC X}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:AJCC X}National guidelines were used in treatment planning </p>
          <p>   {FLD:AJCC X}NCCN </p>
          <p>   {FLD:AJCC X}Other (describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Urinary Bladder Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>{FLD:AJCC 7TH EDITION HDR}</p>
          <p>AJCC CANCER STAGING 7th EDITION--URINARY BLADDER</p>
          <p></p>
          <p>Type of specimen: {FLD:AJCC EDIT50}</p>
          <p>Histopathologic type: {FLD:AJCC EDIT50}</p>
          <p>Tumor size: {FLD:AJCC EDIT50}</p>
          <p>Laterality: {FLD:AJCC X}Bilateral   {FLD:AJCC X}Left     {FLD:AJCC X}Right</p>
          <p></p>
          <p>PRIMARY TUMOR(T):</p>
          <p>{FLD:AJCC 7TH EDITION CLINICAL STAGING TEXT}                          </p>
          <p>{FLD:AJCC 7TH EDITION PATHOLOGIC STAGING TEXT}</p>
          <p></p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p></p>
          <p>{FLD:AJCC X} y clinical  -                               {FLD:AJCC X} y </p>
          <p>pathologic - </p>
          <p>staging completed                                staging completed</p>
          <p>after neoadjuvant therapy but                    after neoadjuvant therapy</p>
          <p>before subsequent surgery.                       AND subsequent surgery.</p>
          <p>                                              </p>
          <p> {FLD:AJCC X} TX   Primary tumor cannot be assessed               {FLD:AJCC </p>
          <p>X} TX</p>
          <p> {FLD:AJCC X} T0   No evidence of primary tumor                   {FLD:AJCC </p>
          <p>X} T0</p>
          <p> {FLD:AJCC X} Ta   Noninvasive papillary carcinoma                {FLD:AJCC </p>
          <p>X} Ta</p>
          <p> {FLD:AJCC X} Tis  Carcinoma in situ: "flat tumor"                {FLD:AJCC </p>
          <p>X} Tis</p>
          <p> {FLD:AJCC X} T1   Tumor invades subepithelial connective tissue  {FLD:AJCC </p>
          <p>X} T1</p>
          <p> {FLD:AJCC X} T2   Tumor invades the muscularis propria           {FLD:AJCC </p>
          <p>X} T2</p>
          <p>                pT2a Tumor invades superficial muscularis propria                  </p>
          <p>pT2a</p>
          <p>            (inner half)</p>
          <p>                pT2b Tumor invades deep muscularis propria (outer                  </p>
          <p>pT2b</p>
          <p>            half)</p>
          <p> {FLD:AJCC X} T3   Tumor invades perivesical tissue               {FLD:AJCC </p>
          <p>X} T3</p>
          <p>                pT3a   microscopically                                             </p>
          <p>pT3a</p>
          <p>                pT3b   macroscopically (extravesical mass)                         </p>
          <p>pT3b</p>
          <p> {FLD:AJCC X} T4   Tumor invades any of the following: prostatic  {FLD:AJCC </p>
          <p>X} T4</p>
          <p>            stroma, seminal vesicles, uterus, vagina, </p>
          <p>            pelvic wall, abdominal wall</p>
          <p> {FLD:AJCC X} T4a  Tumor invades prostatic stroma, uterus, vagina {FLD:AJCC </p>
          <p>X} T4a</p>
          <p> {FLD:AJCC X} T4b  Tumor invades pelvic wall, abdominal wall      {FLD:AJCC </p>
          <p>X} T4b</p>
          <p></p>
          <p></p>
          <p>REGIONAL LYMPH NODES (N):</p>
          <p>            Regional lymph nodes include both primary and</p>
          <p>            secondary drainage regions.  All other nodes </p>
          <p>            above the aortic bifurcation are considered</p>
          <p>            distant lymph nodes.</p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p></p>
          <p> {FLD:AJCC X} NX   Lymph nodes cannot be assessed                 {FLD:AJCC </p>
          <p>X} NX</p>
          <p> {FLD:AJCC X} N0   No lymph node metastasis                       {FLD:AJCC </p>
          <p>X} N0</p>
          <p> {FLD:AJCC X} N1   Single regional lymph node metastasis in the   {FLD:AJCC </p>
          <p>X} N1</p>
          <p>            true pelvis (hypogastric, obturator, </p>
          <p>            external iliac or presacral lymph node)</p>
          <p> {FLD:AJCC X} N2   Multiple regional lymph node metastasis in the {FLD:AJCC </p>
          <p>X} N2</p>
          <p>            true pelvis (hypogastric, obturator,</p>
          <p>            external iliac or presacral lymph node</p>
          <p>            metastasis)</p>
          <p> {FLD:AJCC X} N3   Lymph node metastasis to the common iliac      {FLD:AJCC </p>
          <p>X} N3</p>
          <p>            lymph nodes</p>
          <p></p>
          <p>DISTANT METASTASIS(M):</p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p> {FLD:AJCC X} M0   No distant metastasis</p>
          <p>      {FLD:AJCC 7TH ED PARANASAL DISTANT METS NOTE}</p>
          <p> {FLD:AJCC X} M1   Distant metastasis                             {FLD:AJCC </p>
          <p>X} M1</p>
          <p></p>
          <p>ANATOMIC STAGE PROGNOSTIC GROUPS:</p>
          <p>Clinical Group     T         N         M       Group   Pathologic</p>
          <p>  {FLD:AJCC X}      0a      Ta        N0        M0      0a          {FLD:AJCC </p>
          <p>X}</p>
          <p>  {FLD:AJCC X}      0is     Tis       N0        M0      0is         {FLD:AJCC </p>
          <p>X}</p>
          <p>  {FLD:AJCC X}      I       T1        N0        M0      I           {FLD:AJCC </p>
          <p>X}</p>
          <p>  {FLD:AJCC X}      II      T2a       N0        M0      II          {FLD:AJCC </p>
          <p>X}</p>
          <p>                   T2b       N0        M0               </p>
          <p>  {FLD:AJCC X}      III     T3a       N0        M0      III         {FLD:AJCC </p>
          <p>X}</p>
          <p>                   T3b       N0        M0</p>
          <p>                   T4a       N0        M0</p>
          <p>  {FLD:AJCC X}      IV      T4b       N0        M0      IV          {FLD:AJCC </p>
          <p>X}</p>
          <p>                   Any T     N1-3      M0</p>
          <p>                   Any T     Any N     M1</p>
          <p>  {FLD:AJCC X}                 Stage Unknown                        {FLD:AJCC </p>
          <p>X}</p>
          <p></p>
          <p>Prognostic Factors: (Site-Specific Factors)</p>
          <p>Required for Staging: NONE</p>
          <p>Clinically Significant Factors:</p>
          <p>  Presence or absence of extranodal extension: </p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  Size of the largest tumor deposit in the lymph nodes: </p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p>  World Health Organization/International Society of Urologic Pathology</p>
          <p>       (WHO/ISUP) grade: </p>
          <p>          {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>General Notes:</p>
          <p>For identification of special cases of TNM or pTNM classifications, the "m" </p>
          <p>suffix and "y", "r", and "a" prefixes are used.  Although they do not affect</p>
          <p>the stage grouping, they indicate cases needing separate analysis.</p>
          <p></p>
          <p>Clinical  Stage Category Descriptions               Pathologic</p>
          <p></p>
          <p> {FLD:AJCC X} m   suffix to indicate the presence of primary      {FLD:AJCC </p>
          <p>X} m</p>
          <p>           tumors in a single site and is recorded</p>
          <p>           in parenthesis: pT(m)NM.</p>
          <p></p>
          <p> {FLD:AJCC X} y   prefix to indicate those cases in which         {FLD:AJCC </p>
          <p>X} y</p>
          <p>           classification is performed during or </p>
          <p>           following initial multimodality therapy.</p>
          <p>           The cTNM or pTNM category is identified</p>
          <p>           by a "y" prefix.  The ycTNM or ypTNM </p>
          <p>           categorizes the extent of tumor actually</p>
          <p>           present at the time of that examination.</p>
          <p>           The "y" categorization is not an estimate</p>
          <p>           of tumor prior to multimodality therapy.</p>
          <p></p>
          <p> {FLD:AJCC X} r   prefix to indicate a recurrent tumor when       {FLD:AJCC </p>
          <p>X} r</p>
          <p>           staged after a disease-free interval and </p>
          <p>           is identified by the "r" prefix: rTNM.</p>
          <p></p>
          <p> {FLD:AJCC X} a   prefix to indicate the stage was determined at  {FLD:AJCC </p>
          <p>X} a</p>
          <p>           autopsy: aTNM.</p>
          <p></p>
          <p>Surgical margins is data field recorded by registrars describing the surgical </p>
          <p>margins of the resected primary site specimen as determined only by the </p>
          <p>pathology report.</p>
          <p></p>
          <p>Neoadjuvant treatment is radiation therapy or systemic therapy (consisting of</p>
          <p>chemotherapy, hormone therapy, or immunotherapy) administered prior to a </p>
          <p>definitive surgical procedure.  If the surgical procedure is not performed,</p>
          <p>the administered therapy no longer meets the definition of neoadjuvant </p>
          <p>therapy.</p>
          <p></p>
          <p>Histologic Grade (G): (also known as overall grade)</p>
          <p></p>
          <p>Grading System                                Grade</p>
          <p> {FLD:AJCC X} 2 grade system                            {FLD:AJCC X} Grade I </p>
          <p>or 1</p>
          <p> {FLD:AJCC X} 3 grade system                            {FLD:AJCC X} Grade II </p>
          <p>or 2</p>
          <p> {FLD:AJCC X} 4 grade system                            {FLD:AJCC X} Grade </p>
          <p>III or 3</p>
          <p> {FLD:AJCC X} No 2, 3, or 4 grade system is available   {FLD:AJCC X} Grade IV </p>
          <p>or 4</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p></p>
          <p>Lypmhatic Vessel Invasion (L) and Venous Invasion (V) have been combined </p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.  The </p>
          <p>College of American Pathologists' (CAP) Checklist should be used as the </p>
          <p>primary </p>
          <p>source.  Other sources may be used in the absence of a Checklist.  Priority </p>
          <p>is </p>
          <p>given to positive results.</p>
          <p></p>
          <p>  {FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>  {FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>  {FLD:AJCC X} Not Applicable</p>
          <p>  {FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p></p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be residual </p>
          <p>tumor at the primary site after treatment because of incomplete resection or </p>
          <p>local and regional disease that extends beyond the limit of ability of </p>
          <p>resection.</p>
          <p></p>
          <p>  {FLD:AJCC X} RX   Presence of residual tumor cannot be assessed</p>
          <p>  {FLD:AJCC X} R0   No Residual Tumor</p>
          <p>  {FLD:AJCC X} R1   Microscopic residual tumor</p>
          <p>  {FLD:AJCC X} R2   Macroscopic residual tumor</p>
          <p></p>
          <p>Additional Information:</p>
          <p></p>
          <p> {FLD:AJCC X}Yes {FLD:AJCC X}No Clinical stage was used in treatment planning </p>
          <p>(describe):</p>
          <p>{FLD:WORD PROCESSING 1 LINE N/R HDB}</p>
          <p></p>
          <p> {FLD:AJCC X}Yes {FLD:AJCC X}No National guidelines were used in treatment </p>
          <p>planning: </p>
          <p>          {FLD:AJCC X}National Comprehensive Cancer Network (NCCN)</p>
          <p>          {FLD:AJCC X}Other (describe):</p>
          <p>{FLD:WORD PROCESSING 1 LINE N/R HDB}</p>
          <p></p>
          <p>{FLD:AJCC 7TH EDITION STAGING ILLUSTRATIONS}</p>
          <p> {FLD:AJCC X}Yes {FLD:AJCC X}No Have you completed the illustration page for </p>
          <p>this AJCC Staging form?</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Vagina Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>VAGINA STAGING</p>
          <p> 7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>{FLD:X BOX}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:X BOX}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size: {FLD:AJCC EDIT45}</p>
          <p></p>
          <p>CLIN   PATH   TNM     FIGO    PRIMARY TUMOR (T)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     TX              Primary tumor cannot be 	</p>
          <p>				 		  assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T0              No evidence of primary tumor</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     Tis     *       Carcinoma in situ 			</p>
          <p>						  (preinvasive tumor)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1      I       Cervical carcinoma confined </p>
          <p>						  to uterus</p>
          <p>                              (extension to corpus should be disregarded)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1a     IA      Invasive carcinoma diagnosed </p>
          <p>						  only by Microscopy  Stromal invasion with a 	</p>
          <p>						  maximal depth of 5.0 mm measured from the base </p>
          <p>						  of the epithelium and a horizontal spread of</p>
          <p>                               7.0 mm or less. Vascular space involvement,</p>
          <p>                               venous of lymphatic, does not affect</p>
          <p>                               classification.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1a1    IA1     Measured stromal invasion 3 </p>
          <p>						  mm or less in</p>
          <p>                               depth &amp; 7 mm or less in horizontal spread.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1a2    IA2     Measured stromal invasion 	</p>
          <p>						  more than 3 mm</p>
          <p>                               and not more than 5.0 mm with a horizontal</p>
          <p>                               spread 7 mm or less.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1b     IB      Clinically visible lesion 	</p>
          <p>						  confined to the</p>
          <p>                               cervix or microscopic lesion greater than</p>
          <p>                               T1a2/A2</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1b1    IB1     Clinically visible 4.0 cm or </p>
          <p>						  less</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T1b2    IB2     Clinically visible more than </p>
          <p>						  4.0 cm</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2      II      Cervical carcinoma invades 	</p>
          <p>						  beyond uterus</p>
          <p>                               but not to pelvic wall or lower third of</p>
          <p>                               vagina.</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2a     IIA     Tumor without parametrial 	</p>
          <p>						  invasion</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2a1    IIAI    Clinically visible lesion 4 </p>
          <p>						  cm or less in</p>
          <p>                               Greatest dimension</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T2b     IIB     Tumor with parametrial 	</p>
          <p>						  invasion</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3      III     Tumor extends to pelvic wall </p>
          <p>						  and/or </p>
          <p>                               Involves lower 1/3 of vagina and/or causes</p>
          <p>                               hydronephrosis or nonfunctioning kidney</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3a     IIIA    Tumor involves lower 1/3 	</p>
          <p>						  vagina, no</p>
          <p>                               extension to pelvic wall</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T3b     IIIB    Tumor extends s to pelvic 	</p>
          <p>						  wall and/or</p>
          <p>                               causes hydronephrosis or nonfunctioning</p>
          <p>                               kidney</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     T4      IVA     Tumor invades mucosa of the </p>
          <p>						  bladder or</p>
          <p>                               rectum, and/or extends beyond true pelvis</p>
          <p>                               (bullous edema is not sufficient to</p>
          <p>                               classify a tumor as T4.</p>
          <p>    *FIGO staging no longer includes Stage 0 (Tis)</p>
          <p>   **All macroscopically visible lesions - even with superficial invasion</p>
          <p>     Are T1b/IB.</p>
          <p> </p>
          <p>CLIN   PATH    TNM     FIGO   REGIONAL LYMPH NODES (N)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}                     Regional lymph nodes cannot </p>
          <p>						  be assessed</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N0              No regional lymph node 	</p>
          <p>					  	  metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     N1      IIIB    Regional lymph node 		</p>
          <p>						  metastasis</p>
          <p> </p>
          <p>CLIN   PATH    TNM     FIGO    DISTANT METASTASIS (M)</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M0              No distant metastasis</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     M1      IVB     Distant metastasis 		</p>
          <p>						  (including peritoneal</p>
          <p>                               spread, involvement of supraclavicular or</p>
          <p>                               mediastinal lymph nodes, lung, liver, or </p>
          <p>                               bone)</p>
          <p> </p>
          <p>CLIN   PATH            STAGE GROUPING</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     0*      Tis     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     I       T1      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IA      T1a     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IA1     T1a1    N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IA2     T1a2    N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IB      T1b     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IB1     T1b1    N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IB2     T1b2    N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     II      T2      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIA     T2a     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIA1    T2a1    N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIA2    T2a2    N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIB     T2b     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     III     T3      N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIA    T3a     N0      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IIIB    T3b     Any N   M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}             T1-3    N1      M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVA     T4      Any N   M0</p>
          <p>{FLD:AJCC X}    {FLD:AJCC X}     IVB     Any T   Any N   M1</p>
          <p> </p>
          <p>    FIGO no longer includes Stage 0 (Tis)</p>
          <p></p>
          <p>{FLD:AJCC X}  Stage Unknown</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING:  None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>    FIGO Stage:{FLD:AJCC EDIT50}</p>
          <p>    Pelvic nodal status and method of assessment:{FLD:AJCC EDIT50}</p>
          <p>    Para-aorfic nodal status and method of assessment:{FLD:AJCC EDIT50}</p>
          <p>Distant (mediastinal, scalene) nodal status and method of assessment</p>
          <p>{FLD:AJCC EDIT50}</p>
          <p>Histologic Grade (G) (also known as overall grade)</p>
          <p></p>
          <p>  Grading system</p>
          <p></p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been</p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X}Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X}Not Applicable</p>
          <p>{FLD:AJCC X}Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some</p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X}RX Presence of residual tumor cannot be assessed</p>
          <p>{FLD:AJCC X}R0 No residual tumor</p>
          <p>{FLD:AJCC X}R1 Microscopic residual tumor</p>
          <p>{FLD:AJCC X}R2 Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}Clinical stage was used in treatment planning (describe):</p>
          <p>{FLD:AJCC X}National guidelines were used in treatment planning </p>
          <p>{FLD:AJCC X} NCCN </p>
          <p>{FLD:AJCC X} Other (describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC 7th Ed. Vulva Staging">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>VULVA  </p>
          <p>(Mucosal malignant melanoma is excluded) </p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p>{FLD:AJCC X}y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>{FLD:AJCC X}y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:{FLD:AJCC EDIT45}</p>
          <p>FIGO CLIN PATH         PRIMARY TUMOR (T)</p>
          <p>     {FLD:AJCC X}  {FLD:AJCC X}  TX      Primary tumor cannot be assessed </p>
          <p>     {FLD:AJCC X}  {FLD:AJCC X}  T0      No evidence of primary tumor</p>
          <p>  *  {FLD:AJCC X}  {FLD:AJCC X}  Tis     Carcinoma in situ (Preinvasive 	</p>
          <p>			 carcinoma)</p>
          <p> 1A  {FLD:AJCC X}  {FLD:AJCC X}  T1a     Tumor confined to the vulva or vulva </p>
          <p>			 and perineum, 2cm or &lt; in greatest dimension, and with stromal</p>
          <p>                         invasion no &gt; 1mm  </p>
          <p>1B   {FLD:AJCC X}  {FLD:AJCC X}  T1b     Tumor confined to the vulva or vulva </p>
          <p>			 and perineum, 2cm or &lt; in greatest dimension, &amp; with stromal</p>
          <p>                         invasion &gt; 1mm </p>
          <p> 11  {FLD:AJCC X}  {FLD:AJCC X}  T2***   Tumor confined to the vulva or vulva </p>
          <p>			 and perineum &gt; 2cm</p>
          <p> IVA {FLD:AJCC X}  {FLD:AJCC X}  T3****  Tumor of any size with contiguous 	</p>
          <p>			 spread to the lower urethra &amp;/or vagina or anus</p>
          <p>       *FIGO staging no longer includes Stage 0 (Tis)</p>
          <p>      **The depth of invasion is defined as the measurement of the tumor</p>
          <p>        from the epithelial-stromal junction of the adjacent most</p>
          <p>        superficial dermal papilla to the deepest point of invasion.</p>
          <p>     ***FIGO uses the classification T2 T3.  This is defined at T2 in TNM.</p>
          <p>    ****FICO uses the classification T4.  This is defined at T3 in TNM.</p>
          <p></p>
          <p>FIGO CLIN PATH         REGIONAL LYMPH NODES (N)</p>
          <p>     {FLD:AJCC X}  {FLD:AJCC X}  NX      Regional lymph nodes cannot be 	</p>
          <p>			 assessed</p>
          <p>     {FLD:AJCC X}  {FLD:AJCC X}  N0      No regional lymph node metastasis</p>
          <p>     {FLD:AJCC X}  {FLD:AJCC X}  N1      One or two regional lymph node with </p>
          <p>			 the following features</p>
          <p>IIIA {FLD:AJCC X}  {FLD:AJCC X}  N1a     One or two lymph node metastasis 	</p>
          <p>			 each 5 mm or less</p>
          <p>IIIA {FLD:AJCC X}  {FLD:AJCC X}  N1b     One lymph node metastases 5 mm or 	</p>
          <p>			 greater </p>
          <p>IIIB {FLD:AJCC X}  {FLD:AJCC X}  N2      Regional lymph nodes metastasis with </p>
          <p>			 the following feaures:</p>
          <p>IIIB {FLD:AJCC X}  {FLD:AJCC X}  N2a     Three or more lymph node metastases </p>
          <p>			 each less than 5 mm</p>
          <p>IIIB {FLD:AJCC X}  {FLD:AJCC X}  N2b     Two or more lymph node metastases 5 </p>
          <p>			 mm or greater</p>
          <p>IIIC {FLD:AJCC X}  {FLD:AJCC X}  N2c     Lymph node metastasis with 		</p>
          <p>			 extracapsular spread</p>
          <p>IVA  {FLD:AJCC X}  {FLD:AJCC X}  N3      Fixed or ulcerated regional lymph 	</p>
          <p>			 node metastasis</p>
          <p>                       An effort should be made to describe the site and</p>
          <p>                       Laterality of lymph node metastases. </p>
          <p></p>
          <p>FIGO CLIN PATH         DISTANT METASTASIS (M)</p>
          <p>     {FLD:AJCC X}  {FLD:AJCC X}  M0      No distant metastasis (no pathologic </p>
          <p>			 M0;  uses</p>
          <p>                       clinical M to complete Stage group)</p>
          <p>     {FLD:AJCC X}  {FLD:AJCC X}  M1 IVB  Distant metastasis (including pelvic </p>
          <p>			 lymph nodemetastasis)</p>
          <p> </p>
          <p>CLIN   PATH  STAGE GROUPING                       </p>
          <p> </p>
          <p>{FLD:AJCC X}  {FLD:AJCC X}   0*    Tis      N0       M0 </p>
          <p>{FLD:AJCC X}  {FLD:AJCC X}   I     T1       N0       M0 </p>
          <p>{FLD:AJCC X}  {FLD:AJCC X}]  IA    T1a      N0       M0 </p>
          <p>{FLD:AJCC X}  {FLD:AJCC X}   IB    T1b      N0       M0 </p>
          <p>{FLD:AJCC X}  {FLD:AJCC X}   II    T2       N0       M0 </p>
          <p>{FLD:AJCC X}  {FLD:AJCC X}   IIIA  T1,T2    N1a,N1b  M0 </p>
          <p>{FLD:AJCC X}  {FLD:AJCC X}   IIIB  T1,T2    N2a,N2b  M0 </p>
          <p>{FLD:AJCC X}  {FLD:AJCC X}   IIIC  T1,T2    N2c      M0 </p>
          <p>{FLD:AJCC X}  {FLD:AJCC X}   IVA  T1,T2     N3       M0 </p>
          <p>{FLD:AJCC X}  {FLD:AJCC X}          T3      Any N    M0 </p>
          <p>{FLD:AJCC X}  {FLD:AJCC X}   IVB   Any T     Any N    M1 </p>
          <p>*FIGO no longer includes Stage 0 (Tis) </p>
          <p>{FLD:AJCC X}    Stage Unknown</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFRIC FACTORS)</p>
          <p>REQUIREMENT FOR STAGING: {FLD:AJCC X}None</p>
          <p>CLINCIALLY SIGNIFICANT:</p>
          <p>     FICO Stage:{FLD:AJCC EDIT45}</p>
          <p>     Pelvic nodal status and method of assessment:{FLD:AJCC EDIT45}</p>
          <p>   Femoral-Inguinal nodal status and method of assessment:{FLD:AJCC EDIT45}</p>
          <p></p>
          <p>Histologic Grade (G) (also known as overall grade)</p>
          <p>GRADING SYSTEM    </p>
          <p>{FLD:X BOX} 2 grade system	    			{FLD:X BOX}Grade I or 1</p>
          <p>{FLD:X BOX} 3 grade system 	    		{FLD:X BOX}Grade II or 2</p>
          <p>{FLD:X BOX} 4 grade system 	    		{FLD:X BOX}Grade III or 3</p>
          <p>{FLD:X BOX} No 2,3,or 4 grade system is available	{FLD:X BOX}Grade IV or 4</p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>Checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>{FLD:AJCC X} Lymph-Vascular Invasion Present/Identified</p>
          <p>{FLD:AJCC X} Not Applicable</p>
          <p>{FLD:AJCC X} Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>{FLD:AJCC X} RX  Presence of residual tumor cannot be assessed.</p>
          <p>{FLD:AJCC X} R0  No residual tumor</p>
          <p>{FLD:AJCC X} R1  Microscopic residual tumor</p>
          <p>{FLD:AJCC X} R2  Macroscopic residual tumor</p>
          <p></p>
          <p>{FLD:AJCC X}  Clinical stage was used in the treatment planning (describe):</p>
          <p>{FLD:AJCC EDIT45}</p>
          <p>{FLD:AJCC X}  National guidelines were used in treatment planning</p>
          <p>     {FLD:AJCC X} NCCN</p>
          <p>     {FLD:AJCC X} Other(describe):{FLD:AJCC EDIT50}</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
    </ITEMS>
  </TEMPLATE>
  <TEMPLATE_FIELDS>
    <FIELD NAME="AJCC X">
      <TYPE>B</TYPE>
      <INACTIVE>0</INACTIVE>
      <LENGTH>0</LENGTH>
      <DEFAULT_INDEX>1</DEFAULT_INDEX>
      <REQUIRED>0</REQUIRED>
      <SEPARATE_LINES>0</SEPARATE_LINES>
      <MAX_LENGTH>0</MAX_LENGTH>
      <INDENT>0</INDENT>
      <PAD>0</PAD>
      <MIN_VALUE>0</MIN_VALUE>
      <MAX_VALUE>0</MAX_VALUE>
      <INCREMENT>0</INCREMENT>
      <ITEMS>
        <p>[ ]</p>
        <p>[X]</p>
      </ITEMS>
    </FIELD>
    <FIELD NAME="AJCC EDIT50">
      <TYPE>E</TYPE>
      <INACTIVE>0</INACTIVE>
      <LENGTH>50</LENGTH>
      <DEFAULT_INDEX>0</DEFAULT_INDEX>
      <REQUIRED>0</REQUIRED>
      <SEPARATE_LINES>0</SEPARATE_LINES>
      <MAX_LENGTH>50</MAX_LENGTH>
      <INDENT>0</INDENT>
      <PAD>0</PAD>
      <MIN_VALUE>0</MIN_VALUE>
      <MAX_VALUE>0</MAX_VALUE>
      <INCREMENT>0</INCREMENT>
      <DESCRIPTION>
        <p>11/1/02 MNM</p>
      </DESCRIPTION>
    </FIELD>
    <FIELD NAME="X BOX">
      <TYPE>B</TYPE>
      <INACTIVE>0</INACTIVE>
      <LENGTH>3</LENGTH>
      <LIST_MANAGER_TEXT>[ ]</LIST_MANAGER_TEXT>
      <DEFAULT_INDEX>2</DEFAULT_INDEX>
      <REQUIRED>0</REQUIRED>
      <SEPARATE_LINES>0</SEPARATE_LINES>
      <MAX_LENGTH>0</MAX_LENGTH>
      <INDENT>0</INDENT>
      <PAD>0</PAD>
      <MIN_VALUE>0</MIN_VALUE>
      <MAX_VALUE>0</MAX_VALUE>
      <INCREMENT>0</INCREMENT>
      <ITEMS>
        <p>[X]</p>
        <p>[ ]</p>
      </ITEMS>
    </FIELD>
    <FIELD NAME="WP 2 LINE">
      <TYPE>W</TYPE>
      <INACTIVE>0</INACTIVE>
      <LENGTH>74</LENGTH>
      <DEFAULT_INDEX>0</DEFAULT_INDEX>
      <REQUIRED>0</REQUIRED>
      <SEPARATE_LINES>0</SEPARATE_LINES>
      <MAX_LENGTH>2</MAX_LENGTH>
      <INDENT>0</INDENT>
      <PAD>0</PAD>
      <MIN_VALUE>0</MIN_VALUE>
      <MAX_VALUE>0</MAX_VALUE>
      <INCREMENT>0</INCREMENT>
    </FIELD>
    <FIELD NAME="FREE TEXT 10">
      <TYPE>E</TYPE>
      <INACTIVE>0</INACTIVE>
      <LENGTH>10</LENGTH>
      <DEFAULT_INDEX>0</DEFAULT_INDEX>
      <REQUIRED>0</REQUIRED>
      <SEPARATE_LINES>0</SEPARATE_LINES>
      <MAX_LENGTH>10</MAX_LENGTH>
      <INDENT>0</INDENT>
      <PAD>0</PAD>
      <MIN_VALUE>0</MIN_VALUE>
      <MAX_VALUE>0</MAX_VALUE>
      <INCREMENT>0</INCREMENT>
    </FIELD>
    <FIELD NAME="WP 2">
      <TYPE>W</TYPE>
      <INACTIVE>0</INACTIVE>
      <LENGTH>74</LENGTH>
      <DEFAULT_INDEX>0</DEFAULT_INDEX>
      <REQUIRED>0</REQUIRED>
      <SEPARATE_LINES>0</SEPARATE_LINES>
      <MAX_LENGTH>2</MAX_LENGTH>
      <INDENT>4</INDENT>
      <PAD>4</PAD>
      <MIN_VALUE>0</MIN_VALUE>
      <MAX_VALUE>0</MAX_VALUE>
      <INCREMENT>0</INCREMENT>
      <DESCRIPTION>
        <p>AJM-Word Processing object.  74 columns by 2 rows.  Used by Preventive </p>
        <p>Screen note title</p>
      </DESCRIPTION>
    </FIELD>
    <FIELD NAME="AJCC EDIT45">
      <TYPE>E</TYPE>
      <INACTIVE>0</INACTIVE>
      <LENGTH>45</LENGTH>
      <DEFAULT_INDEX>0</DEFAULT_INDEX>
      <REQUIRED>0</REQUIRED>
      <SEPARATE_LINES>0</SEPARATE_LINES>
      <MAX_LENGTH>45</MAX_LENGTH>
      <INDENT>0</INDENT>
      <PAD>0</PAD>
      <MIN_VALUE>0</MIN_VALUE>
      <MAX_VALUE>0</MAX_VALUE>
      <INCREMENT>0</INCREMENT>
      <DESCRIPTION>
        <p>11/1/02 MNM</p>
      </DESCRIPTION>
    </FIELD>
    <FIELD NAME="AJCC EDIT8">
      <TYPE>E</TYPE>
      <INACTIVE>0</INACTIVE>
      <LENGTH>8</LENGTH>
      <DEFAULT_INDEX>0</DEFAULT_INDEX>
      <REQUIRED>0</REQUIRED>
      <SEPARATE_LINES>0</SEPARATE_LINES>
      <MAX_LENGTH>8</MAX_LENGTH>
      <INDENT>0</INDENT>
      <PAD>0</PAD>
      <MIN_VALUE>0</MIN_VALUE>
      <MAX_VALUE>0</MAX_VALUE>
      <INCREMENT>0</INCREMENT>
      <DESCRIPTION>
        <p>11/1/02 MNM</p>
      </DESCRIPTION>
    </FIELD>
    <FIELD NAME="AJCC EDIT15">
      <TYPE>E</TYPE>
      <INACTIVE>0</INACTIVE>
      <LENGTH>15</LENGTH>
      <DEFAULT_INDEX>0</DEFAULT_INDEX>
      <REQUIRED>0</REQUIRED>
      <SEPARATE_LINES>0</SEPARATE_LINES>
      <MAX_LENGTH>16</MAX_LENGTH>
      <INDENT>0</INDENT>
      <PAD>0</PAD>
      <MIN_VALUE>0</MIN_VALUE>
      <MAX_VALUE>0</MAX_VALUE>
      <INCREMENT>0</INCREMENT>
      <DESCRIPTION>
        <p>11/1/02 MNM</p>
      </DESCRIPTION>
    </FIELD>
    <FIELD NAME="AJCC W-P2LINES">
      <TYPE>W</TYPE>
      <INACTIVE>0</INACTIVE>
      <LENGTH>74</LENGTH>
      <DEFAULT_INDEX>0</DEFAULT_INDEX>
      <REQUIRED>0</REQUIRED>
      <SEPARATE_LINES>0</SEPARATE_LINES>
      <MAX_LENGTH>0</MAX_LENGTH>
      <INDENT>0</INDENT>
      <PAD>0</PAD>
      <MIN_VALUE>0</MIN_VALUE>
      <MAX_VALUE>0</MAX_VALUE>
      <INCREMENT>0</INCREMENT>
    </FIELD>
    <FIELD NAME="AJCC 7TH EDITION HDR">
      <TYPE>T</TYPE>
      <INACTIVE>0</INACTIVE>
      <LENGTH>0</LENGTH>
      <DEFAULT_INDEX>0</DEFAULT_INDEX>
      <REQUIRED>0</REQUIRED>
      <SEPARATE_LINES>1</SEPARATE_LINES>
      <MAX_LENGTH>0</MAX_LENGTH>
      <INDENT>0</INDENT>
      <PAD>0</PAD>
      <MIN_VALUE>0</MIN_VALUE>
      <MAX_VALUE>0</MAX_VALUE>
      <INCREMENT>0</INCREMENT>
      <DESCRIPTION>
        <p>11/8/02 MNM</p>
      </DESCRIPTION>
      <ITEMS>
        <p>*******************************************************************</p>
        <p>*  This template includes the 7th edition of the AJCC Cancer      *</p>
        <p>*  Staging Manual, which goes into effect on all cases diagnosed  *</p>
        <p>*  on or after January 1, 2010.                                   *</p>
        <p>*******************************************************************</p>
      </ITEMS>
    </FIELD>
    <FIELD NAME="AJCC 7TH EDITION CLINICAL STAGING TEXT">
      <TYPE>T</TYPE>
      <INACTIVE>0</INACTIVE>
      <LENGTH>0</LENGTH>
      <DEFAULT_INDEX>0</DEFAULT_INDEX>
      <REQUIRED>0</REQUIRED>
      <SEPARATE_LINES>1</SEPARATE_LINES>
      <MAX_LENGTH>0</MAX_LENGTH>
      <INDENT>0</INDENT>
      <PAD>0</PAD>
      <MIN_VALUE>0</MIN_VALUE>
      <MAX_VALUE>0</MAX_VALUE>
      <INCREMENT>0</INCREMENT>
      <ITEMS>
        <p>CLINICAL STAGING:  </p>
        <p>Extent of disease </p>
        <p>before any treatment.</p>
      </ITEMS>
    </FIELD>
    <FIELD NAME="AJCC 7TH EDITION PATHOLOGIC STAGING TEXT">
      <TYPE>T</TYPE>
      <INACTIVE>0</INACTIVE>
      <LENGTH>0</LENGTH>
      <DEFAULT_INDEX>0</DEFAULT_INDEX>
      <REQUIRED>0</REQUIRED>
      <SEPARATE_LINES>1</SEPARATE_LINES>
      <MAX_LENGTH>0</MAX_LENGTH>
      <INDENT>0</INDENT>
      <PAD>0</PAD>
      <MIN_VALUE>0</MIN_VALUE>
      <MAX_VALUE>0</MAX_VALUE>
      <INCREMENT>0</INCREMENT>
      <ITEMS>
        <p>PATHOLOGIC STAGING:  </p>
        <p>Extent of disease through </p>
        <p>completion of definitive </p>
        <p>surgery.</p>
      </ITEMS>
    </FIELD>
    <FIELD NAME="AJCC 7TH ED PARANASAL DISTANT METS NOTE">
      <TYPE>T</TYPE>
      <INACTIVE>0</INACTIVE>
      <LENGTH>0</LENGTH>
      <DEFAULT_INDEX>0</DEFAULT_INDEX>
      <REQUIRED>0</REQUIRED>
      <SEPARATE_LINES>0</SEPARATE_LINES>
      <MAX_LENGTH>0</MAX_LENGTH>
      <INDENT>0</INDENT>
      <PAD>0</PAD>
      <MIN_VALUE>0</MIN_VALUE>
      <MAX_VALUE>0</MAX_VALUE>
      <INCREMENT>0</INCREMENT>
      <ITEMS>
        <p>(No pathologic M0; Use clinical M to complete stage group.)</p>
      </ITEMS>
    </FIELD>
    <FIELD NAME="WORD PROCESSING 1 LINE N/R HDB">
      <TYPE>W</TYPE>
      <INACTIVE>0</INACTIVE>
      <LENGTH>74</LENGTH>
      <DEFAULT_INDEX>0</DEFAULT_INDEX>
      <REQUIRED>0</REQUIRED>
      <SEPARATE_LINES>0</SEPARATE_LINES>
      <MAX_LENGTH>2</MAX_LENGTH>
      <INDENT>0</INDENT>
      <PAD>0</PAD>
      <MIN_VALUE>0</MIN_VALUE>
      <MAX_VALUE>0</MAX_VALUE>
      <INCREMENT>0</INCREMENT>
    </FIELD>
    <FIELD NAME="AJCC 7TH EDITION STAGING ILLUSTRATIONS">
      <TYPE>T</TYPE>
      <INACTIVE>0</INACTIVE>
      <LENGTH>0</LENGTH>
      <DEFAULT_INDEX>0</DEFAULT_INDEX>
      <REQUIRED>0</REQUIRED>
      <SEPARATE_LINES>1</SEPARATE_LINES>
      <MAX_LENGTH>0</MAX_LENGTH>
      <INDENT>0</INDENT>
      <PAD>0</PAD>
      <MIN_VALUE>0</MIN_VALUE>
      <MAX_VALUE>0</MAX_VALUE>
      <INCREMENT>0</INCREMENT>
      <ITEMS>
        <p>This AJCC Staging form has an hard copy paper illustration form that </p>
        <p>needs to be completed and scanned into Vista Imaging with this note.  </p>
        <p>Please complete this Illustration and scan into the medical </p>
        <p>record.</p>
      </ITEMS>
    </FIELD>
    <FIELD NAME="AJCC W-P INDENT3">
      <TYPE>W</TYPE>
      <INACTIVE>0</INACTIVE>
      <LENGTH>70</LENGTH>
      <DEFAULT_INDEX>0</DEFAULT_INDEX>
      <REQUIRED>0</REQUIRED>
      <SEPARATE_LINES>0</SEPARATE_LINES>
      <MAX_LENGTH>2</MAX_LENGTH>
      <INDENT>2</INDENT>
      <PAD>2</PAD>
      <MIN_VALUE>0</MIN_VALUE>
      <MAX_VALUE>0</MAX_VALUE>
      <INCREMENT>0</INCREMENT>
      <DESCRIPTION>
        <p>11/1/02 MNM</p>
      </DESCRIPTION>
    </FIELD>
    <FIELD NAME="X BUTTON1">
      <TYPE>B</TYPE>
      <INACTIVE>0</INACTIVE>
      <LENGTH>0</LENGTH>
      <DEFAULT_INDEX>1</DEFAULT_INDEX>
      <REQUIRED>0</REQUIRED>
      <SEPARATE_LINES>0</SEPARATE_LINES>
      <MAX_LENGTH>0</MAX_LENGTH>
      <INDENT>0</INDENT>
      <PAD>0</PAD>
      <MIN_VALUE>0</MIN_VALUE>
      <MAX_VALUE>0</MAX_VALUE>
      <INCREMENT>0</INCREMENT>
      <ITEMS>
        <p>[ ]</p>
        <p>[X]</p>
      </ITEMS>
    </FIELD>
    <FIELD NAME="AJCC Y/N">
      <TYPE>R</TYPE>
      <INACTIVE>0</INACTIVE>
      <LENGTH>0</LENGTH>
      <DEFAULT_INDEX>0</DEFAULT_INDEX>
      <REQUIRED>0</REQUIRED>
      <SEPARATE_LINES>0</SEPARATE_LINES>
      <MAX_LENGTH>0</MAX_LENGTH>
      <INDENT>0</INDENT>
      <PAD>0</PAD>
      <MIN_VALUE>0</MIN_VALUE>
      <MAX_VALUE>0</MAX_VALUE>
      <INCREMENT>0</INCREMENT>
      <DESCRIPTION>
        <p>11/1/02 MNM</p>
      </DESCRIPTION>
      <ITEMS>
        <p>Yes</p>
        <p>No</p>
      </ITEMS>
    </FIELD>
    <FIELD NAME="AJCC PRESENT/ABSENT">
      <TYPE>R</TYPE>
      <INACTIVE>0</INACTIVE>
      <LENGTH>0</LENGTH>
      <DEFAULT_INDEX>0</DEFAULT_INDEX>
      <REQUIRED>0</REQUIRED>
      <SEPARATE_LINES>0</SEPARATE_LINES>
      <MAX_LENGTH>0</MAX_LENGTH>
      <INDENT>0</INDENT>
      <PAD>0</PAD>
      <MIN_VALUE>0</MIN_VALUE>
      <MAX_VALUE>0</MAX_VALUE>
      <INCREMENT>0</INCREMENT>
      <DESCRIPTION>
        <p>11/22/09 AJCC (MNM)</p>
      </DESCRIPTION>
      <ITEMS>
        <p>Present</p>
        <p>Absent</p>
      </ITEMS>
    </FIELD>
    <FIELD NAME="FREE TEXT">
      <TYPE>E</TYPE>
      <INACTIVE>0</INACTIVE>
      <LENGTH>60</LENGTH>
      <DEFAULT_INDEX>0</DEFAULT_INDEX>
      <REQUIRED>0</REQUIRED>
      <SEPARATE_LINES>0</SEPARATE_LINES>
      <MAX_LENGTH>69</MAX_LENGTH>
      <INDENT>0</INDENT>
      <PAD>0</PAD>
      <MIN_VALUE>0</MIN_VALUE>
      <MAX_VALUE>0</MAX_VALUE>
      <INCREMENT>0</INCREMENT>
    </FIELD>
  </TEMPLATE_FIELDS>
</CPRS_TEMPLATE>
